



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 169089

TO: Emily M Le
Location: 3c35/3c18
Art Unit: 1648
Friday, August 05, 2005

Case Serial Number: 10/043086

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

Checked 8/08/05
no prior art found.

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: _____ Examiner #: 79936 Date: 7/13/05
Art Unit: _____ Phone Number: 2- _____ Serial Number: 101043086
Location (Bldg/Room#): _____ (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

STAFF USE ONLY

Searcher: noble

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 8/5/05

Searcher Prep & Review Time: 33

Online Time: 39

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

13 Structure (#)

☒ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

☒ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length

____ Interference _____ SPDI _____ Encode/Transl

____ Other (specify)

Jarrell, Noble

From: Le, Emily
Sent: Tuesday, July 12, 2005 4:35 PM
To: Jarrell, Noble
Cc: Housel, James
Subject: Structure and registry search: 10/043086

Noble,

Please provide a search for the attached structures (1 generic and 11 specific structures).

Thanks!

Emily Le
Office, Rem 3C35
Mailbox, Rem 3C18
Tel., 2-0903


Sequence Search:



10043086.doc

I.


49.(currently amended) A compound having the formula



wherein X is O; Y is O; m, n, p and q are each 0; R₄, R₅, R₇ and R₉ are each H; R₈ is phosphono; R₆ is selected from OH, CO₂H and CONH₂; and R₁, R₂ and R₃ are independently selected from C₆ acyl groups and C₁₀ acyl groups; and or a pharmaceutically acceptable salt[s] thereof.


II.

A




MW 1420.9 (6-6-6)

11 5 11 5 11 5
C₆₉H₁₂₇N₂O₁₉P




MW 1505.1 (8-8-8)

11 7 11 7 11 7
C₇₅H₁₃₉N₂O₁₉P




MW 1589.3 (10-10-10)

11 9 11 9 11 9
C₈₁H₁₅₁N₂O₁₉P



MW 1673.4 (12-12-12)


11 11 11 11 11 11
C₈₇H₁₆₃N₂O₁₉P



MW 1757.5 (14-14-14)


11 13 11 13 11 13
C₉₃H₁₇₅N₂O₁₉P

B




MW 1533.2 (6-10-10)

11 5 11 9 11 9
C₇₇H₁₄₃N₂O₁₉P




MW 1533.2 (10-6-10)

11 9 11 5 11 9
C₇₇H₁₄₃N₂O₁₉P




MW 1533.2 (10-10-6)

11 9 11 9 11 3
C₇₇H₁₄₃N₂O₁₉P




MW 1477.0 (6-6-10)

11 5 11 5 11 9
C₇₃H₁₃₅N₂O₁₉P



MW 1477.0 (6-10-6)

11 5 11 9 11 5
C₇₃H₁₃₅N₂O₁₉P



MW 1477.0 (10-6-6)

11 9 11 5 11 5
C₇₃H₁₃₅N₂O₁₉P

=> d his full

(FILE 'HOME' ENTERED AT 06:39:27 ON 05 AUG 2005)

FILE 'HCAPLUS' ENTERED AT 06:39:34 ON 05 AUG 2005

L1 6 SEA ABB=ON PLU=ON (US2003092643 OR US6764840 OR US2002048588
OR US6303347 OR US6113918)/PN

FILE 'REGISTRY' ENTERED AT 06:41:28 ON 05 AUG 2005

FILE 'HCAPLUS' ENTERED AT 06:41:30 ON 05 AUG 2005

L2 TRA L1 1- RN : 313 TERMS

FILE 'REGISTRY' ENTERED AT 06:41:31 ON 05 AUG 2005

L3 313 SEA ABB=ON PLU=ON L2

FILE 'WPIX' ENTERED AT 06:41:39 ON 05 AUG 2005

L4 4 SEA ABB=ON PLU=ON (US2003092643 OR US6764840 OR US2002048588
OR US6303347 OR US6113918)/PN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 06:42:04 ON 05 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Aug 2005 VOL 143 ISS 7

FILE LAST UPDATED: 4 Aug 2005 (20050804/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l1

L1 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:836578 HCAPLUS

DN 139:307973

ED Entered STN: 24 Oct 2003

TI Preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors

IN Johnson, David A.; Sowell, C. Gregory

PA Corixa Corporation, USA

SO U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of U.S. Ser. No. 43,086.

CODEN: USXXCO

DT Patent

LA English

IC A61K031-739; C08B037-00

INCL 514042000; 536053000

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 15, 34, 63

FAN.CNT 10

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE


Search done by Noble Jarrell

PI	US 2003199460	A1	20031023	US 2002-137730	20020430
	US 6113918	A	20000905	US 1997-853826	19970508 <--
	US 6303347	B1	20011016	US 1999-439839	19991112 <--
	US 2002048588	A1	20020425	US 2001-905160	20010712 <--
	US 6764840	B2	20040720		
	US 2003092643	A1	20030515	US 2002-43086	20020108 <--
PRAI	US 1997-853826	A2	19970508		
	US 1999-439839	A1	19991112		
	US 2001-905160	A2	20010712		
	US 2002-43086	A2	20020108		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003199460	IC	A61K031-739IC C08B037-00
	INCL	514042000; 536053000
US 2003199460	NCL	514/042.000; 536/053.000
	ECLA	C07H013/06C; C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--
US 2002048588	NCL	435/101.000; 424/278.100; 536/001.110
	ECLA	C07H015/04D <--
US 2003092643	NCL	514/042.000; 536/053.000; 536/054.000; 424/234.100
	ECLA	C07H013/06C; C07H015/04D <--

OS MARPAT 139:307973
GI



AB Aminoalkyl glucosaminide phosphate compds. (AGP) I were prepared wherein, X is selected from the group consisting of O and S at the axial or equatorial position; Y is selected from the group consisting of O and NH; Q is (CH₂)_n; L is (CH₂)_m; W is (CH₂)_q; n, m, p, q are integers from 0 to 6; R is (CH₂)₁₀Me; R1-R3 are the same or different and are normal fatty acyl residues having from 1 to about 20 carbon atoms and where one of R1-R3 is optionally hydrogen; R4 and R5 are the same or different and are selected from the group consisting of H and methyl; R6 and R7 are the same or different and are selected from the group consisting of H, hydroxy, alkoxy, phosphono, phosphono-oxy, sulfo, sulfo-oxy, amino, mercapto, cyano, nitro, formyl and carboxy, and esters and amides thereof; and R8 and R9 are the same or different and are selected from the group consisting of phosphono and H, and at least one of R8 and R9 is phosphono, that are adjuvants and immuno-effectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as

well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immuno-effectors are also disclosed. Thus, N-[(R)-3-hydroxytetradecanoyl]-O-[2-deoxy-4-O-phosphono-2-[(R)-3-dodecanoyloxytetradecanoylamino]-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]- α -L-D-glucopyranosyl]-L-serine triethylammonium salt was prepared and tested in mice as adjuvants and immuno-effectors. Mice vaccinated with formalin-inactivated influenza and the AGP compds. of the subject invention mounted a protective immune response to an influenza challenge as well as produced antibody to that antigen.

- ST antiinfluenza IgG immunoefector aminoalkyl glucosaminide phosphate prepn; cytokine adjuvant immunoefector antitetanus toxoid amino acid prepn glycoside; aminoalkyl glucosaminide phosphate prepn adjuvant immunoefector antitetanus toxoid antibody
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG, immobilized; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG1; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG2a; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG2b; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Influenza
(anti; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Macrophage
Vaccines
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Amino acids, preparation
Antibodies and Immunoglobulins
Cytokines
Glycosides
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Toxoids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tetanus; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P 216013-82-0P
216013-88-6P 216013-97-7P 216014-06-1P 216014-15-2P 216014-21-0P
216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P 216014-56-1P
216014-63-0P 216014-69-6P 216014-76-5P 216014-82-3P 216014-88-9P
216014-92-5P 216014-98-1P 339078-59-0P 339078-61-4P 339078-63-6P

339078-65-8P 339078-67-0P 339078-69-2P 339078-71-6P 339078-73-8P
 339078-75-0P 339078-77-2P 339078-79-4P 339078-81-8P 339078-85-2P
 339079-17-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 109361-17-3

RL: CAT (Catalyst use); USES (Uses)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 66-84-2 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl chloride 2456-81-7, 4-Pyrrolidinopyridine 2528-61-2, Heptanoyl chloride 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl 3-oxotetradecanoate 22572-40-3, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide methiodide 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66270-36-8, 2,2,2-Trichloro-1,1-dimethylethyl chloroformate 66937-71-1 109977-90-4 122078-72-2 133099-79-3, D-Serine benzyl ester 134304-48-6 166193-98-2 190586-91-5 216014-70-9 339078-52-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 1738-72-3P 2524-64-3P, Diphenyl chlorophosphate 76062-98-1P 87357-76-4P 91578-89-1P 91681-56-0P 122105-45-7P 122210-01-9P 186383-49-3P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P 216013-10-4P 216013-12-6P 216013-13-7P 216013-14-8P 216013-15-9P 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P 216013-26-2P 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P 216013-31-9P 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P 216013-38-6P 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P 216013-53-5P 216013-54-6P 216013-55-7P 216013-56-8P 216013-60-4P 216013-61-5P 216013-62-6P 216013-63-7P 216013-66-0P 216013-67-1P 216013-69-3P 216013-70-6P 216013-71-7P 216013-75-1P 216013-77-3P 216013-78-4P 216013-79-5P 216013-80-8P 216013-83-1P 216013-85-3P 216013-89-7P 216013-90-0P 216013-91-1P 216013-92-2P 216013-93-3P 216013-95-5P 216013-98-8P 216013-99-9P 216014-00-5P 216014-01-6P 216014-02-7P 216014-04-9P 216014-07-2P 216014-08-3P 216014-09-4P 216014-11-8P 216014-12-9P 216014-13-0P 216014-16-3P 216014-17-4P 216014-19-6P 216014-22-1P 216014-23-2P 216014-24-3P 216014-25-4P 216014-26-5P 216014-27-6P 216014-30-1P 216014-31-2P 216014-32-3P 216014-33-4P 216014-34-5P 216014-35-6P 216014-38-9P 216014-39-0P 216014-40-3P 216014-41-4P 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P 216014-52-7P 216014-53-8P 216014-54-9P 216014-57-2P 216014-59-4P 216014-60-7P 216014-61-8P 216014-65-2P 216014-66-3P 216014-67-4P 216014-72-1P 216014-73-2P 216014-74-3P 216014-77-6P 216014-78-7P 216014-80-1P 216014-83-4P 216014-84-5P 216014-85-6P 216014-89-0P 216014-90-3P 216014-93-6P 216014-94-7P 216014-95-8P 216014-99-2P 216015-00-8P 216015-01-9P 220048-54-4P 339078-53-4P 339078-54-5P 339078-58-9P 339078-82-9P 339078-83-0P 339078-86-3P 339078-87-4P 339079-15-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

=> d all 11 2-6

L1 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:376382 HCAPLUS

DN 138:384134

ED Entered STN: 16 May 2003

Search done by Noble Jarrell

TI Vaccine compositions comprising aminoalkyl glucosaminide phosphate compounds as adjuvants and immunoeffectors for treating cancerous and infectious diseases
 IN Johnson, David A.; Sowell, C. Gregory
 PA Corixa Corporation, USA
 SO U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 905,160.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K039-02
 ICS A61K031-739; C07H005-04
 INCL 514042000; 536053000; 536054000; 424234100
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 1, 63

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003092643	A1	20030515	US 2002-43086	20020108 <--
	US 6113918	A	20000905	US 1997-853826	19970508 <--
	US 6303347	B1	20011016	US 1999-439839	19991112 <--
	US 2002048588	A1	20020425	US 2001-905160	20010712 <--
	US 6764840	B2	20040720		
	US 2003199460	A1	20031023	US 2002-137730	20020430
PRAI	US 1997-853826	A2	19970508		
	US 1999-439839	A1	19991112		
	US 2001-905160	A2	20010712		
	US 2002-43086	A2	20020108		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003092643	ICM	A61K039-02
	ICS	A61K031-739; C07H005-04
	INCL	514042000; 536053000; 536054000; 424234100
US 2003092643	NCL	514/042.000; 536/053.000; 536/054.000; 424/234.100
	ECLA	C07H013/06C; C07H015/04D <--
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--
US 2002048588	NCL	435/101.000; 424/278.100; 536/001.110
	ECLA	C07H015/04D <--
US 2003199460	NCL	514/042.000; 536/053.000
	ECLA	C07H013/06C; C07H015/04D

OS MARPAT 138:384134

AB Aminoalkyl glucosaminide phosphate (AGP) compds. that are adjuvants and immunoeffectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compns. and methods for using the compds. as adjuvants and immunoeffectors are also disclosed.

ST vaccine antigen tumor protein immune adjuvant aminoalkyl glucosaminide phosphate; cancer infection antigen vaccine immune adjuvant aminoalkyl glucosaminide phosphate

IT Macrophage

(activation; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Immunostimulants

(adjuvants; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Functional groups

- (aminoalkyl phosphate; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Blood serum
Mucous membrane
(antibody production; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(aqueous; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(carriers; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Immunity
(cell-mediated; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT T cell (lymphocyte)
(cytotoxic; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Glycosides
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(group; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatitis B surface; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Solutions
(isotonic, agent; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Oils
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metabolizable; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(nasal, intra-; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Cytokines
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(production; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(solns.; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Toxoids
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetanus; vaccine compns. comprising aminoalkyl glucosaminide phosphate

compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Vaccines
(tumor; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Animal
Antioxidants
Egg, poultry
Emulsions
Human
Immunomodulators
Immunostimulants
Infection
Influenza virus
Mammalia
Microparticles
Microspheres
Surfactants
Vaccines
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Ovalbumin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Antigens
Polynucleotides
Tumor antigens
Tumor antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Phosphatidylcholines, biological studies
Phosphatidylethanolamines, biological studies
Sphingomyelins
Sphingosines
Tocopherols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Antitumor agents
(vaccines; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Infection
(viral; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 125978-95-2P, Nitric oxide synthetase
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inducible; vaccine compns. comprising aminoalkyl glucosaminide

phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 10102-43-9P, Nitric oxide, biological studies
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 66-84-2 76-05-1, Trifluoroacetic acid, reactions 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 764-85-2, Nonanoyl chloride 1738-72-3, L-Serine benzyl ester 2528-61-2, Heptanoyl chloride 6791-49-7, L-Serinamide 15219-34-8, Oxalyl bromide 16357-59-8, 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl 3-oxotetradecanoate 22572-40-3, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide methiodide 28715-21-1 58577-87-0 58577-88-1 66270-36-8, 2,2,2-Trichloro-1,1-dimethylethyl chloroformate 66937-71-1, N-(2-Hydroxyethyl)glycine tert-butyl ester 105464-42-4 109977-90-4 122078-72-2 133099-79-3 134304-48-6 142982-11-4 166193-98-2 216014-70-9 216014-83-4 252042-31-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 76062-98-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P
 186383-49-3P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
 216013-10-4P 216013-11-5P 216013-12-6P 216013-13-7P 216013-14-8P
 216013-16-0P 216013-20-6P 216013-22-8P 216013-26-2P 216013-27-3P
 216013-28-4P 216013-29-5P 216013-30-8P 216013-31-9P 216013-35-3P
 216013-36-4P 216013-37-5P 216013-42-2P 216013-43-3P 216013-44-4P
 216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P
 216013-60-4P 216013-61-5P 216013-62-6P 216013-66-0P 216013-67-1P
 216013-69-3P 216013-71-7P 216013-77-3P 216013-78-4P 216013-80-8P
 216013-83-1P 216013-85-3P 216013-89-7P 216013-90-0P 216013-91-1P
 216013-92-2P 216013-93-3P 216013-98-8P 216013-99-9P 216014-00-5P
 216014-01-6P 216014-02-7P 216014-07-2P 216014-08-3P 216014-09-4P
 216014-11-8P 216014-12-9P 216014-17-4P 216014-22-1P 216014-23-2P
 216014-24-3P 216014-25-4P 216014-26-5P 216014-30-1P 216014-31-2P
 216014-32-3P 216014-33-4P 216014-34-5P 216014-38-9P 216014-40-3P
 216014-41-4P 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P
 216014-52-7P 216014-53-8P 216014-57-2P 216014-59-4P 216014-60-7P
 216014-65-2P 216014-66-3P 216014-72-1P 216014-73-2P 216014-77-6P
 216014-80-1P 216014-84-5P 216014-85-6P 216014-89-0P 216014-90-3P
 216014-93-6P 216014-94-7P 216014-99-2P 216015-00-8P 339078-53-4P
 339078-54-5P 367273-92-5P 525604-08-4P 525604-09-5P 525604-12-0P
 525604-15-3P 525604-20-0P 525604-23-3P 525604-28-8P 525604-32-4P
 525604-35-7P 525604-38-0P 525604-41-5P 525604-44-8P 525604-47-1P
 525604-50-6P 525604-53-9P 525604-56-2P 525604-59-5P 525604-62-0P
 525604-65-3P 525604-68-6P 525604-76-6P 525604-79-9P 525604-81-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 216013-09-1P 216013-19-3P 216013-47-7P 216013-65-9P 216013-73-9P
 216014-37-8P 216014-98-1P 339078-67-0P 339078-71-6P 339078-75-0P
 339078-77-2P 339079-17-3P 367273-94-7P 525604-11-9P 525604-14-2P
 525604-17-5P 525604-19-7P 525604-22-2P 525604-34-6P 525604-37-9P
 525604-40-4P 525604-43-7P 525604-46-0P 525604-49-3P 525604-52-8P
 525604-55-1P 525604-58-4P 525604-61-9P 525604-64-2P 525604-67-5P
 525604-70-0P 525604-72-2P 525604-74-4P 525604-78-8P 525604-83-5P
 525604-85-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);

USES (Uses)

(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

- IT 3416-24-8DP, 2-Deoxy-2-amino-glucose, aminoalkyl phosphate derivs.
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT 56-81-5, Glycerol, biological studies 63-89-8 83-44-3 102-71-6, Triethanolamine, biological studies 111-02-4, Squalene 121-44-8, Triethylamine, biological studies 360-65-6 998-07-2, 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine 1305-62-0, Calcium hydroxide, biological studies 7732-18-5, Water, biological studies 10103-46-5, Calcium phosphate 21645-51-2, Aluminum hydroxide, biological studies 106392-12-5, PLURONIC F 68
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT 525604-07-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (vaccine compns. comprising m p 43aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

L1 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:182118 HCAPLUS

DN 136:217004

ED Entered STN: 14 Mar 2002

TI Preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors

IN Johnson, David A.; Sowell, C. Gregory

PA Corixa Corporation, USA

SO U.S., 37 pp., Cont.-in-part of U.S. 6,113,918.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K045-00

ICS C07H001-00; C07H011-04; C07H013-02

INCL 424278100

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 15, 63

FAN.CNT 10


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355257	B1	20020312	US 1998-74720	19980507
	US 6113918	A	20000905	US 1997-853826	19970508 <--
	ES 2224397	T3	20050301	ES 1998-922138	19980507
PRAI	US 1997-853826	A2	19970508		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6355257	ICM	A61K045-00
	ICS	C07H001-00; C07H011-04; C07H013-02
	INCL	424278100
US 6355257	NCL	424/278.100; 536/001.110; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--

OS MARPAT 136:217004

GI



I

- AB Aminoalkyl glucosamine phosphate compds. I (R = substituted alkyl; R1, R2 = H, phosphono; R3, R4 = fatty acid residue; R5 = undecyl; X = O, S; Y = O, NH) were prepared as adjuvants and immunoeffectors. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosamine ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immunoeffectors are also disclosed. Thus, N-carboxymethyl-N-[(R)-3-decanoyloxytetradecanoyl]-3-aminopropyl-2-deoxy-4-O-phosphono-2-[(R)-3-decanoyloxytetradecanoylamino]-3-O-[(R)-3-decanoyloxytetradecanoyl]-β-D-glucopyranoside triethylammonium salt was prepared and tested as adjuvant and immunoeffector for anti-tetanus and anti-influenza activities.
- ST virucide vaccine aminoalkyl glucosamine phosphate prepn; cytokine prodn vaccine aminoalkyl glucosamine phosphate; vaccine antiinfluenza aminoalkyl glucosamine phosphate prepn; immunization antitetanus aminoalkyl glucosamine phosphate prepn; antitetanus IgG aminoalkyl glucosamine phosphate prepn; aminoalkyl glucosamine phosphate prepn immunoeffector adjuvant
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG, immobilized; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antiviral agents
Immunization
Vaccines
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Glycosides
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT 109361-17-3

RL: CAT (Catalyst use); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT	216013-09-1P	216013-19-3P	216013-24-0P	216013-34-2P	216013-41-1P
	216013-47-7P	216013-52-4P	216013-59-1P	216013-65-9P	216013-73-9P
	216013-82-0P	216013-88-6P	216013-97-7P	216014-06-1P	216014-15-2P
	216014-21-0P	216014-29-8P	216014-37-8P	216014-46-9P	216014-50-5P
	216014-56-1P	216014-63-0P	216014-69-6P	216014-76-5P	216014-82-3P
	216014-88-9P	216014-92-5P	216014-98-1P		

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT	76062-98-1P	87357-76-4P	91681-56-0P	122105-45-7P	122210-01-9P
	216013-02-4P	216013-03-5P	216013-05-7P	216013-06-8P	216013-07-9P
	216013-10-4P	216013-11-5P	216013-12-6P	216013-13-7P	216013-14-8P
	216013-15-9P	216013-16-0P	216013-20-6P	216013-21-7P	216013-22-8P
	216013-26-2P	216013-27-3P	216013-28-4P	216013-29-5P	216013-30-8P
	216013-31-9P	216013-32-0P	216013-35-3P	216013-36-4P	216013-37-5P
	216013-38-6P	216013-42-2P	216013-43-3P	216013-44-4P	216013-45-5P
	216013-49-9P	216013-50-2P	216013-53-5P	216013-54-6P	216013-55-7P
	216013-56-8P	216013-60-4P	216013-61-5P	216013-62-6P	216013-63-7P
	216013-66-0P	216013-67-1P	216013-69-3P	216013-70-6P	216013-71-7P
	216013-75-1P	216013-77-3P	216013-78-4P	216013-79-5P	216013-80-8P
	216013-83-1P	216013-85-3P	216013-86-4P	216013-89-7P	216013-90-0P
	216013-91-1P	216013-92-2P	216013-93-3P	216013-95-5P	216013-98-8P
	216013-99-9P	216014-00-5P	216014-01-6P	216014-02-7P	216014-04-9P
	216014-07-2P	216014-08-3P	216014-09-4P	216014-11-8P	216014-12-9P
	216014-13-0P	216014-16-3P	216014-17-4P	216014-19-6P	216014-22-1P
	216014-23-2P	216014-24-3P	216014-25-4P	216014-26-5P	216014-27-6P
	216014-30-1P	216014-31-2P	216014-32-3P	216014-33-4P	216014-34-5P
	216014-35-6P	216014-38-9P	216014-39-0P	216014-40-3P	216014-41-4P
	216014-42-5P	216014-44-7P	216014-47-0P	216014-48-1P	216014-52-7P
	216014-53-8P	216014-54-9P	216014-57-2P	216014-59-4P	216014-60-7P
	216014-61-8P	216014-65-2P	216014-66-3P	216014-67-4P	216014-72-1P
	216014-73-2P	216014-74-3P	216014-77-6P	216014-78-7P	216014-80-1P
	216014-83-4P	216014-84-5P	216014-85-6P	216014-89-0P	216014-90-3P
	216014-93-6P	216014-94-7P	216014-95-8P	216014-99-2P	216015-00-8P
	216015-01-9P				

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic

preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT	66-84-2, D-Glucosamine hydrochloride	99-73-0, 2,4'-Dibromoacetophenone
	111-64-8, Octanoyl chloride	112-13-0, Decanoyl chloride
		112-16-3, Lauroyl chloride
		112-37-8, Undecanoic acid
		112-64-1, Myristoyl chloride
	764-85-2, Nonanoyl chloride	1738-72-3, L-Serine benzyl ester
	2528-61-2, Heptanoyl chloride	22348-97-6, Methyl 3-oxotetradecanoate
	58577-87-0	65414-74-6, L-Serinamide hydrochloride
		66270-36-8
	66937-71-1	91578-89-1
		122078-72-2
		133099-79-3, D-Serine benzyl ester
	142982-11-4	166193-98-2
		216013-74-0
		216014-70-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bulusu; Cyclic Analogues of Lipid A: Synthesis and Biological Activities 1992, P3463 HCAPLUS
- (2) Eustache; Carbohydrate Research 1994, V251, P251 HCAPLUS
- (3) Ikeda; Chem Pharm Bull 1993, V41(10), P1879 HCAPLUS
- (4) Ikeda; Synthesis of Biologically Active N-Acylated L-serine Containing Glucosamine-4-Phosphate Derivatives of Lipid A 1993, P1879 HCAPLUS
- (5) Miyajima; Chem Pharm Bull 1996, V44(12), P2268
- (6) Miyajima; Lipid A and Related Compounds XXXI 1996, P2268
- (7) Shimizu; Antitumor Activity and Biological Effects of Chemically

- Synthesized Monosaccharide Analogues of Lipid A in Mice 1985, P4621 HCAPLUS
 (8) Shimizu; Biological Activities and Antitumor Effects of Synthetic Lipid A
 Analogs Linked N-Acylated Serine 1995, P425 HCAPLUS
 (9) Shimizu; Biological Activities of Chemically Synthesized N-acylated
 Serine-linked Lipid A Analog in Mice 1994, P659 HCAPLUS

L1 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:757768 HCAPLUS

DN 135:302901

ED Entered STN: 17 Oct 2001

TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants
 and immunoeffectors

IN Johnson, David A.; Sowell, C. Gregory

PA Corixa Corporation, USA

SO U.S., 44 pp., Cont.-in-part of U.S. 6,113,918.

CODEN: USXXAM

DT Patent

LA English

IC ICM C12P019-04

ICS A61K045-00; C07H001-00; C07H015-00; C07H011-04

INCL 435101000

CC 15-2 (Immunochemistry)

Section cross-reference(s): 63

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6303347	B1	20011016	US 1999-439839	19991112 <--
	US 6113918	A	20000905	US 1997-853826	19970508 <--
	ES 2224397	T3	20050301	ES 1998-922138	19980507
	CA 2391299	AA	20010517	CA 2000-2391299	20001113
	WO 2001034617	A2	20010517	WO 2000-US31340	20001113
	WO 2001034617	A3	20011108		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1230250	A2	20020814	EP 2000-982119	20001113
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000015501	A	20030225	BR 2000-15501	20001113
	JP 2003514783	T2	20030422	JP 2001-537329	20001113
	NZ 518860	A	20041126	NZ 2000-518860	20001113
	US 2002045586	A1	20020418	US 2001-808669	20010314
	US 6699846	B2	20040302		
	US 2002048588	A1	20020425	US 2001-905160	20010712 <--
	US 6764840	B2	20040720		
	AU 2001019189	A5	20010606	AU 2001-19189	20011113
	AU 773921	B2	20040610		
	US 2003092643	A1	20030515	US 2002-43086	20020108 <--
	US 2003199460	A1	20031023	US 2002-137730	20020430
	NO 2002002207	A	20020710	NO 2002-2207	20020508
PRAI	US 1997-853826	A2	19970508		
	US 1991-815250	A	19911281		
	US 1998-138305	A1	19980821		
	US 1999-429238	A	19991028		
	US 1999-439839	A	19991112		
	US 2000-190444P	P	20000317		
	WO 2000-US31340	W	20001113		
	US 2001-905160	A2	20010712		
	US 2002-43086	A2	20020108		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6303347	ICM	C12P019-04
	ICS	A61K045-00; C07H001-00; C07H015-00; C07H011-04
	INCL	435101000
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--
WO 2001034617	ECLA	C07H013/06C; C07H015/04D
US 2002045586	NCL	514/053.000; 514/054.000; 514/175.000; 536/053.000; 536/055.000; 536/055.100; 536/123.130
	ECLA	A61K031/70L15L; C07H015/04
US 2002048588	NCL	435/101.000; 424/278.100; 536/001.110
	ECLA	C07H015/04D <--
US 2003092643	NCL	514/042.000; 536/053.000; 536/054.000; 424/234.100
	ECLA	C07H013/06C; C07H015/04D <--
US 2003199460	NCL	514/042.000; 536/053.000
	ECLA	C07H013/06C; C07H015/04D

OS MARPAT 135:302901

AB Aminoalkyl glucosaminide phosphate (AGP) compds. that are adjuvants and immunoeffectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immunoeffectors are also disclosed.

ST adjuvant immunoeffector aminoalkyl glucosaminide phosphate compd

IT Immunoglobulins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (A; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunoglobulins

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses) (G1; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunoglobulins

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses) (G2a; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunoglobulins

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses) (G2b; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunoglobulins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (G; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunoglobulins

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses) (M; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Macrophage

- (activation; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
(adjuvants; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antioxidants
Egg, poultry
Emulsions
Influenza virus
Vaccines
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antibodies
Cytokines
Immunoglobulins
Ovalbumin
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antigens
Phosphatidylcholines, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Phosphatidylethanolamines, biological studies
Sphingomyelins
Sphingosines
Tocopherols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Structure-activity relationship
(antigenic; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(carriers; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT T cell (lymphocyte)
(cytotoxic; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Micelles
(dispersion; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatitis B surface; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
(immunoeffector; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(liqs., dispersions; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Cell activation
(macrophage; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(microparticles; aminoalkyl glucosaminide phosphate compds. and their

use as adjuvants and immunoeffectors)

IT Drug delivery systems
(microspheres; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunity
(mucosal; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Drug delivery systems
(nasal, intra-; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Drug delivery systems
(oily, metabolizable; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Toxoids
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetanus; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 60-18-4, L-Tyrosine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adsorbate; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 125978-95-2, Nitric oxide synthetase
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 3416-24-8D, 2-Deoxy-2-amino-D-glucose, aminoalkyl phosphate derivs.
27194-79-2D, D-Glucosamine phosphate, aminoalkyl derivs.
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 66-84-2, D-Glucosamine hydrochloride 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl chloride 1738-72-3, L-Serine benzyl ester 2528-61-2, Heptanoyl chloride 2937-50-0, Allyl chloroformate 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl 3-oxotetradecanoate 33243-33-3 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66937-71-1, N-(2-Hydroxyethyl)glycine tert-butyl ester 91578-89-1 109977-90-4 122078-72-2 133099-79-3, D-Serine benzyl ester 134304-48-6 142982-11-4 166193-98-2 216013-74-0 216013-98-8 216014-16-3 216014-22-1 216014-30-1 216014-38-9 216014-70-9 252042-31-2 339078-52-3 367273-92-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 58577-88-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P
186383-49-3P 195434-34-5P 216013-03-5P 216013-05-7P 216013-06-8P
216013-07-9P 216013-10-4P 216013-12-6P 216013-13-7P 216013-14-8P
216013-15-9P 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P
216013-26-2P 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P
216013-31-9P 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P
216013-38-6P 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P
216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P
216013-56-8P 216013-60-4P 216013-61-5P 216013-62-6P 216013-63-7P
216013-83-1P 216013-85-3P 216013-86-4P 216013-89-7P 216013-90-0P
216013-91-1P 216013-93-3P 216013-95-5P 216013-99-9P 216014-00-5P
216014-02-7P 216014-04-9P 216014-07-2P 216014-08-3P 216014-09-4P
216014-12-9P 216014-13-0P 216014-17-4P 216014-19-6P 216014-23-2P
216014-24-3P 216014-26-5P 216014-27-6P 216014-31-2P 216014-32-3P
216014-34-5P 216014-35-6P 216014-39-0P 216014-40-3P 216014-42-5P
216014-44-7P 216014-47-0P 216014-48-1P 216014-52-7P 216014-53-8P
216014-54-9P 216014-57-2P 216014-59-4P 216014-60-7P 216014-61-8P

216014-65-2P 216014-66-3P 216014-67-4P 216014-72-1P 216014-73-2P
 216014-74-3P 216014-77-6P 216014-78-7P 216014-80-1P 216014-83-4P
 216014-84-5P 216014-85-6P 216014-89-0P 216014-90-3P 216014-93-6P
 216014-94-7P 216014-95-8P 216014-99-2P 216015-00-8P 216015-01-9P
 220048-54-4P 339078-58-9P 339078-82-9P 339078-86-3P 367273-64-1P
 367273-66-3P 367273-67-4P 367273-68-5P 367273-69-6P 367273-70-9P
 367273-71-0P 367273-74-3P 367273-75-4P 367273-76-5P 367273-77-6P
 367273-78-7P 367273-79-8P 367273-82-3P 367273-83-4P 367273-86-7P
 367273-87-8P 367273-88-9P 367273-89-0P 367273-95-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 339078-83-0P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
 216013-47-7P 216013-52-4P 216013-59-1P 216013-82-0P 216013-88-6P
 216013-97-7P 216014-06-1P 216014-15-2P 216014-21-0P 216014-29-8P
 216014-37-8P 216014-46-9P 216014-50-5P 216014-56-1P 216014-63-0P
 216014-69-6P 216014-76-5P 216014-82-3P 216014-88-9P 216014-92-5P
 216014-98-1P 339078-61-4P 339078-63-6P 339078-67-0P 339078-69-2P
 339078-71-6P 339078-73-8P 339078-75-0P 339078-77-2P 339078-79-4P
 339078-81-8P 339079-17-3P 367273-73-2P 367273-81-2P 367273-91-4P
 367273-94-7P 367273-97-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT 56-81-5, Glycerol, biological studies 83-44-3 102-71-6,
 Triethanolamine, biological studies 111-02-4, Squalene 121-44-8,
 Triethylamine, biological studies 123-78-4, Sphingosine 360-65-6
 923-61-5 998-07-2, 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine
 1305-62-0, Calcium hydroxide, biological studies 7732-18-5, Water,
 biological studies 10103-46-5, Calcium phosphate 21645-51-2, Aluminum
 hydroxide, biological studies 106392-12-5D, PLURONIC F 68, block
 copolymer

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Baldrige; IBC Vaccine Conference 1998
- (2) Bulusu; J Med Chem 1992, V35(19), P3463 HCAPLUS
- (3) Eustache; Carbohydrate Research 1994, V251, P251 HCAPLUS
- (4) Ikeda; Chem Pharm Bull 1993, V41(10), P1879 HCAPLUS
- (5) Johnson; US 6113918 2000 HCAPLUS
- (6) Johnson; Bioorg Med Chem Lett 1999, V9(15), P2273 HCAPLUS
- (7) Meyers; US B14912094 1994
- (8) Miyajima; Chem Pharm Bull 1996, V44(12), P2268
- (9) Myers; US 4912094 1990 HCAPLUS
- (10) Shimizu; Chem Pharm Bull 1985, V33(10), P4621 HCAPLUS
- (11) Shimizu; Int J Immunopharmacol 1994, V16(8), P659 HCAPLUS
- (12) Shimizu; Int J Immunopharmacol 1995, V17(5), P425 HCAPLUS

L1 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:360008 HCAPLUS

DN 134:353474

ED Entered STN: 18 May 2001

TI Preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors

IN Johnson, David A.; Sowell, C. Gregory

PA Corixa Corporation, USA

SO PCT Int. Appl., 147 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 15, 34, 63

FAN.CNT 10


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034617	A2	20010517	WO 2000-US31340	20001113
	WO 2001034617	A3	20011108		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6303347	B1	20011016	US 1999-439839	19991112 <--
	CA 2391299	AA	20010517	CA 2000-2391299	20001113
	EP 1230250	A2	20020814	EP 2000-982119	20001113
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2000015501	A	20030225	BR 2000-15501	20001113
	JP 2003514783	T2	20030422	JP 2001-537329	20001113
	NZ 518860	A	20041126	NZ 2000-518860	20001113
	AU 2001019189	A5	20010606	AU 2001-19189	20011113
	AU 773921	B2	20040610		
	NO 2002002207	A	20020710	NO 2002-2207	20020508
PRAI	US 1999-439839	A	19991112		
	US 1997-853826	A2	19970508		
	WO 2000-US31340	W	20001113		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001034617	ICM	C07H
WO 2001034617	ECLA	C07H013/06C; C07H015/04D
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D <--

OS MARPAT 134:353474

GI



AB Aminoalkyl glucosaminide phosphate compds. (AGP) I were prepared wherein, X is selected from the group consisting of O and S at the axial or equatorial position; Y is selected from the group consisting of O and NH;

Q is (CH₂)_n; L is (CH₂)_m; W is (CH₂)_q; n, m, p, q are integers from 0 to 6; R is (CH₂)₁₀Me; R₁-R₃ are the same or different and are normal fatty acyl residues having from 1 to about 20 carbon atoms and where one of R₁-R₃ is optionally hydrogen; R₄ and R₅ are the same or different and are selected from the group consisting of H and methyl; R₆ and R₇ are the same or different and are selected from the group consisting of H, hydroxy, alkoxy, phosphono, phosphonoxy, sulfo, sulfoxy, amino, mercapto, cyano, nitro, formyl and carboxy, and esters and amides thereof; and R₈ and R₉ are the same or different and are selected from the group consisting of phosphono and H, and at least one of R₈ and R₉ is phosphono, that are adjuvants and immuno-effectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immuno-effectors are also disclosed. Thus, N-[(R)-3-hydroxytetradecanoyl]-O-[2-deoxy-4-O-phosphono-2-[(R)-3-dodecanoyloxytetradecanoylamino]-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-α-L-D-glucopyranosyl]-L-serine triethylammonium salt was prepared and tested in mice as adjuvants and immuno-effectors. Mice vaccinated with formalin-inactivated influenza and the AGP compds. of the subject invention mounted a protective immune response to an influenza challenge as well as produced antibody to that antigen.

- ST antiinfluenza IgG immunoeffector aminoalkyl glucosaminide phosphate prepn;
cytokine adjuvant immunoeffector antitetanus toxoid amino acid prepn
glycoside; aminoalkyl glucosaminide phosphate prepn adjuvant
immunoeffector antitetanus toxoid antibody
- IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(G1; preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)
- IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(G2a; preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)
- IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(G2b; preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)
- IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(G; preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)
- IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosaminide phosphates and their use
as adjuvants and immuno-effectors)
- IT Influenza
(anti; preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)
- IT Macrophage
(preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)
- IT Amino acids, preparation
Antibodies
Cytokines
Glycosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosaminide phosphates and their use as
adjuvants and immuno-effectors)

IT Toxoids
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (tetanus; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
 216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P 216013-82-0P
 216013-88-6P 216013-97-7P 216014-06-1P 216014-15-2P 216014-21-0P
 216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P 216014-56-1P
 216014-63-0P 216014-69-6P 216014-76-5P 216014-82-3P 216014-88-9P
 216014-92-5P 216014-98-1P 339078-59-0P 339078-61-4P 339078-63-6P
 339078-65-8P 339078-67-0P 339078-69-2P 339078-71-6P 339078-73-8P
 339078-75-0P 339078-77-2P 339078-79-4P 339078-81-8P 339078-85-2P
 339079-17-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 109361-17-3
 RL: CAT (Catalyst use); USES (Uses)
 (preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 66-84-2 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride
 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8,
 Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl
 chloride 2456-81-7, 4-Pyrrolidinopyridine 2528-61-2, Heptanoyl
 chloride 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6,
 Methyl 3-oxotetradecanoate 22572-40-3, 1-(3-Dimethylaminopropyl)-3-
 ethylcarbodiimide methiodide 58577-87-0 65414-74-6, L-Serinamide
 hydrochloride 66270-36-8, 2,2,2-Trichloro-1,1-dimethylethyl
 chloroformate 66937-71-1 109977-90-4 122078-72-2 133099-79-3,
 D-Serine benzyl ester 134304-48-6 166193-98-2 190586-91-5
 216014-70-9 339078-52-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 1738-72-3P 2524-64-3P, Diphenyl chlorophosphate 76062-98-1P
 87357-76-4P 91578-89-1P 91681-56-0P 122105-45-7P 122210-01-9P
 186383-49-3P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
 216013-10-4P 216013-12-6P 216013-13-7P 216013-14-8P 216013-15-9P
 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P 216013-26-2P
 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P 216013-31-9P
 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P 216013-38-6P
 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P 216013-53-5P
 216013-54-6P 216013-55-7P 216013-56-8P 216013-60-4P 216013-61-5P
 216013-62-6P 216013-63-7P 216013-66-0P 216013-67-1P 216013-69-3P
 216013-70-6P 216013-71-7P 216013-75-1P 216013-77-3P 216013-78-4P
 216013-79-5P 216013-80-8P 216013-83-1P 216013-85-3P 216013-89-7P
 216013-90-0P 216013-91-1P 216013-92-2P 216013-93-3P 216013-95-5P
 216013-98-8P 216013-99-9P 216014-00-5P 216014-01-6P 216014-02-7P
 216014-04-9P 216014-07-2P 216014-08-3P 216014-09-4P 216014-11-8P
 216014-12-9P 216014-13-0P 216014-16-3P 216014-17-4P 216014-19-6P
 216014-22-1P 216014-23-2P 216014-24-3P 216014-25-4P 216014-26-5P
 216014-27-6P 216014-30-1P 216014-31-2P 216014-32-3P 216014-33-4P
 216014-34-5P 216014-35-6P 216014-38-9P 216014-39-0P 216014-40-3P
 216014-41-4P 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P
 216014-52-7P 216014-53-8P 216014-54-9P 216014-57-2P 216014-59-4P
 216014-60-7P 216014-61-8P 216014-65-2P 216014-66-3P 216014-67-4P
 216014-72-1P 216014-73-2P 216014-74-3P 216014-77-6P 216014-78-7P
 216014-80-1P 216014-83-4P 216014-84-5P 216014-85-6P 216014-89-0P
 216014-90-3P 216014-93-6P 216014-94-7P 216014-95-8P 216014-99-2P
 216015-00-8P 216015-01-9P 220048-54-4P 339078-53-4P 339078-54-5P
 339078-58-9P 339078-82-9P 339078-83-0P 339078-86-3P 339078-87-4P
 339079-15-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bulusu, M; J Med Chem 1992, V35, P3463 HCAPLUS
- (2) Ikeda, K; Chem Pharm Bull 1993, V41(10), P1879 HCAPLUS
- (3) Miyajima, K; Chem Pharm Bull 1996, V44(12), P2268
- (4) Shimizu, T; Chem Pharm Bull 1985, V33(10), P4621 HCAPLUS
- (5) Shimizu, T; Int J Immunopharmac 1994, V16(8), P659 HCAPLUS
- (6) Shimizu, T; Int J Immunopharmac 1995, V17(5), P425 HCAPLUS

L1 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:745066 HCAPLUS

DN 130:14164

ED Entered STN: 24 Nov 1998

TI Preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immuno-effectors

IN Johnson, David A.; Sowell, C. Gregory

PA Ribic Immunochem Research, Inc., USA

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H015-04

ICS A61K031-70

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 15, 63

FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850399	A1	19981112	WO 1998-US9385	19980507
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6113918	A	20000905	US 1997-853826	19970508 <--
CA 2288601	AA	19981112	CA 1998-2288601	19980507
AU 9874747	A1	19981127	AU 1998-74747	19980507
AU 740663	B2	20011108		
EP 983286	A1	20000308	EP 1998-922138	19980507
EP 983286	B1	20040728		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9809791	A	20000627	BR 1998-9791	19980507
JP 2002512623	T2	20020423	JP 1998-548512	19980507
NZ 500938	A	20020531	NZ 1998-500938	19980507
AP 1181	A	20030630	AP 1999-1693	19980507
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
AT 272067	E	20040815	AT 1998-922138	19980507
PL 188046	B1	20041130	PL 1998-343205	19980507
ES 2224397	T3	20050301	ES 1998-922138	19980507
MX 9910262	A	20000831	MX 1999-10262	19991108
PRAI US 1997-853826	A	19970508		
WO 1998-US9385	W	19980507		


CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9850399	ICM	C07H015-04
	ICS	A61K031-70
WO 9850399	ECLA	C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000

Search done by Noble Jarrell

AP 1181 ECLA C07H015/04D
 OS MARPAT 130:14164 ECLA C07H015/04D
 GI

<--



- AB Aminoalkyl glucosamine phosphate compds. I (R = substituted alkyl; R1, R2 = H, phosphono; R3, R4 = fatty acid residue; R5 = undecyl; X = O, S; Y = O, NH) were prepared as adjuvants and immunoeffectors. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosamine ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immunoeffectors are also disclosed. Thus, N-carboxymethyl-N-[(R)-3-decanoyloxytetradecanoyl]-3-aminopropyl-2-deoxy-4-O-phosphono-2-[(R)-3-decanoyloxytetradecanoylamino]-3-O-[(R)-3-decanoyloxytetradecanoyl]-β-D-glucopyranoside triethylammonium salt was prepared and tested as adjuvant and immunoeffector for anti-tetanus and anti-influenza activities.
- ST virucide vaccine aminoalkyl glucosamine phosphate prepn; cytokine prodn vaccine aminoalkyl glucosamine phosphate; vaccine antiinfluenza aminoalkyl glucosamine phosphate prepn; immunization antitetanus aminoalkyl glucosamine phosphate prepn; antitetanus IgG aminoalkyl glucosamine phosphate prepn; aminoalkyl glucosamine phosphate prepn immunoeffector adjuvant
- IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (G; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
 (adjuvants; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antiviral agents
 Immunization
 Vaccines
 (preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Glycosides
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antibodies
 Cytokines
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
 216013-47-7P 216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P

216013-82-0P 216013-88-6P 216013-97-7P 216014-06-1P 216014-15-2P
 216014-21-0P 216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P
 216014-56-1P 216014-63-0P 216014-69-6P 216014-76-5P 216014-82-3P
 216014-88-9P 216014-92-5P 216014-98-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 109361-17-3

RL: CAT (Catalyst use); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 76062-98-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P

216013-02-4P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
 216013-10-4P 216013-11-5P 216013-12-6P 216013-13-7P 216013-14-8P
 216013-15-9P 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P
 216013-26-2P 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P
 216013-31-9P 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P
 216013-38-6P 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P
 216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P
 216013-56-8P 216013-60-4P 216013-61-5P 216013-62-6P 216013-63-7P
 216013-66-0P 216013-67-1P 216013-69-3P 216013-70-6P 216013-71-7P
 216013-75-1P 216013-77-3P 216013-78-4P 216013-79-5P 216013-80-8P
 216013-83-1P 216013-85-3P 216013-86-4P 216013-89-7P 216013-90-0P
 216013-91-1P 216013-92-2P 216013-93-3P 216013-95-5P 216013-98-8P
 216013-99-9P 216014-00-5P 216014-01-6P 216014-02-7P 216014-04-9P
 216014-07-2P 216014-08-3P 216014-09-4P 216014-11-8P 216014-12-9P
 216014-13-0P 216014-16-3P 216014-17-4P 216014-19-6P 216014-22-1P
 216014-23-2P 216014-24-3P 216014-25-4P 216014-26-5P 216014-27-6P
 216014-30-1P 216014-31-2P 216014-32-3P 216014-33-4P 216014-34-5P
 216014-35-6P 216014-38-9P 216014-39-0P 216014-40-3P 216014-41-4P
 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P 216014-52-7P
 216014-53-8P 216014-54-9P 216014-57-2P 216014-59-4P 216014-60-7P
 216014-61-8P 216014-65-2P 216014-66-3P 216014-67-4P 216014-72-1P
 216014-73-2P 216014-74-3P 216014-77-6P 216014-78-7P 216014-80-1P
 216014-83-4P 216014-84-5P 216014-85-6P 216014-89-0P 216014-90-3P
 216014-93-6P 216014-94-7P 216014-95-8P 216014-99-2P 216015-00-8P
 216015-01-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 66-84-2, D-Glucosamine hydrochloride 99-73-0, 2,4'-Dibromoacetophenone
 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3,
 Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl
 chloride 764-85-2, Nonanoyl chloride 1738-72-3, L-Serine benzyl ester
 2528-61-2, Heptanoyl chloride 22348-97-6, Methyl 3-oxotetradecanoate
 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66270-36-8
 66937-71-1 91578-89-1 122078-72-2 133099-79-3, D-Serine benzyl ester
 142982-11-4 166193-98-2 216013-74-0 216014-70-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Eustache, J; Carbohydrate Research 1994, V251, P251 HCAPLUS
- (2) Ikeda, K; Chemical and Pharmaceutical Bulletin 1993, V41(10), P1879 HCAPLUS
- (3) Miyajima, K; Chemical and Pharmaceutical Bulletin 1996, V44(12), P2268

=> b wpix

FILE 'WPIX' ENTERED AT 06:42:29 ON 05 AUG 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

Search done by Noble Jarrell

FILE LAST UPDATED: 2 AUG 2005 <20050802/UP>
 MOST RECENT DERWENT UPDATE: 200549 <200549/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:

<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV.

FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.

PLEASE CHECK:

<http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/>
 FOR DETAILS. <<<

'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all l4 tot

L4 ANSWER 1 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-801176 [75] WPIX

CR 1998-610316 [51]; 2001-355479 [37]; 2002-380932 [41]; 2002-655177 [70];
 2004-051328 [05]

DNC C2003-221153

TI Aminoalkyl glucosaminide phosphate compounds useful for treating cancer,
 or useful as adjuvants and immunoeffectors.

DC A96 B03 B04 D16

IN JOHNSON, D A; SOWELL, C G

PA (CORI-N) CORIXA CORP

CYC 1

PI US 2003092643 A1 20030515 (200375)* 60 A61K039-02 <--

ADT US 2003092643 A1 CIP of US 1997-853826 19970508, Cont of US 1999-439839
 19991112, CIP of US 2001-905160 20010712, US 2002-43086 20020108

FDT US 2003092643 A1 CIP of US 6113918, Cont of US 6303347

PRAI US 2002-43086 20020108; US 1997-853826 19970508;

US 1999-439839 19991112; US 2001-905160 20010712

IC ICM A61K039-02

ICS A61K031-739; C07H005-04

AB US2003092643 A UPAB: 20040120

NOVELTY - An immunoeffector compound (I) comprising aminoalkyl
 glucosaminide phosphate is new.

DETAILED DESCRIPTION - Immunoeffector compound having the structure
 (I) is new.

X = O or S;

Y = O or NH;

n, m, p, q = 0-6;

R1, R2, R3 = normal fatty acyl residues having 1-20C and where one
 of R1, R2 or R3 is option- ally hydrogen, which are same or different;

R4, R5 = H and methyl, which are same or different;

R6, R7 = H, hydroxy, alkoxy, phosphono, phosphonooxy, sulfo,
 sulfooxy, amino, mercap- to, cyano, nitro, formyl and carboxy, and esters
 and its amides, which are same or different; and

R8 and R9 = H and phosphono, which are same or different, and at
 least one of R8 and R9 is phosphono.

INDEPENDENT CLAIMS are also included for the following:

(1) an immunogenic composition comprising (I), an antigen and a

suitable carrier;

- (2) a pharmaceutical composition (C1) comprising (I) and a carrier;
- (3) a composition (C2) comprising (I) and or more peptide; and
- (4) a composition (C3) comprising (I) and one or more polynucleotide.

ACTIVITY - Virucide.

The virucide effect of 2-((R)-3-Tetradecanoyloxytetradecanoylamino)ethyl 2-deoxy-4-O-3-phosphono-3-O-((R)-3-tetradecanoyloxytetradecanoyl)-2-((R)-3-tetradecanoyloxytetradecanoylamino) beta -D-glucopyranoside (B19) was as follows. Mice were administered with hepatitis B surface antigen (HBsAg) intranasally with B19 which produced serum IgG and IgA titers to that antigen. Secretory IgA was detected in vaginal washes and the induction of a cytotoxic T-lymphocyte response was detected by cytotoxicity assay. Groups of BALB/c mice were given a primary immunization intranasally with 2.5 micro g HBsAg+10 micro g AGP-AF in a volume of 20 micro l. AGP-AF was prepared. Twenty-one days later mice were given a secondary immunization of 7.5 micro g HBsAg+10 micro g AGP-AF intranasally in 20 micro l volume. A tertiary immunization identical in composition to the secondary immunization was administered 28 days after the secondary immunization. Assays were conducted to detect cytotoxic T-lymphocyte activity at 16 days post secondary immunization and 8 days post tertiary immunization. Serum and mucosal antibody titers were assessed at 22 days post secondary immunization and 21 days post tertiary immunization. Antibody assays were conducted by standard enzyme linked immunosorbent assay (ELISA) methods. Cytotoxicity assays were conducted and better results were displayed for B19.

MECHANISM OF ACTION - Stimulator of immune response (claimed).

USE - (C1) is useful for enhancing immune response of a mammal. (III) or (IV) is useful for eliciting an immune response in a mammal (human), which involves administering (III) or (IV). The immune response is immuno protective (claimed).

DESCRIPTION OF DRAWING(S) - The figure shows the graph depicting the percentage of human subjects achieving seroprotection by hepatitis B surface antigen (AgB) alone or in combination with the aminoalkyl glucosaminide phosphate (AGP).

Dwg.1/4

FS CPI

FA AB; GI; DCN

MC CPI: A12-V01; B01-D02; B04-B01B; B04-C01; B04-E02F; B04-E03F; B05-B01P; B06-A01; B07-A02B; B10-B03B; B10-B04B; B10-J02; B14-A02; B14-G01; D05-H12

L4 ANSWER 2 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2002-655177 [70] WPIX

CR 1998-610316 [51]; 2001-355479 [37]; 2002-380932 [41]; 2003-801176 [75]; 2004-051328 [05]

DNC C2002-183971

TI New Aminoalkyl glucoaminide phosphate derivatives, useful for enhancing immune response and in vaccines.

DC B03

IN JOHNSON, D A; SOWELL, C G

PA (JOHN-I) JOHNSON D A; (SOWE-I) SOWELL C G; (CORI-N) CORIXA CORP

CYC 1

PI US 2002048588 A1 20020425 (200270)* 45 A61K031-70 <--

US 6764840 B2 20040720 (200448) C12P019-04 <--

ADT US 2002048588 A1 CIP of US 1997-853826 19970508, Cont of US 1999-439849 19991112, US 2001-905160 20010712; US 6764840 B2 CIP of US 1997-853826 19970508, Cont of US 1999-439849 19991112, US 2001-905160 20010712

FDT US 2002048588 A1 CIP of US 6113918; US 6764840 B2 CIP of US 6113918

PRAI US 1999-439849 19991112; US 1997-853826 19970508;

US 2001-905160 20010712

IC ICM A61K031-70; C12P019-04

ICS A61K039-00; A61K047-00; C07H001-00; C07H005-04

AB US2002048588 A UPAB: 20040728

NOVELTY - Aminoalkyl glucoaminide phosphate compounds are new.

DETAILED DESCRIPTION - Aminoalkyl glucoaminide phosphate compounds of formula (I) are new.

X = O or S at the axial or equatorial position;
 Y = O or NH;
 m, n, p, q = 0 to 6;
 R1, R2, R3 = 1-20C fatty acyl residues and one is optionally H;
 R4, R5 = H or Me;
 R6, R7 = H, OH, alkoxy, phosphono, phosphonoxy, sulfo, sulfoxy,
 NH2, SH, CN, NO2, CHO, COOH, esters or amides;
 R8, R9 = phosphono or H, provided that at least one is phosphono.
 INDEPENDENT CLAIMS are included for:
 (1) a method for enhancing immune response comprising administration
 of (I);
 (2) a vaccine composition comprising (I), an antigen and a carrier;
 and
 (3) compositions comprising (I).

ACTIVITY - Immunostimulant.

USE - Compounds (I) are useful for enhancing immune response and in
 can be used in the form of a vaccine.

Dwg.0/0

FS CPI
 FA AB; GI; DCN
 MC CPI: B04-B01B; B05-B01M; B14-G01; B14-S11

L4 ANSWER 3 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2001-355479 [37] WPIX

CR 1998-610316 [51]; 2002-380932 [41]; 2002-655177 [70]; 2003-801176 [75];
 2004-051328 [05]

DNC C2001-110191

TI Aminoalkyl glucosaminide phosphate compounds useful as immunoeffectors for
 augmenting antibody production, stimulating cytokine production and
 activating macrophages.

DC B03

IN JOHNSON, D A; SOWELL, C G; SOWELL, G C

PA (CORI-N) CORIXA CORP

CYC 95

PI WO 2001034617 A2 20010517 (200137)* EN 174 C07H000-00
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2001019189 A 20010606 (200152)

US 6303347 B1 20011016 (200164)

C12P019-04 <--

NO 2002002207 A 20020710 (200258)

C07H000-00

EP 1230250 A2 20020814 (200261) EN

C07H013-06

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT

RO SE SI TR

BR 2000015501 A 20030225 (200320)

C07H013-06

JP 2003514783 W 20030422 (200336)

190

C07H015-04

CN 1409720 A 20030409 (200345)

C07H013-06

MX 2002004774 A1 20030101 (200373)

C07H000-00000

AU 773921 B2 20040610 (200467)

C07H013-06

NZ 518860 A 20041126 (200479)

C07H015-04

ADT WO 2001034617 A2 WO 2000-US31340 20001113; AU 2001019189 A AU 2001-19189
 20001113; US 6303347 B1 CIP of US 1997-853826 19970508, US 1999-439839
 19991112; NO 2002002207 A WO 2000-US31340 20001113, NO 2002-2207 20020508;
 EP 1230250 A2 EP 2000-982119 20001113, WO 2000-US31340 20001113; BR
 2000015501 A BR 2000-15501 20001113, WO 2000-US31340 20001113; JP
 2003514783 W WO 2000-US31340 20001113, JP 2001-537329 20001113; CN 1409720
 A CN 2000-816859 20001113; MX 2002004774 A1 WO 2000-US31340 20001113, MX
 2002-4774 20020510; AU 773921 B2 Div ex AU 1998-74747 19980507, AU
 2001-19189 20001113; NZ 518860 A NZ 2000-518860 20001113, WO 2000-US31340
 20001113

FDT AU 2001019189 A Based on WO 2001034617; US 6303347 B1 CIP of US 6113918;
 EP 1230250 A2 Based on WO 2001034617; BR 2000015501 A Based on WO
 2001034617; JP 2003514783 W Based on WO 2001034617; MX 2002004774 A1 Based

on WO 2001034617; AU 773921 B2 Previous Publ. AU 2001019189, Based on WO 2001034617; NZ 518860 A Based on WO 2001034617

PRAI US 1999-439839 19991112; US 1997-853826 19970508

IC ICM C07H000-00; C07H000-00000; C07H013-06; C07H015-04; C12P019-04
ICS A61K009-127; A61K031-7028; A61K039-00; A61K039-39; A61K045-00;
A61K047-02; A61K047-06; A61K047-10; A61K047-18; A61K047-22;
A61K047-24; A61K047-26; A61K047-34; A61P037-02; A61P037-04;
A61P043-00; C07H001-00; C07H011-04; C07H015-00; C07H015-14

AB WO 200134617 A UPAB: 20041208

NOVELTY - Aminoalkyl glucosaminide phosphate compounds (I), are new.

DETAILED DESCRIPTION - Aminoalkyl glucosaminide phosphate compounds of formula (I) are new.

X = O or S;

Y = O or NH;

n,m,p,q = 0-6:

R1-R3 = 1-20C fatty acid residue where one of R1-R3 is optionally H;

R4, R5 = H or methyl;

R6, R7 = H, OH, alkoxy, phosphono, phosphonoxy, sulfo, sulfoxy, amino, mercapto, CN, nitro, formyl, carboxyl or their esters or amides; and

R8, R9 = H or phosphono, provided that one of R8 and R9 is phosphono;

INDEPENDENT CLAIMS are also included for the following:

(a) a vaccine composition comprising (I), an antigen and a carrier;
(b) a composition (II) comprising (I) and a carrier (III); and
(c) a method for enhancing the immune response of a mammal by administering (I).

ACTIVITY - Immunoeffectors.

(I) were evaluated for inducible nitric oxide synthetase activity (NOS ED50) which correlates with macrophage activation which is an indication of immune stimulation. Mouse peritoneal exudates cells were harvested and the adherent cell population was isolated. The adherent cells were exposed to varying concentrations of (I) and the resulting induction and secretion of nitrite was measured. The NOS ED50 values represent a concentration of (I) required to stimulate half the maximum amount of nitrite release and correspond to the concentration required to stimulate macrophages. N-((R)-3-decanoyloxytetradecanoyl)-O-(2-deoxy-4-O-phosphono-2-((R)-3-decanoyloxytetradecanoylamino)-3-O-((R)-3-decanoyloxytetradecanoyl)-beta-D-glucopyranosyl)-L-serine triethylammonium salt (Ia) had an ED50 value of 0.06 nanograms/ml.

MECHANISM OF ACTION - None given.

USE - (I) are useful as immunoeffectors for enhancing antibody production in immunized animals, stimulating cytokine production and activating macrophages. They also stimulate a cell-mediated immune response including a cytotoxic T-lymphocyte response.

ADVANTAGE - (I) are effective and safe adjuvants potentiating both a humoral and cellular immune response. Prior art adjuvants such as alum have side effects and enhances humoral immunity only. Other prior art compounds often display toxic properties, are unstable and/or have unsubstantial immunostimulatory effects.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B01-D02; B04-B04C; B05-B01M; B05-B01P; B10-B04B; B14-G01

L4 ANSWER 4 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1998-610316 [51] WPIX

CR 2001-355479 [37]; 2002-380932 [41]; 2002-655177 [70]; 2003-801176 [75];
2004-051328 [05]

DNC C1998-183001

TI New amino-alkyl glucosamine phosphate compounds - useful for augmenting antibody production in immunised animals, stimulating cytokine production and activating macrophages.

DC B03

IN JOHNSON, D A; SOWELL, C G; JOHNSON, A; SOWELL, G

PA (CORI-N) CORIXA CORP; (RIBI-N) RIBI IMMUNOCHEM RES INC

CYC 74

PI WO 9850399 A1 19981112 (199851)* EN 140 C07H015-04
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KP KR LC LK
 LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA UZ VN YU ZW
 AU 9874747 A 19981127 (199915) C07H015-04
 EP 983286 A1 20000308 (200017) EN C07H015-04
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 BR 9809791 A 20000627 (200039) C07H015-04
 US 6113918 A 20000905 (200044) A61K045-00 <--
 CN 1265112 A 20000830 (200059) C07H015-04
 HU 2000004147 A2 20010428 (200131) C07H015-04
 MX 9910262 A1 20000801 (200137) C07H015-04
 KR 2001012333 A 20010215 (200154) C07H015-04
 AU 740663 B 20011108 (200176) C07H015-04
 JP 2002512623 W 20020423 (200243) 145 C07H015-04
 NZ 500938 A 20020531 (200246) C07H015-04
 EP 983286 B1 20040728 (200452) EN C07H015-04
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 DE 69825271 E 20040902 (200457) C07H015-04
 ES 2224397 T3 20050301 (200519) C07H015-04
 DE 69825271 T2 20050728 (200549) C07H015-04

ADT WO 9850399 A1 WO 1998-US9385 19980507; AU 9874747 A AU 1998-74747
 19980507; EP 983286 A1 EP 1998-922138 19980507, WO 1998-US9385 19980507;
 BR 9809791 A BR 1998-9791 19980507, WO 1998-US9385 19980507; US 6113918 A
 US 1997-853826 19970508; CN 1265112 A CN 1998-806169 19980507; HU
 2000004147 A2 WO 1998-US9385 19980507, HU 2000-4147 19980507; MX 9910262
 A1 MX 1999-10262 19991108; KR 2001012333 A KR 1999-710285 19991106; AU
 740663 B AU 1998-74747 19980507; JP 2002512623 W JP 1998-548512 19980507,
 WO 1998-US9385 19980507; NZ 500938 A NZ 1998-500938 19980507, WO
 1998-US9385 19980507; EP 983286 B1 EP 1998-922138 19980507, WO 1998-US9385
 19980507; DE 69825271 E DE 1998-625271 19980507, EP 1998-922138 19980507,
 WO 1998-US9385 19980507; ES 2224397 T3 EP 1998-922138 19980507; DE
 69825271 T2 DE 1998-625271 19980507, EP 1998-922138 19980507, WO
 1998-US9385 19980507

FDT AU 9874747 A Based on WO 9850399; EP 983286 A1 Based on WO 9850399; BR
 9809791 A Based on WO 9850399; HU 2000004147 A2 Based on WO 9850399; AU
 740663 B Previous Publ. AU 9874747, Based on WO 9850399; JP 2002512623 W
 Based on WO 9850399; NZ 500938 A Based on WO 9850399; EP 983286 B1 Based
 on WO 9850399; DE 69825271 E Based on EP 983286, Based on WO 9850399; ES
 2224397 T3 Based on EP 983286; DE 69825271 T2 Based on EP 983286, Based on
 WO 9850399

PRAI US 1997-853826 19970508

IC ICM A61K045-00; C07H015-04
 ICS A61K031-70; A61K031-7028; A61K039-39; A61P037-04; C07H001-00;
 C07H011-04; C07H015-00; C07H015-14

AB WO 9850399 A UPAB: 20050802
 Aminoalkyl glucosamine phosphate compounds of formula (I) are new. X = O
 or S; Y = O or NH; n, m, p, q = 0-6; R1-R3 = 7-16C normal fatty acyl
 residues; R4, R5 = H or Me; R6, R7 = H, OH, alkoxy, phosphono,
 phosphonooxy, sulpo, sulphoxy, NH2, SH, CN, NO2, formyl or carboxy (or
 their esters or amides); R8, R9 = H or phosphono, but not both H.
 USE - (I) are immuno-effector molecules which augment antibody
 production in immunised animals, stimulate cytokine production and
 activate macrophages. They are used for enhancing immune response
 (claimed), i. e. as adjuvants. Vaccines and pharmaceutical compositions
 containing (I) are claimed.
 ADVANTAGE - (I) have potent immuno-modulating effects, and can
 improve the efficacy and safety of existing vaccines or provide synthetic
 peptide or carbohydrate antigens with sufficient antigenicity for use in
 vaccines.
 Dwg.0/0

FS CPI
 FA AB; GI; DCN
 MC CPI: B04-G01; B05-B01E; B05-B01M; B14-G01

=> b home

FILE 'HOME' ENTERED AT 06:42:38 ON 05 AUG 2005

=>

=> d his full

(FILE 'HOME' ENTERED AT 06:39:27 ON 05 AUG 2005)

FILE 'HCAPLUS' ENTERED AT 06:39:34 ON 05 AUG 2005

L1 6 SEA ABB=ON PLU=ON (US2003092643 OR US6764840 OR US2002048588
OR US6303347 OR US6113918)/PN

FILE 'REGISTRY' ENTERED AT 06:41:28 ON 05 AUG 2005

FILE 'HCAPLUS' ENTERED AT 06:41:30 ON 05 AUG 2005

L2 TRA L1 1- RN : 313 TERMS

FILE 'REGISTRY' ENTERED AT 06:41:31 ON 05 AUG 2005

L3 313 SEA ABB=ON PLU=ON L2

FILE 'WPIX' ENTERED AT 06:41:39 ON 05 AUG 2005

L4 4 SEA ABB=ON PLU=ON (US2003092643 OR US6764840 OR US2002048588
OR US6303347 OR US6113918)/PN

FILE 'REGISTRY' ENTERED AT 07:39:44 ON 05 AUG 2005

L5 STR

L6 6 SEA SSS SAM L5

L7 125 SEA SSS FUL L5
SAV TEM LE086F0/A L7

L8 37 SEA ABB=ON PLU=ON L7 AND L3

L9 14 SEA ABB=ON PLU=ON C69H127N2O19P OR C75H139N2O19P OR C81H151N2
O19P OR C87H163N2O19P

L10 26 SEA ABB=ON PLU=ON C93H175N2O19P OR C77H143N2O19P OR C73H135N2
O19P

L11 38 SEA ABB=ON PLU=ON (L9 OR L10) AND L7

L12 STR L5

L13 4 SEA SUB=L7 SSS SAM L12

L14 63 SEA SUB=L7 SSS FUL L12

L15 38 SEA ABB=ON PLU=ON L14 AND L11

L16 25 SEA ABB=ON PLU=ON L14 NOT L15

FILE 'HCAPLUS' ENTERED AT 08:36:00 ON 05 AUG 2005

E JONHSON D/AU

E JOHNSON D/AU

L17 596 SEA ABB=ON PLU=ON ("JOHNSON D"/AU OR "JOHNSON D A"/AU OR
"JOHNSON D A G"/AU OR "JOHNSON D A W"/AU OR "JOHNSON D ALAN
E"/AU)

E JOHNSON DAV/AU

L18 13 SEA ABB=ON PLU=ON "JOHNSON DAVE"/AU

E JOHNSON DAVID/AU

L19 556 SEA ABB=ON PLU=ON ("JOHNSON DAVID"/AU OR "JOHNSON DAVID
A"/AU OR "JOHNSON DAVID A G"/AU OR "JOHNSON DAVID AARON"/AU OR
"JOHNSON DAVID ALAN"/AU OR "JOHNSON DAVID ALEXANDER"/AU OR
"JOHNSON DAVID ALFRED"/AU OR "JOHNSON DAVID ALLAN"/AU OR
"JOHNSON DAVID ANDREW"/AU OR "JOHNSON DAVID ANTHONY"/AU OR
"JOHNSON DAVID ARTHUR"/AU)

E SOWELL G/AU

L20 13 SEA ABB=ON PLU=ON ("SOWELL G A"/AU OR "SOWELL GLENN ALLEN"/AU
OR "SOWELL GREG"/AU OR "SOWELL GREGORY"/AU)

E SOWELL C/AU

L21 28 SEA ABB=ON PLU=ON ("SOWELL C G"/AU OR "SOWELL C GREGORY"/AU
OR "SOWELL CHARLES GREGORY"/AU OR "SOWELL CHARLES L"/AU)

E CORIXA/CS, PA

L22 476 SEA ABB=ON PLU=ON CORIXA/CS, PA

L23 14 SEA ABB=ON PLU=ON L16

L24 18 SEA ABB=ON PLU=ON L11

L25 14 SEA ABB=ON PLU=ON L23 AND (L17 OR L18 OR L19 OR L20 OR L21
OR L22)

L26 18 SEA ABB=ON PLU=ON L24 AND (L17 OR L18 OR L19 OR L20 OR L21
OR L22)

Search done by Noble Jarrell

FILE 'USPATFULL, USPAT2' ENTERED AT 08:38:55 ON 05 AUG 2005

```

L27      10 SEA ABB=ON  PLU=ON  L16
L28      11 SEA ABB=ON  PLU=ON  L11
          E JOHNSON D/AU
L29      1 SEA ABB=ON  PLU=ON  "JOHNSON D ALAN E"/AU
          E JOHNSON DAV/AU
L30      243 SEA ABB=ON  PLU=ON  ("JOHNSON DAVE"/AU OR "JOHNSON DAVID"/AU
          OR "JOHNSON DAVID A"/AU OR "JOHNSON DAVID ALAN"/AU OR "JOHNSON
          DAVID ALLAN"/AU OR "JOHNSON DAVID ANDREW"/AU OR "JOHNSON DAVID
          AUGUST"/AU)
          E SOWELL/AU
L31      23 SEA ABB=ON  PLU=ON  ("SOWELL C GREGORY"/AU OR "SOWELL GREG"/AU)
L32      255 SEA ABB=ON  PLU=ON  CORIXA/CS,PA
L33      10 SEA ABB=ON  PLU=ON  L27 AND (L29 OR L30 OR L31 OR L32)
L34      11 SEA ABB=ON  PLU=ON  L28 AND (L29 OR L30 OR L31 OR L32)

```

FILE 'HCAOLD' ENTERED AT 08:40:37 ON 05 AUG 2005

```

L35      0 SEA ABB=ON  PLU=ON  L16
L36      0 SEA ABB=ON  PLU=ON  L11

```

FILE 'HCAPLUS' ENTERED AT 08:40:55 ON 05 AUG 2005

```

L37      19 SEA ABB=ON  PLU=ON  (L25 OR L26)

```

FILE 'USPATFULL, USPAT2' ENTERED AT 08:41:00 ON 05 AUG 2005

```

L38      12 SEA ABB=ON  PLU=ON  (L33 OR L34)

```

=> b reg

FILE 'REGISTRY' ENTERED AT 08:42:59 ON 05 AUG 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 4 AUG 2005 HIGHEST RN 858414-27-4
 DICTIONARY FILE UPDATES: 4 AUG 2005 HIGHEST RN 858414-27-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```

*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****


```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que sta l7
 L5 STR

Search done by Noble Jarrell



VAR G1=OH/CO2H/43

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L7 125 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 753 ITERATIONS

125 ANSWERS

SEARCH TIME: 00.00.02

=> d ide l11 tot

L11 ANSWER 1 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN

RN 566170-30-7 REGISTRY

ED Entered STN: 14 Aug 2003

CN L-Serine, O-~~[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)~~

FS STEREOSEARCH

MF C73 H135 N2 O19 P . C6 H15 N

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 566170-29-4

CMF C73 H135 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 2 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN

RN 566170-29-4 REGISTRY

ED Entered STN: 14 Aug 2003

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN CRX 570

FS STEREOSEARCH

DR 854921-06-5


MF C73 H135 N2 O19 P

CI COM

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.




3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 3 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 566170-28-3 REGISTRY
 ED Entered STN: 14 Aug 2003
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono- β -D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-, compd. with
 N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C77 H143 N2 O19 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 566170-27-2
 CMF C77 H143 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8
 CMF C6 H15 N

Search done by Noble Jarrell




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 4 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 566170-27-2 REGISTRY
ED Entered STN: 14 Aug 2003
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]- (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN CRX 569
FS STEREOSEARCH
DR 854920-86-8
MF C77 H143 N2 O19 P
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L11 ANSWER 5 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 566170-26-1 REGISTRY
ED Entered STN: 14 Aug 2003
CN L-Serine, O-[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-
O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C73 H135 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 362594-92-1
CMF C73 H135 N2 O19 P

Search done by Noble Jarrell


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L11 ANSWER 6 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 566170-25-0 REGISTRY
ED Entered STN: 14 Aug 2003
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C73 H135 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 362594-91-0

CMF C73 H135 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 7 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN

RN 566170-24-9 REGISTRY

ED Entered STN: 14 Aug 2003

CN L-Serine, O-[2-deoxy-2-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C77 H143 N2 O19 P . C6 H15 N

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 362594-90-9

CMF C77 H143 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L11 ANSWER 8 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 566170-23-8 REGISTRY
 ED Entered STN: 14 Aug 2003
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with
 N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C77 H143 N2 O19 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 566170-22-7

CMF C77 H143 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 9 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 566170-22-7 REGISTRY
 ED Entered STN: 14 Aug 2003
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
 [[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN CRX 565
 FS STEREOSEARCH
 DR 854920-84-6
 MF C77 H143 N2 O19 P
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 10 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 376394-26-2 REGISTRY
 ED Entered STN: 18 Dec 2001
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-, compd. with
 N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)


OTHER NAMES:

CN RC 526
 FS STEREOSEARCH
 MF C69 H127 N2 O19 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, TOXCENTER,
 USPAT2, USPATFULL

CM 1

CRN 245515-64-4
 CMF C69 H127 N2 O19 P

Absolute stereochemistry.




CM 2

CRN 121-44-8

Search done by Noble Jarrell

CMF C6 H15 N




4 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 11 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 362594-92-1 REGISTRY
 ED Entered STN: 17 Oct 2001
 CN L-Serine, O-[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CRX 567
 FS STEREOSEARCH
 DR 854921-05-4
 MF C73 H135 N2 O19 P
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 12 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 362594-91-0 REGISTRY
 ED Entered STN: 17 Oct 2001
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN CRX 568
 FS STEREOSEARCH
 DR 854921-04-3
 MF C73 H135 N2 O19 P
 CI COM

Search done by Noble Jarrell

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 13 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 362594-90-9 REGISTRY
ED Entered STN: 17 Oct 2001
CN L-Serine, O-[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CRX 566
FS STEREOSEARCH
DR 854918-95-9
MF C77 H143 N2 O19 P
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



Search done by Noble Jarrell

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L11 ANSWER 14 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 339079-17-3 REGISTRY
ED Entered STN: 31 May 2001
CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxodecyl]oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C77 H143 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 339079-16-2

CMF C77 H143 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N




4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 15 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 339079-16-2 REGISTRY
ED Entered STN: 31 May 2001
CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxodecyl]oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C77 H143 N2 O19 P

Search done by Noble Jarrell

CI COM
SR CA

Absolute stereochemistry.




L11 ANSWER 16 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-77-2 REGISTRY
 ED Entered STN: 31 May 2001
 CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C73 H135 N2 O19 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 339078-76-1

CMF C73 H135 N2 O19 P

Absolute stereochemistry.



CM 2

Search done by Noble Jarrell

$$\begin{array}{c} \text{Et} \\ | \\ \text{Et}-\text{N}-\text{Et} \end{array}$$


```
L11 ANSWER 17 OF 38  REGISTRY  COPYRIGHT 2005 ACS on STN
RN 339078-76-1  REGISTRY
ED Entered STN: 31 May 2001
CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-
[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-
oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono- $\alpha$ -D-
glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C73 H135 N2 O19 P
CI COM
SR CA
```

[illegible]

CM 1

Search done by Noble Jarrell


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N




4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 19 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-74-9 REGISTRY
 ED Entered STN: 31 May 2001
 CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono-α-D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C73 H135 N2 O19 P
 CI COM
 SR CA

Absolute stereochemistry.




L11 ANSWER 20 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-73-8 REGISTRY
 ED Entered STN: 31 May 2001
 CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxodecyl]oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C73 H135 N2 O19 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1


CRN 339078-72-7
 CMF C73 H135 N2 O19 P

Absolute stereochemistry.



CM 2


CRN 121-44-8
 CMF C6 H15 N



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 21 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 339078-72-7 REGISTRY
ED Entered STN: 31 May 2001
CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C73 H135 N2 O19 P
CI COM
SR CA

Absolute stereochemistry.




L11 ANSWER 22 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 339078-71-6 REGISTRY
ED Entered STN: 31 May 2001
CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C77 H143 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 339078-70-5
CMF C77 H143 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N




4 REFERENCES IN FILE CA (1907 TO DATE).

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 23 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-70-5 REGISTRY
 ED Entered STN: 31 May 2001
 CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxodecyl]oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxodecyl]oxy]tetradecyl]amino]-4-O-phosphono-α-D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C77 H143 N2 O19 P
 CI COM
 SR CA

Absolute stereochemistry.




L11 ANSWER 24 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-69-2 REGISTRY
 ED Entered STN: 31 May 2001
 CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C77 H143 N2 O19 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 339078-68-1

CMF C77 H143 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8


CMF C6 H15 N



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 25 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 339078-68-1 REGISTRY
ED Entered STN: 31 May 2001
CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C77 H143 N2 O19 P
CI COM
SR CA

Absolute stereochemistry.




L11 ANSWER 26 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 339078-67-0 REGISTRY
ED Entered STN: 31 May 2001
CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C69 H127 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 339078-66-9
CMF C69 H127 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N




4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 27 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-66-9 REGISTRY
 ED Entered STN: 31 May 2001
 CN Hexanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[[1-oxohexyl]oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C69 H127 N2 O19 P
 CI COM
 SR CA

Absolute stereochemistry.




L11 ANSWER 28 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 245515-64-4 REGISTRY
 ED Entered STN: 29 Oct 1999
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN CRX 526
 FS STEREOSEARCH
 DR 854916-69-1
 MF C69 H127 N2 O19 P
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, PROUSDDR, TOXCENTER

Absolute stereochemistry.



6 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L11 ANSWER 29 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 216014-29-8 REGISTRY
 ED Entered STN: 23 Dec 1998
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxooctyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxooctyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-

Search done by Noble Jarrell

OTHER NAMES:

CM 1

Absolute stereochemistry.



CM 2


$$\begin{array}{c} \text{Et} \\ | \\ \text{Et}-\text{N}-\text{Et} \end{array}$$

L11 ANSWER 30 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216014-28-7 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O- [2-deoxy-3-O- [(3R)-1-oxo-3- [(1-oxooctyl)oxy]tetradecyl]-2-
[[(3R)-1-oxo-3- [(1-oxooctyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N- [(3R)-1-oxo-3- [(1-oxooctyl)oxy]tetradecyl]- (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN CRX 555
FS STEREOSEARCH
DR 854917-96-7
MF C75 H139 N2 O19 P
CI .COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 31 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216014-15-2 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)


OTHER NAMES:

CN RC 527
FS STEREOSEARCH
DR 376394-30-8
MF C81 H151 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE,
TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 216014-14-1
CMF C81 H151 N2 O19 P

Absolute stereochemistry.




Search done by Noble Jarrell

CM 2

CRN 121-44-8

CMF C6 H15 N




11 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 32 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 216014-14-1 REGISTRY
 ED Entered STN: 23 Dec 1998
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN CRX 527
 FS STEREOSEARCH
 DR 854918-07-3
 MF C81 H151 N2 O19 P
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 33 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 216014-06-1 REGISTRY
 ED Entered STN: 23 Dec 1998
 CN D-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with
 N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C81 H151 N2 O19 P . C6 H15 N


Search done by Noble Jarrell

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1


CRN 216014-05-0
CMF C81 H151 N2 O19 P

Absolute stereochemistry.



CM 2


CRN 121-44-8
CMF C6 H15 N



6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 34 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216014-05-0 REGISTRY
ED Entered STN: 23 Dec 1998
CN D-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]- (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C81 H151 N2 O19 P
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



```
L11 ANSWER 35 OF 38  REGISTRY  COPYRIGHT 2005 ACS on STN
RN 216013-88-6  REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]-2-
  [[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
  glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]-, compd.
  with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
```

CN RC 560
FS STEREOSEARCH
DR 376394-32-0
MF C87 H163 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, PROUSSDDR, TOXCENTER, USPAT2, USPATFULL


CRN 216013-87-5
CMF C87 H163 N2 O19 P

The chemical structure shows a central six-membered ring with the following substituents:

- Top-left:** A long alkyl chain $\text{Me}-(\text{CH}_2)_{10}-$ connected to an oxygen atom, which is part of an ester linkage to a CH_2 group. This CH_2 group is further connected to a carbonyl group ($\text{C}=\text{O}$).
- Top-right:** A nitrogen atom (NH) is attached to the ring. It is part of an amide linkage to a CH_2 group, which is connected to a carbonyl group ($\text{C}=\text{O}$). This carbonyl is further connected to a CH_2 group, which is connected to a phosphorus atom (P). The phosphorus atom is also connected to a long alkyl chain $(\text{CH}_2)_{10}-\text{Me}$.
- Right:** A hydroxyl group (OH) is attached to the ring via an oxygen atom.
- Bottom-right:** A phosphate group (OPO_3H_2) is attached to the ring via an oxygen atom.
- Bottom-left:** A long alkyl chain $\text{Me}-(\text{CH}_2)_{10}-$ is connected to an oxygen atom, which is part of an ester linkage to a CH_2 group. This CH_2 group is further connected to a carbonyl group ($\text{C}=\text{O}$).
- Internal:** The ring has several other substituents, including a carboxylic acid derivative ($\text{S}-\text{CO}_2\text{H}$) and a long alkyl chain $(\text{CH}_2)_{10}-\text{Me}$.

CRN 121-44-8

CMF C6 H15 N




8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 36 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216013-87-5 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]- (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN CRX 560
FS STEREOSEARCH
DR 854918-50-6
MF C87 H163 N2 O19 P
CI COM
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, TOXCENTER

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 37 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216013-82-0 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-
β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-
, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN RC 512
FS STEREOSEARCH
DR 376394-46-6
MF C93 H175 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, TOXCENTER, USPAT2, USPATFULL

Search done by Noble Jarrell


CRN 216013-81-9
CMF C93 H175 N2 O19 P

$$\begin{array}{c} \text{Et} \\ | \\ \text{Et}-\text{N}-\text{Et} \end{array}$$

L11 ANSWER 38 OF 38 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216013-81-9 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-
β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-
(9CI) (CA INDEX NAME)


OTHER NAMES:
CN CRX 512
FS STEREOSEARCH
DR 854918-92-6
MF C93 H175 N2 O19 P
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Search done by Noble Jarrell



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d que sta l16
L5 STR




VAR G1=OH/CO2H/43
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L7 125 SEA FILE=REGISTRY SSS FUL L5
L9 14 SEA FILE=REGISTRY ABB=ON PLU=ON C69H127N2O19P OR C75H139N2O19
P OR C81H151N2O19P OR C87H163N2O19P
L10 26 SEA FILE=REGISTRY ABB=ON PLU=ON C93H175N2O19P OR C77H143N2O19
P OR C73H135N2O19P
L11 38 SEA FILE=REGISTRY ABB=ON PLU=ON (L9 OR L10) AND L7
L12 STR



VAR G1=OH/CO2H/43

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE

L14 63 SEA FILE=REGISTRY SUB=L7 SSS FUL L12

L15 38 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L11

L16 25 SEA FILE=REGISTRY ABB=ON PLU=ON L14 NOT L15

=> d ide l16 tot

L16 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 854923-92-5 REGISTRY

ED Entered STN: 13 Jul 2005

CN INDEX NAME NOT YET ASSIGNED


FS STEREOSEARCH

MF C81 H152 N3 O18 P

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 525604-83-5 REGISTRY
ED Entered STN: 05 Jun 2003
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxodecyl)oxy]-, (3R)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C81 H152 N3 O18 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 525604-82-4
CMF C81 H152 N3 O18 P


Absolute stereochemistry.



CM 2

Search done by Noble Jarrell


CRN 121-44-8
CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L16 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 525604-82-4 REGISTRY
ED Entered STN: 05 Jun 2003
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxodecyl)oxy]-, (3R)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C81 H152 N3 O18 P
CI COM
SR CA

Absolute stereochemistry.



L16 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 521333-28-8 REGISTRY
ED Entered STN: 28 May 2003
CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]dodecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]pentadecyl]-4-O-phosphono- β -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C80 H149 N2 O19 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 5 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 367273-91-4 REGISTRY
ED Entered STN: 06 Nov 2001
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxohexyl)oxy]-, (3R)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C69 H128 N3 O18 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USP&T FULL

CM 1

CRN 367273-90-3
CMF C69 H128 N3 O18 P

Absolute stereochemistry.




CM 2

CRN 121-44-8

Search done by Noble Jarrell


CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L16 ANSWER 6 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 367273-90-3 REGISTRY
ED Entered STN: 06 Nov 2001
CN Hexanoic acid, (1R)-1-[2-[[[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy)methyl]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C69 H128 N3 O18 P
CI COM
SR CA

Absolute stereochemistry.



L16 ANSWER 7 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 362594-89-6 REGISTRY
ED Entered STN: 17 Oct 2001
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-4-O-phosphono- β -D-glucopyranosyl]oxy)methyl]-2-oxoethyl]-3-[(1-oxododecyl)oxy]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C87 H164 N3 O18 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE).
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16. ANSWER 8 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 362594-88-5 REGISTRY
ED Entered STN: 17 Oct 2001
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxooctyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxooctyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxooctyl)oxy]-, (3R)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C75 H140 N3 O18 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE).
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16. ANSWER 9 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 362594-87-4 REGISTRY
ED Entered STN: 17 Oct 2001

Search done by Noble Jarrell

CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-2-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]oxy)methyl]-2-oxoethyl]-3-[(1-oxohexadecyl)oxy]-, (3R)-(9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C93 H176 N3 O18 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 10 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 339078-61-4 REGISTRY

ED Entered STN: 31 May 2001

CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-α-D-glucopyranosyl]oxy)methyl]-2-oxoethyl]-3-[(1-oxododecyl)oxy]-, (3R)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C77 H144 N3 O18 P . C6 H15 N


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 339078-60-3
CMF C77 H144 N3 O18 P


Absolute stereochemistry.



CM 2

CRN 121-44-8


CMF C6 H15 N



3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 11 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-60-3 REGISTRY
 ED Entered STN: 31 May 2001
 CN Decanoic acid, (1R)-1-[2-[[[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono- α -D-glucopyranosyl]oxy]methyl]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C77 H144 N3 O18 P
 CI COM
 SR CA

Absolute stereochemistry.




L16 ANSWER 12 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 339078-59-0 REGISTRY
 ED Entered STN: 31 May 2001
 CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxohexyl)oxy]-, (3R)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C69 H128 N3 O18 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 245515-66-6

CMF C69 H128 N3 O18 P

Absolute stereochemistry.




CM 2

CRN 121-44-8

Search done by Noble Jarrell


CMF C6 H15 N



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 13 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 245515-66-6 REGISTRY
ED Entered STN: 29 Oct 1999
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxohexyl)oxy]-, (3R)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C69 H128 N3 O18 P
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 14 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216014-85-6 REGISTRY
ED Entered STN: 23 Dec 1998
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-4-O-(diphenoxyphosphinyl)-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxodecyl)oxy]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C93 H160 N3 O18 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Search done by Noble Jarrell




6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
L16 ANSWER 15 OF 25  REGISTRY  COPYRIGHT 2005 ACS on STN
RN 216014-82-3  REGISTRY
ED Entered STN: 23 Dec 1998
CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy)methyl]-2-oxoethyl]-3-[(1-oxodecyl)oxy]-, (3R)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C81 H152 N3 O18 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, PROUDDDR, SYNTHLINE, TOXCENTER, USPATFULL
```

CRN 216014-81-2
CMF C81 H152 N3 O18 P.

Absolute stereochemistry.




Search done by Noble Jarrell

CM 2

CRN 121-44-8

CMF C6 H15 N



6 REFERENCES IN FILE CA (1907 TO DATE)

6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 16 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 216014-81-2 REGISTRY

ED Entered STN: 23 Dec 1998

CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxodecyl)oxy]-, (3R)- (9CI)
(CA INDEX NAME)

FS STEREOSEARCH


MF C81 H152 N3 O18 P

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 17 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 216014-80-1 REGISTRY

ED Entered STN: 23 Dec 1998

CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-4-O-(diphenoxyphosphinyl)-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxotetradecyl)oxy]-, (3R)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C105 H184 N3 O18 P

Search done by Noble Jarrell

SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


6 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 18 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 216014-76-5 REGISTRY
 ED Entered STN: 23 Dec 1998
 CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxotetradecyl)oxy]-, (3R)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C93 H176 N3 O18 P . C6 H15 N
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 216014-75-4
 CMF C93 H176 N3 O18 P


Absolute stereochemistry.



CM 2

CRN 121-44-8


CMF C6 H15 N



5 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 19 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 216014-75-4 REGISTRY
 ED Entered STN: 23 Dec 1998
 CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxotetradecyl)oxy]-, (3R)-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C93 H176 N3 O18 P
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




```
L16 ANSWER 20 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216014-37-8 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]-2-
  [[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
  glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]-, compd.
  with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
```

OTHER NAMES:

CM 1


CRN 216014-36-7
CMF C72 H133 N2 O19 P

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 21 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 216014-36-7 REGISTRY

ED Entered STN: 23 Dec 1998

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CRX 554

FS STEREOSEARCH

DR 854917-93-4


MF C72 H133 N2 O19 P

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 22 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 216014-21-0 REGISTRY

ED Entered STN: 23 Dec 1998

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxononyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxononyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxononyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN RC 537

FS STEREOSEARCH

DR 376394-29-5

MF C78 H145 N2 O19 P . C6 H15 N


Search done by Noble Jarrell

SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1


CRN 216014-20-9
 CMF C78 H145 N2 O19 P

Absolute stereochemistry.



CM 2

CRN 121-44-8
 CMF C6 H15 N




8 REFERENCES IN FILE CA (1907 TO DATE)
 8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 23 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 216014-20-9 REGISTRY
 ED Entered STN: 23 Dec 1998
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxononyl)oxy]tetradecyl]-2-
 [[[(3R)-1-oxo-3-[(1-oxononyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxononyl)oxy]tetradecyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN CRX 537
 FS STEREOSEARCH
 DR 854918-03-9
 MF C78 H145 N2 O19 P
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



L16 ANSWER 24 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN
RN 216013-97-7 REGISTRY
ED Entered STN: 23 Dec 1998
CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxoundecyl)oxy]tetradecyl]-2-
[[(3R)-1-oxo-3-[(1-oxoundecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxoundecyl)oxy]tetradecyl]-, compd.
with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)


CN RC 538
FS STEREOSEARCH
DR 376394-31-9
MF C84 H157 N2 O19 P . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, PROUSSDDR, TOXCENTER, USPAT2, USPATFULL

CRN 216013-96-6
CMF C84 H157 N2 O19 P

The chemical structure shows a central sugar moiety with substituents R, S, N, and O. It is linked to various fatty acid chains (Me, (CH2)9, (CH2)10) and a phosphate group (OPO3H2).

CRN 121-44-8

CMF C6 H15 N



8 REFERENCES IN FILE CA (1907 TO DATE)

8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 25 OF 25 REGISTRY COPYRIGHT 2005 ACS on STN

RN 216013-96-6 REGISTRY

ED Entered STN: 23 Dec 1998

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxoundecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3-[(1-oxoundecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
 glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxoundecyl)oxy]tetradecyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN CRX 538

FS STEREOSEARCH

DR 854918-14-2


MF C84 H157 N2 O19 P

CI COM

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b hcap

FILE 'HCAPLUS' ENTERED AT 08:43:56 ON 05 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching

Search done by Noble Jarrell

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 4 Aug 2005 (20050804/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitr 137 tot

L37 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:431458 HCAPLUS
DN 142:463966
ED Entered STN: 20 May 2005
TI Processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction
IN Johnson, David A.; Johnson, Craig L.; Bazin-Lee, Helene G.; Sowell, C. Gregory
PA Corixa Corporation, A Corporation of the State of Delaware, USA
SO U.S. Pat. Appl. Publ., 32 pp., Cont.-in-part of U.S. Ser. No. 472,991.
CODEN: USXXCO
DT Patent
LA English
IC ICM C07H005-04
ICS C12P019-04
INCL 536018700; 536055300
CC 33-7 (Carbohydrates)
Section cross-reference(s): 15, 34
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005107600	A1	20050519	US 2004-897194	20040721
	WO 2004005308	A2	20040115	WO 2003-US21504	20030708
	WO 2004005308	A3	20040422		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004267007	A1	20041230	US 2004-472991	20040812
PRAI	US 2002-394487P	P	20020708		
	WO 2003-US21504	W	20030708		
	US 2004-472991	A2	20040812		
	US 2003-438585P	P	20030106		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005107600	ICM	C07H005-04
	ICS	C12P019-04
	INCL	536018700; 536055300
US 2005107600	NCL	536/018.700; 536/055.300
WO 2004005308	ECLA	C07H005/02; C07H011/04; C07H013/04; C07H015/04
US 2004267007	NCL	536/120.000

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB This invention relates to processes for production of alkylamino glucosaminide phosphate compds., and of disaccharide compds. I, wherein PG is a protecting group that forms an ester, an ether, or a carbonate with the oxygen atom of a hydroxy group or that forms an amide or a carbonate with the nitrogen atom of an amino group, including various novel intermediates and intermediate processes. In one aspect, glycosyl halides are produced by reaction of an O-silyl glycoside with a dihalo-Me alkyl ether. Thus, amino glycoside II was prepared via glycosylation reaction.
- ST glycolipid alkylamino glycoside disaccharide amino acid prepn; alkylamino glucosaminide phosphate disaccharide immunoeffector glycoside amino acid prepn
- IT Glycosides
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (amino; processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)
- IT Disaccharides
 Glycolipids
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)
- IT 851445-31-3P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)
- IT 216014-15-2P 216014-46-9P 216014-50-5P 216014-59-4P
 640291-35-6P 640291-36-7P 640291-37-8P 640291-38-9P 640291-41-4P
 640291-42-5P 640291-43-6P 640291-44-7P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)
- IT 66-84-2 4885-02-3 17341-93-4 35946-66-8 66471-00-9 77987-49-6
 79733-86-1 82911-81-7 87357-76-4 108549-23-1 122105-45-7
 640291-27-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)
- IT 97562-23-7P 122210-05-3P 126497-01-6P 640291-15-2P 640291-16-3P
 640291-17-4P 640291-18-5P 640291-19-6P 640291-20-9P 640291-21-0P
 640291-22-1P 640291-23-2P 640291-24-3P 640291-25-4P 640291-26-5P
 640291-28-7P 640291-29-8P 640291-30-1P 640291-31-2P 640291-32-3P
 640291-33-4P 640291-40-3P 851445-28-8P 851445-29-9P 851445-30-2P
 851445-32-4P 851445-33-5P 851445-34-6P 851445-35-7P 851445-36-8P
 851445-37-9P 851445-38-0P 851445-39-1P 851445-40-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)
- IT 2456-81-7
 RL: RGT (Reagent); RACT (Reactant or reagent)
 (processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)

IT 216014-15-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)(processes for the production of amino-alkyl glucosaminide phosphate and
disaccharide immunoeffectors, and intermediates therefor via
glycosylation reaction)

RN 216014-15-2 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-
glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216014-14-1

CMF C81 H151 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L37 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:389589 HCAPLUS

DN 143:53141

ED Entered STN: 06 May 2005

TI A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine
Models of Inflammatory Bowel DiseaseAU Fort, Madeline M.; Mozaffarian, Afsane; Stoeve, Axel G.; Correia, Jean
da Silva; Johnson, David A.; Crane, R. Thomas; Ulevitch, Richard
J.; Persing, David H.; Bielefeldt-Ohmann, Helle; Probst, Peter; Jeffery,
Eric; Fling, Steven P.; Hershberg, Robert M.

CS Corixa Corporation, Seattle, WA, 98101, USA

SO Journal of Immunology (2005), 174(10), 6416-6423

CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

CC 1-7 (Pharmacology)

AB Current evidence indicates that the chronic inflammation observed in the intestines of patients with inflammatory bowel disease is due to an aberrant immune response to enteric flora. The authors have developed a lipid A-mimetic, CRX-526, which has antagonistic activity for TLR4 and can block the interaction of LPS with the immune system. CRX-526 can prevent the expression of proinflammatory genes stimulated by LPS in vitro. This antagonist activity of CRX-526 is directly related to its structure, particularly secondary fatty acyl chain length. In vivo, CRX-526 treatment blocks the ability of LPS to induce TNF- α release. Importantly, treatment with CRX-526 inhibits the development of moderate-to-severe disease in two mouse models of colonic inflammation: the dextran sodium sulfate model and multidrug resistance gene 1 α -deficient mice. By blocking the interaction between enteric bacteria and the innate immune system, CRX-526 may be an effective therapeutic mol. for inflammatory bowel disease.

ST CRX526 TLR4 antagonist antiinflammatory inflammatory bowel disease

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD48; synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I κ B- α (NF- κ B inhibitor α); synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF- κ B (nuclear factor of κ light chain gene enhancer in B-cells); synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TAP-1 (transporter in antigen processing 1); synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TLR-4 (Toll-like receptor-4); synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TSG-14; synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Intestine, disease

(inflammatory; synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interferon γ -inducible protein-10; synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Anti-inflammatory agents

Gene expression profiles, animal

Human

Microarray technology

(synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Fas antigen

Interleukin 1 receptor antagonist

Interleukin 1 β

Interleukin 6

Melanoma growth-stimulating activity- α

Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT Interleukin 2 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α chain; synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT 329900-75-6, COX-2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

IT 245515-64-4, CRX 526 362594-91-0, CRX 567
 362594-92-1, CRX 568 566170-29-4, CRX 570
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


(1) Abreu, M; J Immunol 2001, V167, P1609 HCAPLUS
 (2) Akashi, S; J Exp Med 2003, V198, P1035 HCAPLUS
 (3) Akira, S; Nat Immunol 2001, V2, P675 HCAPLUS
 (4) Baker, P; Infect Immun 1992, V60, P2694 HCAPLUS
 (5) Barton, G; Curr Opin Immunol 2002, V14, P380 HCAPLUS
 (6) Beutler, B; Immunity 2001, V15, P5 HCAPLUS
 (7) Cario, E; Infect Immun 2000, V68, P7010 HCAPLUS
 (8) Cooper, H; Lab Invest 1993, V69, P238 HCAPLUS
 (9) Da Silva, C; J Biol Chem 2002, V277, P1845
 (10) Duchmann, R; Clin Exp Immunol 1995, V102, P448 MEDLINE
 (11) Duchmann, R; Res Immunol 1997, V148, P589 MEDLINE
 (12) Elson, C; Int Rev Immunol 2000, V19, P63 HCAPLUS
 (13) Hausmann, M; Gastroenterology 2002, V122, P1987 HCAPLUS
 (14) Hornef, M; J Exp Med 2003, V198, P1225 HCAPLUS
 (15) Hugot, J; Nature 2001, V411, P599 HCAPLUS
 (16) Janeway, C; Annu Rev Immunol 2002, V20, P197 HCAPLUS
 (17) Johnson, D; Bioorg Med Chem Lett 1999, V9, P2273 HCAPLUS
 (18) Johnson, G; Crit Rev Immunol 2003, V23, P15 HCAPLUS
 (19) Kawata, T; Br J Pharmacol 1999, V127, P853 HCAPLUS
 (20) Kobayashi, M; J Clin Invest 2003, V111, P1297 HCAPLUS
 (21) Kopp, E; Curr Opin Immunol 2003, V15, P396 HCAPLUS
 (22) Lange, S; APMIS 1996, V104, P823 MEDLINE
 (23) Maggio-Price, L; Am J Pathol 2002, V160, P739 HCAPLUS
 (24) Means, T; J Immunol 2001, V166, P4074 HCAPLUS
 (25) Ogura, Y; Nature 2001, V411, P603 HCAPLUS
 (26) Panwala, C; J Immunol 1998, V161, P5733 HCAPLUS
 (27) Persing, D; Trends Microbiol 2002, V10, P332 HCAPLUS
 (28) Poltorak, A; Proc Natl Acad Sci USA 2000, V97, P2163 HCAPLUS
 (29) Probst, P; Eur J Immunol 1997, V27, P2634 HCAPLUS
 (30) Rakoff-Nahoum, S; Cell 2004, V118, P229 HCAPLUS
 (31) Sandborn, W; Gastroenterology 2002, V122, P1592 HCAPLUS
 (32) Sands, B; Gastroenterology 2000, V118, P568 HCAPLUS
 (33) Shanahan, F; Gut 2001, V48, P609 MEDLINE
 (34) Smith, P; J Immunol 2001, V167, P2651 HCAPLUS
 (35) Stover, A; J Biol Chem 2003, V279, P4440
 (36) Strober, W; Annu Rev Immunol 2002, V20, P495 HCAPLUS
 (37) Takeda, K; Annu Rev Immunol 2003, V21, P335 HCAPLUS
 (38) Takeda, K; Immunity 1999, V10, P39 HCAPLUS

IT 245515-64-4, CRX 526
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease)

RN 245515-64-4 HCAPLUS

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:389130 HCAPLUS

DN 143:70999

ED Entered STN: 06 May 2005

TI Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge

AU Cluff, Christopher W.; Baldridge, Jory R.; Stoeber, Axel G.; Evans, Jay T.; Johnson, David A.; Lacy, Michael J.; Clawson, Valerie G.; Yorgensen, Vonnice M.; Johnson, Craig L.; Livesay, Mark T.; Hershberg, Robert M.; Persing, David H.

CS Corixa Corporation, Seattle, WA, 98101, USA

SO Infection and Immunity (2005), 73(5), 3044-3052

CODEN: INFIBR; ISSN: 0019-9567

PB American Society for Microbiology

DT Journal

LA English

CC 1-3 (Pharmacology)

AB A compound family of synthetic lipid A mimetics (termed the aminoalkyl glucosaminide phosphates [AGPs]) was evaluated in murine infectious disease models of protection against challenge with *Listeria monocytogenes* and influenza virus. For the *Listeria* model, i.v. administration of AGPs was followed by i.v. bacterial challenge 24 h later. Spleens were harvested 2 days postchallenge for the enumeration of CFU. For the influenza virus model, mice were challenged with virus via the intranasal/intrapulmonary route 48 h after intranasal/intrapulmonary administration of AGPs. The severity of disease was assessed daily for 3 wk following challenge. Several types of AGPs provided strong protection against influenza virus or *Listeria* challenge in wild-type mice, but they were inactive in the C3H/HeJ mouse, demonstrating the dependence of the AGPs on toll-like receptor 4 (TLR4) signaling for the protective effect. Structure-activity relationship studies showed that the activation of innate immune effectors by AGPs depends primarily on the lengths of the secondary acyl chains within the three acyl-oxy-acyl residues and also on the nature of the functional group attached to the aglycon component. We conclude that the administration of synthetic TLR4 agonists provides rapid pharmacol. induction of innate resistance to infectious challenge by two different pathogen classes, that this effect is mediated via TLR4, and that structural differences between AGPs can have dramatic effects on agonist activity in vivo.

ST toll receptor aminoalkyl glucosaminidine phosphate virus infection vaccine
IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(TLR-4 (Toll-like receptor-4); synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT Influenza virus
Listeria monocytogenes
Structure-activity relationship
Vaccines
(synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT Infection
(viral; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216013-81-9
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 512; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 854923-92-5
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 522; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-49-2
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 524; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-55-0
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 525; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 245515-64-4
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 526; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-14-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 527; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-45-8
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 529; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-20-9
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 537; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216013-96-6
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 538; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 857026-80-3
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 545; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-36-7
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRX 554; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-28-7
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)
 (CRX 555; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-62-9
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 557; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216013-87-5
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 560; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 566170-22-7
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 565; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 362594-90-9
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 566; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 362594-92-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 567; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 362594-91-0
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 568; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 566170-27-2
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 569; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 566170-29-4
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 570; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 216014-68-5
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 571; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

IT 854923-97-0
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRX 573; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Akira, S; Curr Opin Immunol 2003, V15, P5 HCAPLUS
- (2) Ayabe, T; Nat Immunol 2000, V1, P113 HCAPLUS
- (3) Baldridge, J; J Endotoxin Res 2002, V8, P453 HCAPLUS
- (4) Berger, F; Adv Pharmacol 1967, V5, P19 HCAPLUS
- (5) Caamano, J; Clin Microbiol Rev 2002, V15, P414 HCAPLUS
- (6) Evans, J; Expert Rev Vaccines 2003, V2, P219 HCAPLUS
- (7) Friedland, N; Proc Natl Acad Sci USA 2003, V100, P2512 HCAPLUS
- (8) Gioannini, T; Proc Natl Acad Sci USA 2004, V101, P4186 HCAPLUS
- (9) Gruber, A; J Biol Chem 2004, V279, P28475 HCAPLUS
- (10) Hagberg, L; Infect Immun 1984, V46, P839 MEDLINE
- (11) Hoebe, K; Nature 2003, V424, P743 HCAPLUS

Search done by Noble Jarrell

- (12) Johnson, A; Clin Microbiol Rev 1994, V7, P277 HCAPLUS
 (13) Johnson, D; Bioorg Med Chem Lett 1999, V9, P2273 HCAPLUS
 (14) Johnson, D; J Med Chem 1999, V42, P4640 HCAPLUS
 (15) Kaisho, T; Biochim Biophys Acta 2002, V1589, P1 HCAPLUS
 (16) Kawai, T; Immunity 1999, V11, P115 HCAPLUS
 (17) Kennedy, M; J Biol Chem 2004
 (18) Macela, A; FEMS Immunol Med Microbiol 1996, V13, P235 HCAPLUS
 (19) Masihi, K; Int J Immunopharmacol 1986, V8, P339 HCAPLUS
 (20) Medzhitov, R; Immunol Rev 2000, V173, P89 HCAPLUS
 (21) Miyake, K; Trends Microbiol 2004, V12, P186 HCAPLUS
 (22) Mullen, G; Proc Natl Acad Sci USA 2003, V100, P3919 HCAPLUS
 (23) Muller, J; Immunobiology 1993, V187, P233 MEDLINE
 (24) Myers, K; Cellular and molecular aspects of endotoxin reactions 1990, P145 HCAPLUS
 (25) Neter, E; Curr Top Microbiol Immunol 1969, V47, P82 HCAPLUS
 (26) Nikolic-Zugic, J; Immunol Res 1991, V10, P54 HCAPLUS
 (27) O'Brien, A; J Immunol 1980, V124, P20 MEDLINE
 (28) O'Neill, L; J Endotoxin Res 2003, V9, P55 HCAPLUS
 (29) Persing, D; Trends Microbiol 2002, V10, P332 HCAPLUS
 (30) Poltorak, A; Blood Cells Mol Dis 1998, V24, P340 HCAPLUS
 (31) Poltorak, A; Blood Cells Mol Dis 1999, V25, P78 HCAPLUS
 (32) Poltorak, A; Science 1998, V282, P2085 HCAPLUS
 (33) Re, F; J Immunol 2003, V171, P5272 HCAPLUS
 (34) Rosenstreich, D; Crit Rev Immunol 1982, V3, P263 MEDLINE
 (35) Singh, J; Anim Reprod Sci 2000, V59, P159 HCAPLUS
 (36) Stover, A; J Biol Chem 2003
 (37) Sweet, M; J Leukoc Biol 1996, V60, P8 HCAPLUS
 (38) Toshchakov, V; Nat Immunol 2002, V3, P392 HCAPLUS
 (39) Triantafyllou, M; J Cell Sci 2002, V115, P2603 HCAPLUS
 (40) Ulrich, J; Advances in the biosciences 1988, V68, P167
 (41) Visintin, A; J Biol Chem 2003, V278, P48313 HCAPLUS
 (42) Visintin, A; Proc Natl Acad Sci USA 2001, V98, P12156 HCAPLUS
 (43) Woods, J; Infect Immun 1988, V56, P1950 MEDLINE
 (44) Wright, C; J Mol Biol 2000, V304, P411 HCAPLUS
 (45) Wright, C; J Mol Biol 2003, V331, P951 HCAPLUS
 (46) Yamamoto, M; Science 2003, V301, P640 HCAPLUS

IT 216013-81-9


RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRX 512; synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge)

RN 216013-81-9 HCAPLUS

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



Search done by Noble Jarrell

L37 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:610053 HCAPLUS
 DN 141:162352
 ED Entered STN: 30 Jul 2004
 TI Certain aminoalkyl glucosaminide phosphate compounds and their use
 IN Johnson, David A.
 PA Corixa Corporation, USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 15, 33


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004062599	A2	20040729	WO 2004-US377	20040106
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				

PRAI US 2003-438585P P 20030106

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004062599	ICM	A61K
WO 2004062599	ECLA	C07H005/02; C07H011/04; C07H013/04; C07H015/04
OS	MARPAT	141:162352
GI		



I

AB Aminoalkyl glucosaminide phosphates, such as I [R = CO₂H, CH₂OPO₃H₂; R₁, R₂, R₃ = aliphatic acyl], were described and claimed for therapeutic use as adjuvants and immunoeffectors. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages.

ST glucosaminide phosphate adjuvant immunoeffector cytokine prodn macrophage activation; antibody prodn glucosaminide phosphate adjuvant immunoeffector

IT Immunostimulants
 (adjuvants; therapeutic use of aminoalkyl glucosaminide phosphates as adjuvants and immunoeffectors which augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages)

IT Drug delivery systems

Macrophage

(therapeutic use of aminoalkyl glucosaminide phosphates as adjuvants and immunoeffectors which augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages)

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(therapeutic use of aminoalkyl glucosaminide phosphates as adjuvants and immunoeffectors which augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages)

IT 216014-15-2DP, RC 527, analogs 376394-26-2DP, RC 526, analogs

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(therapeutic use of aminoalkyl glucosaminide phosphates as adjuvants and immunoeffectors which augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages)

IT 216014-15-2DP, RC 527, analogs

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(therapeutic use of aminoalkyl glucosaminide phosphates as adjuvants and immunoeffectors which augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages)

RN 216014-15-2 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216014-14-1

CMF C81 H151 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L37 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:96950 HCAPLUS
DN 140:331799
ED Entered STN: 06 Feb 2004
TI Structure-Activity Relationship of Synthetic Toll-like Receptor 4 Agonists
AU Stoeever, Axel G.; Da Silva Correia, Jean; Evans, Jay T.; Cluff, Christopher W.; Elliott, Mark W.; Jeffery, Eric W.; Johnson, David A.; Lacy, Michael J.; Baldrige, Jory R.; Probst, Peter; Ulevitch, Richard J.; Persing, David H.; Hershberg, Robert M.
CS Corixa Corporation, Seattle, WA, 98104, USA
SO Journal of Biological Chemistry (2004), 279(6), 4440-4449
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
CC 1-3 (Pharmacology)
AB Important questions remain regarding the impact of variations in the structure of the lipid A portion of lipopolysaccharide on activation of cells via the Toll-like receptor 4 complex. We have studied a series of synthetic lipid A mimetic compds. known as aminoalkyl glucosaminide phosphates in which the length of the secondary acyl chain has been systematically varied. Using transcriptional profiling of human monocytes and responses of Toll-like receptor 4 complex cell transfectants, we demonstrate a clear dependence of length on secondary acyl chain on Toll-like receptor 4 activation. Compds. with secondary acyl chains less than eight carbons in length have dramatically reduced activity, and substitutions of the left-sided secondary acyl chain had the most important effect on the Toll-like receptor 4 agonist activity of these mols. The structure-function relationships of these compds. assessed via the induction of chemokines and cytokines following in vivo administration closely mirrored those seen with cell-based studies. This novel set of synthetic lipid A mimetics will be useful for Toll-like receptor 4-based investigations and may have clin. utility as stand-alone immunomodulators.
ST Toll receptor TLR4 agonist immunomodulator structure activity gene expression
IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-4 (Toll-like receptor-4); structure-activity relationship of synthetic Toll-like receptor 4 agonists as immunomodulators)
IT Structure-activity relationship (immunomodulating; structure-activity relationship of synthetic Toll-like receptor 4 agonists as immunomodulators)
IT DNA microarray technology
Gene expression profiles, animal
Human
Immunomodulators (structure-activity relationship of synthetic Toll-like receptor 4 agonists as immunomodulators)
IT Interleukin 8
Macrophage inflammatory protein 1 α
Monocyte chemoattractant protein-1
RANTES (chemokine)
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (structure-activity relationship of synthetic Toll-like receptor 4 agonists as immunomodulators)
IT 216013-81-9 216013-87-5 216014-14-1
216014-28-7 245515-64-4 362594-90-9
362594-91-0 362594-92-1 566170-22-7
566170-27-2 566170-29-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (structure-activity relationship of synthetic Toll-like receptor 4 agonists as immunomodulators)
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Baker, P; Infect Immun 1992, V60, P2694 HCAPLUS
- (2) Bauer, S; Proc Natl Acad Sci U S A 2001, V98, P9237 HCAPLUS
- (3) Bishop, R; EMBO J 2000, V19, P5071 HCAPLUS
- (4) Brandenburg, K; Biophys J 2002, V83, P322 HCAPLUS
- (5) Chuang, T; Biochim Biophys Acta 2001, V1518, P157 HCAPLUS
- (6) Da Silva, C; J Biol Chem 2001, V276, P21129
- (7) Da Silva, C; J Biol Chem 2002, V277, P1845
- (8) Eberwine, J; Proc Natl Acad Sci U S A 1992, V89, P3010 HCAPLUS
- (9) Eisen, M; Proc Natl Acad Sci U S A 1998, V95, P14863 HCAPLUS
- (10) Flo, T; J Biol Chem 2002, V277, P35489 HCAPLUS
- (11) Guo, L; Cell 1998, V95, P189 HCAPLUS
- (12) Hajjar, A; Nat Immunol 2002, V3, P354 HCAPLUS
- (13) Hegde, P; BioTechniques 2000, V29, P548 HCAPLUS
- (14) Hemmi, H; Nat Immunol 2002, V3, P196 HCAPLUS
- (15) Johnson, D; Bioorg Med Chem Lett 1999, V9, P2273 HCAPLUS
- (16) Kimbrell, D; Nat Rev Genet 2001, V2, P256 HCAPLUS
- (17) Krieg, A; Vaccine 2000, V19, P618 HCAPLUS
- (18) Lee, J; Proc Natl Acad Sci U S A 1993, V90, P9930 HCAPLUS
- (19) Lemaitre, B; Cell 1996, V86, P973 HCAPLUS
- (20) Luo, L; Nat Med 1999, V5, P117 HCAPLUS
- (21) Martin, M; Infect Immun 2003, V71, P2498 HCAPLUS
- (22) Mujumdar, S; Bioconj Chem 1996, V7, P356 HCAPLUS
- (23) Mullarkey, M; J Pharmacol Exp Ther 2003, V304, P1093 HCAPLUS
- (24) Persing, D; Trends Immunol 2002, V10, P332 HCAPLUS
- (25) Poltorak, A; Proc Natl Acad Sci U S A 2000, V97, P2163 HCAPLUS
- (26) Poltorak, A; Science 1998, V282, P2085 HCAPLUS
- (27) Probst, P; Eur J Immunol 1997, V27, P2634 HCAPLUS
- (28) Rock, F; Proc Natl Acad Sci U S A 1998, V95, P588 HCAPLUS
- (29) Takeda, K; Annu Rev Immunol 2003, V21, P335 HCAPLUS
- (30) Takeuchi, O; Gene (Amst) 1999, V231, P59 HCAPLUS
- (31) Tamai, R; Immunology 2003, V110, P66 HCAPLUS
- (32) Tobias, P; Immunobiology 1993, V187, P227 HCAPLUS
- (33) van Gelder, R; Proc Natl Acad Sci U S A 1990, V87, P1663 HCAPLUS
- (34) Visintin, A; Proc Natl Acad Sci U S A 2001, V98, P12156 HCAPLUS
- (35) Xing, Z; Am J Respir Cell Mol Biol 1994, V10, P148 HCAPLUS
- (36) Yang, S; Infect Immun 2001, V69, P2025 HCAPLUS


IT 216013-81-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(structure-activity relationship of synthetic Toll-like receptor 4
agonists as immunomodulators)

RN 216013-81-9 HCAPLUS

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-
[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-
β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



Search done by Noble Jarrell



L37 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:41489 HCAPLUS
 DN 140:77363
 ED Entered STN: 18 Jan 2004
 TI Processes for the production of aminoalkyl glucosaminide phosphate and
 disaccharide immuno-effectors, and intermediates therefor
 IN Johnson, David A.; Johnson, Craig L.; Bazin-Lee, Helene G.;
 Sowell, C. Gregory
 PA Corixa Corporation, USA
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07H015-04
 ICS C07H005-02; C07H011-04; C07H013-04
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 15, 34

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005308	A2	20040115	WO 2003-US21504	20030708
	WO 2004005308	A3	20040422		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492446	AA	20040115	CA 2003-2492446	20030708
	EP 1521762	A2	20050413	EP 2003-763418	20030708
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012656	A	20050607	BR 2003-12656	20030708
	US 2005107600	A1	20050519	US 2004-897194	20040721
	US 2004267007	A1	20041230	US 2004-472991	20040812
PRAI	US 2002-394487P	P	20020708		
	US 2003-438585P	P	20030106		
	WO 2003-US21504	W	20030708		
	US 2004-472991	A2	20040812		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004005308	ICM	C07H015-04
	ICS	C07H005-02; C07H011-04; C07H013-04
WO 2004005308	ECLA	C07H005/02; C07H011/04; C07H013/04; C07H015/04
US 2005107600	NCL	536/018.700; 536/055.300
US 2004267007	NCL	536/120.000
OS	MARPAT	140:77363
GI		



- AB This invention relates to processes for production of alkylamino glucosaminide phosphate compds., and of disaccharide compds., including various novel intermediates and intermediate processes. Reaction of an O-silyl glycoside I, wherein R has the formula $R_1R_2R_3Si$, in which R_1 - R_3 are independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and optionally substituted Ph; PG represents a protecting group that forms an ester, an ether or a carbonate with the oxygen atom of a hydroxy group or that forms an amide or a carbamate with the nitrogen atom of an amino group, resp., with a dihalo-Me alkyl ether gave glycosyl halides I,. In one aspect, glycosyl halides I, wherein A is Cl, Br, F are produced by reaction of an O-silyl glycoside I with a dihalo-Me alkyl ether. Thus, 2-deoxy-4-O-diphenylphosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-6-O-(2,2,2-trichloro-1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)- α -D-glucopyranosyl chloride was prepared from D-glucosamine hydrochloride via chlorination reaction.
- ST serine aminoalkyl glucosaminide phosphate disaccharide prepn glycoside monosaccharide halogenation
- IT Halogenation
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immuno-effectors via silylation and halogenation reactions)
- IT Glycosides
Monosaccharides
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immuno-effectors via silylation and halogenation reactions)
- IT 66270-36-8P
RL: IMF (Industrial manufacture); PREP (Preparation)
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)
- IT 97562-23-7P 114360-77-9P 126497-01-6P 640291-15-2P 640291-16-3P
640291-17-4P 640291-18-5P 640291-19-6P 640291-20-9P 640291-21-0P
640291-22-1P 640291-23-2P 640291-24-3P 640291-25-4P 640291-26-5P
640291-28-7P 640291-29-8P 640291-30-1P 640291-31-2P 640291-32-3P
640291-33-4P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)
- IT 216014-15-2P 216014-59-4P 640291-35-6P 640291-36-7P
640291-37-8P 640291-38-9P 640291-40-3P 640291-41-4P 640291-42-5P
640291-43-6P 640291-44-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)
- IT 66-84-2, D-Glucosamine hydrochloride 4885-02-3 13686-37-8 25781-01-5
82911-81-7 87357-76-4 122105-45-7 122210-05-3 252042-31-2
640291-27-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)
- IT 2456-81-7 22572-40-3
RL: RGT (Reagent); RACT (Reactant or reagent)
(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)
- IT 216014-15-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)

RN 216014-15-2 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216014-14-1

CMF C81 H151 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L37 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:836578 HCAPLUS

DN 139:307973

ED Entered STN: 24 Oct 2003

TI Preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors

IN Johnson, David A.; Sowell, C. Gregory

PA Corixa Corporation, USA

SO U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of U.S. Ser. No. 43,086.

CODEN: USXXCO

DT Patent

LA English

IC A61K031-739; C08B037-00

INCL 514042000; 536053000

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 15, 34, 63

FAN.CNT 10

Search done by Noble Jarrell


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003199460	A1	20031023	US 2002-137730	20020430
	US 6113918	A	20000905	US 1997-853826	19970508
	US 6303347	B1	20011016	US 1999-439839	19991112
	US 2002048588	A1	20020425	US 2001-905160	20010712
	US 6764840	B2	20040720		
	US 2003092643	A1	20030515	US 2002-43086	20020108
PRAI	US 1997-853826	A2	19970508		
	US 1999-439839	A1	19991112		
	US 2001-905160	A2	20010712		
	US 2002-43086	A2	20020108		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003199460	IC	A61K031-739IC C08B037-00
	INCL	514042000; 536053000
US 2003199460	NCL	514/042.000; 536/053.000
	ECLA	C07H013/06C; C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 2002048588	NCL	435/101.000; 424/278.100; 536/001.110
	ECLA	C07H015/04D
US 2003092643	NCL	514/042.000; 536/053.000; 536/054.000; 424/234.100
	ECLA	C07H013/06C; C07H015/04D

OS MARPAT 139:307973

GI



AB Aminoalkyl glucosaminide phosphate compds. (AGP) I were prepared wherein, X is selected from the group consisting of O and S at the axial or equatorial position; Y is selected from the group consisting of O and NH; Q is (CH₂)_n; L is (CH₂)_m; W is (CH₂)_q; n, m, p, q are integers from 0 to 6; R is (CH₂)₁₀Me; R₁-R₃ are the same or different and are normal fatty acyl residues having from 1 to about 20 carbon atoms and where one of R₁-R₃ is optionally hydrogen; R₄ and R₅ are the same or different and are selected from the group consisting of H and methyl; R₆ and R₇ are the same or different and are selected from the group consisting of H, hydroxy, alkoxy, phosphono, phosphono-oxy, sulfo, sulfo-oxy, amino, mercapto, cyano, nitro, formyl and carboxy, and esters and amides thereof; and R₈ and R₉ are the same or different and are selected from the group consisting of phosphono and H, and at least one of R₈ and R₉ is phosphono, that are adjuvants and immuno-effectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl

residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immuno-effectors are also disclosed. Thus, N-[(R)-3-hydroxytetradecanoyl]-O-[2-deoxy-4-O-phosphono-2-[(R)-3-dodecanoyloxytetradecanoylamino]-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]- α -L-D-glucopyranosyl]-L-serine triethylammonium salt was prepared and tested in mice as adjuvants and immuno-effectors. Mice vaccinated with formalin-inactivated influenza and the AGP compds. of the subject invention mounted a protective immune response to an influenza challenge as well as produced antibody to that antigen.

- ST antiinfluenza IgG immunoefector aminoalkyl glucosaminide phosphate prepn; cytokine adjuvant immunoefector antitetanus toxoid amino acid prepn glycoside; aminoalkyl glucosaminide phosphate prepn adjuvant immunoefector antitetanus toxoid antibody
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG, immobilized; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG1; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG2a; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG2b; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Influenza
(anti; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Macrophage
Vaccines
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Amino acids, preparation
Antibodies and Immunoglobulins
Cytokines
Glycosides
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT Toxoids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tetanus; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)
- IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P
216013-82-0P 216013-88-6P 216013-97-7P
216014-06-1P 216014-15-2P 216014-21-0P
216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P

216014-56-1P 216014-63-0P 216014-69-6P 216014-76-5P
 216014-82-3P 216014-88-9P 216014-92-5P 216014-98-1P
 339078-59-0P 339078-61-4P 339078-63-6P 339078-65-8P
 339078-67-0P 339078-69-2P 339078-71-6P
 339078-73-8P 339078-75-0P 339078-77-2P
 339078-79-4P 339078-81-8P 339078-85-2P 339079-17-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 109361-17-3

RL: CAT (Catalyst use); USES (Uses)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 66-84-2 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl chloride 2456-81-7, 4-Pyrrolidinopyridine 2528-61-2, Heptanoyl chloride 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl 3-oxotetradecanoate 22572-40-3, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide methiodide 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66270-36-8, 2,2,2-Trichloro-1,1-dimethylethyl chloroformate 66937-71-1 109977-90-4 122078-72-2 133099-79-3, D-Serine benzyl ester 134304-48-6 166193-98-2 190586-91-5
 216014-70-9 339078-52-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 1738-72-3P 2524-64-3P, Diphenyl chlorophosphate 76062-98-1P
 87357-76-4P 91578-89-1P 91681-56-0P 122105-45-7P 122210-01-9P
 186383-49-3P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
 216013-10-4P 216013-12-6P 216013-13-7P 216013-14-8P 216013-15-9P
 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P 216013-26-2P
 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P 216013-31-9P
 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P 216013-38-6P
 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P 216013-53-5P
 216013-54-6P 216013-55-7P 216013-56-8P 216013-60-4P 216013-61-5P
 216013-62-6P 216013-63-7P 216013-66-0P 216013-67-1P 216013-69-3P
 216013-70-6P 216013-71-7P 216013-75-1P 216013-77-3P 216013-78-4P
 216013-79-5P 216013-80-8P 216013-83-1P 216013-85-3P 216013-89-7P
 216013-90-0P 216013-91-1P 216013-92-2P 216013-93-3P 216013-95-5P
 216013-98-8P 216013-99-9P 216014-00-5P 216014-01-6P 216014-02-7P
 216014-04-9P 216014-07-2P 216014-08-3P 216014-09-4P 216014-11-8P
 216014-12-9P 216014-13-0P 216014-16-3P 216014-17-4P 216014-19-6P
 216014-22-1P 216014-23-2P 216014-24-3P 216014-25-4P 216014-26-5P
 216014-27-6P 216014-30-1P 216014-31-2P 216014-32-3P 216014-33-4P
 216014-34-5P 216014-35-6P 216014-38-9P 216014-39-0P 216014-40-3P
 216014-41-4P 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P
 216014-52-7P 216014-53-8P 216014-54-9P 216014-57-2P 216014-59-4P
 216014-60-7P 216014-61-8P 216014-65-2P 216014-66-3P 216014-67-4P
 216014-72-1P 216014-73-2P 216014-74-3P 216014-77-6P 216014-78-7P
 216014-80-1P 216014-83-4P 216014-84-5P 216014-85-6P
 216014-89-0P 216014-90-3P 216014-93-6P 216014-94-7P 216014-95-8P
 216014-99-2P 216015-00-8P 216015-01-9P 220048-54-4P 339078-53-4P
 339078-54-5P 339078-58-9P 339078-82-9P 339078-83-0P 339078-86-3P
 339078-87-4P 339079-15-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 216013-82-0P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosaminide phosphates and their use as

adjuvants and immuno-effectors)


RN 216013-82-0 HCAPLUS
 CN L-Serine, O- [2-deoxy-3-O- [(3R)-1-oxo-3- [(1-oxotetradecyl)oxy]tetradecyl]-2-
 [[(3R)-1-oxo-3- [(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-
 β -D-glucopyranosyl]-N- [(3R)-1-oxo-3- [(1-oxotetradecyl)oxy]tetradecyl]-
 , compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216013-81-9

CMF C93 H175 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L37 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:570634 HCAPLUS
 DN 139:127985
 ED Entered STN: 25 Jul 2003
 TI Prophylactic and therapeutic treatment of infectious and other diseases
 with mono- and disaccharide-based compounds
 IN Persing, David H.; Crane, Richard T.; Elliot, Gary T.; Ulrich, J. Terry;
 Lacy, Michael J.; Johnson, David A.; Baldrige, Jory R.; Wang,
 Rong
 PA USA
 SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 861,466.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K031-739
 INCL 514042000; 536053000
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 33
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

Search done by Noble Jarrell

PI	US 2003139356	A1	20030724	US 2001-991376	20011120
	US 2002077304	A1	20020620	US 2001-861466	20010518
	US 6800613	B2	20041005		
	US 2003105032	A1	20030605	US 2002-128156	20020422
	US 2004147480	A1	20040729	US 2004-757233	20040113
PRAI	US 2001-861466	A2	20010518		
	US 2000-205820P	P	20000519		
	US 2001-281567P	P	20010404		
	US 2001-991376	A2	20011120		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003139356	ICM	A61K031-739
	INCL	514042000; 536053000
US 2003139356	NCL	514/042.000; 536/053.000
	ECLA	C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D
US 2002077304	NCL	514/024.000; 514/025.000; 536/017.200
	ECLA	C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D
US 2003105032	NCL	514/042.000; 536/053.000
	ECLA	A61K031/7024; C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D
US 2004147480	NCL	514/054.000
	ECLA	A61K031/7024; C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D

OS MARPAT 139:127985

AB Methods and compns. for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compds. for selectively stimulating immune responses in animals and plants.

ST saccharide deriv bacteria virus fungus infection allergy therapy prophylaxis

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD 56; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD11B; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD54; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Cell adhesion molecules

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ICAM-1 (intercellular adhesion mol. 1); prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Cell adhesion molecules

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NCAM (neural cell adhesion mol.); prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNF- α ; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Dermatitis

(atopic; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Infection

(bacterial; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Mycosis

(candidiasis, vaginal; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Disease, animal
 (chronic rhinosinusitis; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Infection
 (chronic viral hepatitis; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Arthritis
 (chronic; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Intestine, disease
 (inflammatory; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (infusions; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (inhalants; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (injections, i.v.; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Lipid A
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monophosphates; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (nasal; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Pneumonia
 (nosocomial; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (oral; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (parenterals; prophylaxis and treatment of infectious diseases and allergy with mono- and disaccharide-based compds.)

IT Allergy inhibitors
 Animal
 Antibacterial agents
 Antiviral agents
 Asthma
 Autoimmune disease
 Candida
 Enterobacter
 Escherichia
 Firmicutes
 Fungicides
 Gram-negative bacteria
 Human
 Human immunodeficiency virus
 Human papillomavirus
 Immunostimulants
 Infection
 Influenza
 Klebsiella
 Listeria monocytogenes
 Multiple sclerosis
 Mycosis
 Periodontium, disease
 Pneumocystis carinii
 Pneumonia
 Proteus (bacterium)
 Pseudomonas
 Psoriasis

Rheumatoid arthritis
 Serratia
 Staphylococcus
 (prophylaxis and treatment of infectious diseases and allergy with
 mono- and disaccharide-based compds.)

IT CD14 (antigen)
 CD3 (antigen)
 CD69 (antigen)
 CD86 (antigen)
 Fas antigen
 Interleukin 10
 Interleukin 1 β
 Interleukin 2
 Interleukin 4
 Interleukin 5
 Interleukin 8
 Macrophage inflammatory protein 1 β
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prophylaxis and treatment of infectious diseases and allergy with
 mono- and disaccharide-based compds.)

IT Allergy
 (seasonal; prophylaxis and treatment of infectious diseases and allergy
 with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (transdermal; prophylaxis and treatment of infectious diseases and
 allergy with mono- and disaccharide-based compds.)

IT Drug delivery systems
 (transmucosal; prophylaxis and treatment of infectious diseases and
 allergy with mono- and disaccharide-based compds.)

IT Hepatitis
 (viral, chronic; prophylaxis and treatment of infectious diseases and
 allergy with mono- and disaccharide-based compds.)

IT Infection
 (viral; prophylaxis and treatment of infectious diseases and allergy
 with mono- and disaccharide-based compds.)

IT Interleukin 2 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α chain; prophylaxis and treatment of infectious diseases and
 allergy with mono- and disaccharide-based compds.)

IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α M; prophylaxis and treatment of infectious diseases and allergy
 with mono- and disaccharide-based compds.)

IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ ; prophylaxis and treatment of infectious diseases and allergy
 with mono- and disaccharide-based compds.)

IT 216013-41-1 216013-65-9 216013-73-9 216013-82-0
 216013-88-6, RC 560 216013-97-7, RC 538
 216014-06-1 216014-15-2, RC 527 216014-21-0,
 RC 537 216014-29-8, RC 555 216014-37-8, RC 554
 216014-46-9, RC-529 216014-50-5, RC-524 216014-56-1 216014-63-0
 216014-69-6, RC 571 216014-82-3 216014-98-1 253119-91-4,
 RC-552 376394-26-2, RC 526 566169-92-4, RC 515 566170-07-8,
 RC 517 566170-10-3, RC 519 566170-11-4, RC 523 566170-17-0, RC 544
 566170-18-1, RC 577 566170-21-6 566170-23-8
 566170-24-9 566170-25-0 566170-26-1
 566170-28-3 566170-30-7 566170-32-9, RC 573
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (prophylaxis and treatment of infectious diseases and allergy with
 mono- and disaccharide-based compds.)

IT 2644-64-6, Dipalmitoylphosphatidylcholine 4537-76-2,
 Distearoylphosphatidylethanolamine 4537-77-3, Dipalmitoyl phosphatidyl
 glycerol 4537-78-4, Distearoyl phosphatidyl glycerol 4539-70-2,
 Distearoylphosphatidylcholine 5681-36-7, Dipalmitoylphosphatidylethanol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prophylaxis and treatment of infectious diseases and allergy with
mono- and disaccharide-based compds.)


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(prophylaxis and treatment of infectious diseases and allergy with
mono- and disaccharide-based compds.)

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-
[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-
β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-
, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CRN 216013-81-9
CMF C93 H175 N2 O19 P

The chemical structure shows a central core with several substituents. At the top, there is a carboxylic acid group (CO₂H) attached to a sulfur atom (S), which is linked via an ether oxygen to a chiral center (R). This chiral center is also bonded to an amide group (NH-C(=O)-CH₂-R) and a long alkyl chain ((CH₂)₁₀-Me). The central core is a six-membered ring with an oxygen atom at the top. It has a phosphate group (OPO₃H₂) at the bottom, a hydroxyl group (OH) on the right, and a chiral center (R) on the left. The left chiral center is bonded to an amide group (NH-C(=O)-CH₂-R) and a long alkyl chain ((CH₂)₁₂-Me). The right chiral center is bonded to an ether oxygen, which is linked to a long alkyl chain ((CH₂)₁₂-Me). The bottom chiral center is bonded to an ester group (O-C(=O)-CH₂-R) and a long alkyl chain ((CH₂)₁₀-Me).

CRN 121-44-8
CMF C6 H15 N



L37 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:435302 HCAPLUS
DN 138:379230
ED Entered STN: 06 Jun 2003
TI Prophylactic and therapeutic treatment of infectious and other diseases
with mono- and disaccharide-based compounds
IN Persing, David H.; Crane, Richard Thomas; Elliott, Gary T.; Ulrich, J.
Terry; Lacy, Michael J.; Johnson, David A.; Baldrige, Jory R.;
Wang, Ronq

Search done by Noble Jarrell

PA USA
 SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 991,376.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K031-7008
 ICS A61K031-737
 INCL 514042000; 536053000
 CC 1-7 (Pharmacology)
 Section cross-reference(s): 15, 33, 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003105032	A1	20030605	US 2002-128156	20020422
	US 2002077304	A1	20020620	US 2001-861466	20010518
	US 6800613	B2	20041005		
	US 2003139356	A1	20030724	US 2001-991376	20011120
	ZA 2002009438	A	20040220	ZA 2002-9438	20021120
PRAI	US 2000-205820P	P	20000519		
	US 2001-281567P	P	20010404		
	US 2001-861466	A2	20010518		
	US 2001-991376	A2	20011120		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003105032	ICM	A61K031-7008
	ICS	A61K031-737
	INCL	514042000; 536053000
US 2003105032	NCL	514/042.000; 536/053.000
	ECLA	A61K031/7024; C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D
US 2002077304	NCL	514/024.000; 514/025.000; 536/017.200
	ECLA	C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D
US 2003139356	NCL	514/042.000; 536/053.000
	ECLA	C07H011/00; C07H013/04C; C07H013/06C; C07H015/14D

OS MARPAT 138:379230

AB Methods and compns. for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compds. for selectively stimulating immune responses in animals and plants.

ST infectious disease treatment monosaccharide disaccharide immunostimulant human

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TLR-1 (Toll-like receptor-1); prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Dermatitis

(atopic; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Infection

(bacterial; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Mycosis

(candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Infection

(chronic viral hepatitis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Immunity

(disorder; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to

- toxicity)
- IT Surfactants
(drug formulations containing; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Interleukin 10
Interleukin 6
Interleukin 8
Macrophage inflammatory protein 1 β
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(induction; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Human immunodeficiency virus
(infection treatment in relation to infection with; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT AIDS (disease)
(infection treatment in; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Mouth, disease
Vagina, disease
(infection, candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Enterobacter
Escherichia
Human papillomavirus
Klebsiella
Periodontium, disease
Pneumocystis carinii
Proteus (bacterium)
Pseudomonas
Serratia
Staphylococcus
(infection; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Intestine, disease
(inflammatory; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(infusions; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(inhalants; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(injections, i.v.; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Lipid A
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monophosphates; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(mucosal; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

- IT Drug delivery systems
(nasal; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Infection
Pneumonia
(nosocomial; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Infection
(oral, candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(oral; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(parenterals; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Allergy
Allergy inhibitors
Antiarthritics
Antiasthmatics
Antirheumatic agents
Autoimmune disease
Drug delivery systems
Hay fever
Human
Immunostimulants
Infection
Influenza
Mycosis
Pneumonia
Psoriasis
(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Disaccharides
Monosaccharides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Inflammation
Nose, disease
(rhinitis, allergic and infectious; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Inflammation
Respiratory tract, disease
(sinusitis, allergic and infectious; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(transdermal; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Infection
(vaginal, candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Hepatitis
(viral, chronic; prophylactic and therapeutic treatment of infectious

and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Infection

(viral; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT 216013-82-0 216013-88-6 216013-97-7

216014-15-2 216014-21-0 216014-29-8

216014-37-8 376394-26-2

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT 2644-64-6, Dipalmitoyl phosphatidylcholine 4537-76-2, Distearoyl phosphatidylethanolamine 4537-77-3, Dipalmitoyl phosphatidyl glycerol 4537-78-4, Distearoyl phosphatidyl glycerol 4539-70-2, Distearoyl phosphatidylcholine 5681-36-7, Dipalmitoyl phosphatidylethanolamine 17966-25-5, Distearoyl phosphatidic acid 18656-38-7, Dimyristoyl phosphatidylcholine 19698-29-4, Dipalmitoyl phosphatidic acid 20255-95-2, Dimyristoyl phosphatidylethanolamine 30170-00-4, Dimyristoyl phosphatidic acid 61361-72-6, Dimyristoyl phosphatidyl glycerol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(surfactant, drug formulations containing; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT 216013-82-0

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

RN 216013-82-0 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-, compd. with N,N-diethylethylamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216013-81-9

CMF C93 H175 N2 O19 P

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N

Et

Et-N-Et

L37 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:376382 HCAPLUS
DN 138:384134
ED Entered STN: 16 May 2003
TI Vaccine compositions comprising aminoalkyl glucosaminide phosphate compounds as adjuvants and immunoeffectors for treating cancerous and infectious diseases
IN Johnson, David A.; Sowell, C. Gregory
PA Corixa Corporation, USA
SO U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 905,160.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K039-02
ICS A61K031-739; C07H005-04
INCL 514042000; 536053000; 536054000; 424234100
CC 15-2 (Immunochemistry)
Section cross-reference(s): 1, 63

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003092643	A1	20030515	US 2002-43086	20020108
	US 6113918	A	20000905	US 1997-853826	19970508
	US 6303347	B1	20011016	US 1999-439839	19991112
	US 2002048588	A1	20020425	US 2001-905160	20010712
	US 6764840	B2	20040720		
	US 2003199460	A1	20031023	US 2002-137730	20020430
PRAI	US 1997-853826	A2	19970508		
	US 1999-439839	A1	19991112		
	US 2001-905160	A2	20010712		
	US 2002-43086	A2	20020108		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003092643	ICM	A61K039-02
	ICS	A61K031-739; C07H005-04
	INCL	514042000; 536053000; 536054000; 424234100
US 2003092643	NCL	514/042.000; 536/053.000; 536/054.000; 424/234.100
	ECLA	C07H013/06C; C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 2002048588	NCL	435/101.000; 424/278.100; 536/001.110
	ECLA	C07H015/04D
US 2003199460	NCL	514/042.000; 536/053.000
	ECLA	C07H013/06C; C07H015/04D

OS MARPAT 138:384134

AB Aminoalkyl glucosaminide phosphate (AGP) compds. that are adjuvants and immunoeffectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the

Search done by Noble Jarrell

- glucosaminide ring and comprise three 3- alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compns. and methods for using the compds. as adjuvants and immunoeffectors are also disclosed.
- ST vaccine antigen tumor protein immune adjuvant aminoalkyl glucosaminide phosphate; cancer infection antigen vaccine immune adjuvant aminoalkyl glucosaminide phosphate
- IT Macrophage
(activation; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Immunostimulants
(adjuvants; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Functional groups
(aminoalkyl phosphate; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Blood serum
Mucous membrane
(antibody production; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(aqueous; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(carriers; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Immunity
(cell-mediated; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT T cell (lymphocyte)
(cytotoxic; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Glycosides
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(group; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatitis B surface; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Solutions
(isotonic, agent; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Oils
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metabolizable; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
(nasal, intra-; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating

- cancerous and infectious diseases)
- IT Cytokines
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (production; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Drug delivery systems
 (solns.; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Toxoids
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tetanus; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Vaccines
 (tumor; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Animal
 Antioxidants
 Egg, poultry
 Emulsions
 Human
 Immunomodulators
 Immunostimulants
 Infection
 Influenza virus
 Mammalia
 Microparticles
 Microspheres
 Surfactants
 Vaccines
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Ovalbumin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Antigens
 Polynucleotides
 Tumor antigens
 Tumor antigens
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)
- IT Phosphatidylcholines, biological studies
 Phosphatidylethanolamines, biological studies
 Sphingomyelins
 Sphingosines
 Tocopherols
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Antitumor agents
(vaccines; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT Infection
(viral; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 125978-95-2P, Nitric oxide synthetase
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inducible; vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 10102-43-9P, Nitric oxide, biological studies
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 66-84-2 76-05-1, Trifluoroacetic acid, reactions 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 764-85-2, Nonanoyl chloride 1738-72-3, L-Serine benzyl ester 2528-61-2, Heptanoyl chloride 6791-49-7, L-Serinamide 15219-34-8, Oxalyl bromide 16357-59-8, 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl 3-oxotetradecanoate 22572-40-3, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide methiodide 28715-21-1 58577-87-0 58577-88-1 66270-36-8, 2,2,2-Trichloro-1,1-dimethylethyl chloroformate 66937-71-1, N-(2-Hydroxyethyl)glycine tert-butyl ester 105464-42-4 109977-90-4 122078-72-2 133099-79-3 134304-48-6 142982-11-4 166193-98-2 216014-70-9 216014-83-4 252042-31-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 76062-98-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P
186383-49-3P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
216013-10-4P 216013-11-5P 216013-12-6P 216013-13-7P 216013-14-8P
216013-16-0P 216013-20-6P 216013-22-8P 216013-26-2P 216013-27-3P
216013-28-4P 216013-29-5P 216013-30-8P 216013-31-9P 216013-35-3P
216013-36-4P 216013-37-5P 216013-42-2P 216013-43-3P 216013-44-4P
216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P
216013-60-4P 216013-61-5P 216013-62-6P 216013-66-0P 216013-67-1P
216013-69-3P 216013-71-7P 216013-77-3P 216013-78-4P 216013-80-8P
216013-83-1P 216013-85-3P 216013-89-7P 216013-90-0P 216013-91-1P
216013-92-2P 216013-93-3P 216013-98-8P 216013-99-9P 216014-00-5P
216014-01-6P 216014-02-7P 216014-07-2P 216014-08-3P 216014-09-4P
216014-11-8P 216014-12-9P 216014-17-4P 216014-22-1P 216014-23-2P
216014-24-3P 216014-25-4P 216014-26-5P 216014-30-1P 216014-31-2P
216014-32-3P 216014-33-4P 216014-34-5P 216014-38-9P 216014-40-3P
216014-41-4P 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P
216014-52-7P 216014-53-8P 216014-57-2P 216014-59-4P 216014-60-7P
216014-65-2P 216014-66-3P 216014-72-1P 216014-73-2P 216014-77-6P
216014-80-1P 216014-84-5P 216014-85-6P 216014-89-0P
216014-90-3P 216014-93-6P 216014-94-7P 216014-99-2P 216015-00-8P
339078-53-4P 339078-54-5P 367273-92-5P 525604-08-4P 525604-09-5P
525604-12-0P 525604-15-3P 525604-20-0P 525604-23-3P 525604-28-8P
525604-32-4P 525604-35-7P 525604-38-0P 525604-41-5P 525604-44-8P
525604-47-1P 525604-50-6P 525604-53-9P 525604-56-2P 525604-59-5P

525604-62-0P 525604-65-3P 525604-68-6P 525604-76-6P 525604-79-9P
525604-81-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 216013-09-1P 216013-19-3P 216013-47-7P 216013-65-9P 216013-73-9P
216014-37-8P 216014-98-1P 339078-67-0P
339078-71-6P 339078-75-0P 339078-77-2P
339079-17-3P 367273-94-7P 525604-11-9P 525604-14-2P
525604-17-5P 525604-19-7P 525604-22-2P 525604-34-6P 525604-37-9P
525604-40-4P 525604-43-7P 525604-46-0P 525604-49-3P 525604-52-8P
525604-55-1P 525604-58-4P 525604-61-9P 525604-64-2P 525604-67-5P
525604-70-0P 525604-72-2P 525604-74-4P 525604-78-8P
525604-83-5P 525604-85-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 3416-24-8DP, 2-Deoxy-2-amino-glucose, aminoalkyl phosphate derivs.
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 56-81-5, Glycerol, biological studies 63-89-8 83-44-3 102-71-6,
Triethanolamine, biological studies 111-02-4, Squalene 121-44-8,
Triethylamine, biological studies 360-65-6 998-07-2,
1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine 1305-62-0, Calcium hydroxide, biological studies 7732-18-5, Water, biological studies 10103-46-5, Calcium phosphate 21645-51-2, Aluminum hydroxide, biological studies 106392-12-5, PLURONIC F 68

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)


IT 525604-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(vaccine compns. comprising m p 43aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

IT 216014-80-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(vaccine compns. comprising aminoalkyl glucosaminide phosphate compds. as adjuvants and immunoeffectors for treating cancerous and infectious diseases)

RN 216014-80-1 HCAPLUS

CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-4-O-(diphenoxyphosphinyl)-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxotetradecyl)oxy]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:356202 HCAPLUS
 DN 138:367577
 ED Entered STN: 09 May 2003
 TI Viral vector and immunostimulant for enhancing vaccine immune response
 without neutralizing antibody response to the viral vector
 IN Mossman, Sally P.; Evans, Lawrence S.; Swanson, Ryan Michael
 PA Corixa Corporation, USA
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037275	A2	20030508	WO 2002-US36426	20021028
WO 2003037275	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003228279	A1	20031211	US 2002-283484	20021029
PRAI US 2001-335512P	P	20011031		
US 2002-369715P	P	20020403		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003037275	ICM	A61K
WO 2003037275	ECLA	A61K039/39
US 2003228279	NCL	424/093.200; 514/054.000; 424/085.100; 424/085.200; 536/053.000
	ECLA	A61K039/39

OS MARPAT 138:367577

AB Comps. and methods comprising a recombinant virus and an immunostimulant are provided for enhancing the immune response to a polypeptide expressed from the recombinant virus. Preferably this is done without also

enhancing the neutralizing antibody response to the recombinant virus. Illustrative compns. comprise an adenovirus and an adjuvant such as, for example, monophosphoryl lipid A, an alkyl glucosaminide phosphate, a saponin, or a combination thereof. The disclosed compns. and methods are useful, for example, in the treatment of diseases such as cancer or infectious disease.

- ST virus vector immunostimulant adjuvant aminoalkyl glucosaminide phosphate vaccine antigen; infection cancer vaccine tumor antigen recombinant viral vector adjuvant
- IT Antigens
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (TbH9; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Carbohydrates, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (acylated; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunostimulants
 (adjuvants, AS-2; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunostimulants
 (adjuvants, Freund's incomplete; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunostimulants
 (adjuvants, Freund's; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunostimulants
 (adjuvants, Merch Adjuvant 65; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunostimulants
 (adjuvants; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Microspheres
 (biodegradable; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Drug delivery systems
 (carriers; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Polysaccharides, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cationic or anionic; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunity
 (cell-mediated, Th1; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Immunity
 (humoral; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)
- IT Drug delivery systems
 (injections, i.m.; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Drug delivery systems
(injections, s.c.; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Drug delivery systems
(intradermal; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Biodegradable materials
(microsphere; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Lipid A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monophosphates; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); REM (Removal or disposal); BIOL (Biological study); PROC (Process)
(neutralizing; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Emulsions
(oil-in-water; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Quillaja
(saponins; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Drug delivery systems
(suspensions; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Saponins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triterpenoid; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Vaccines
(tumor; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Antitumor agents
(vaccines; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Adeno-associated virus
Poxviridae
(vector; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Adenoviral vectors
Alphavirus
Antitumor agents
Avipoxvirus
CD4-positive T cell
CD8-positive T cell
Human
Immunostimulants
Infection
Mammalia
Mycobacterium tuberculosis
T cell (lymphocyte)
Vaccines

Vaccinia virus
 Viral vectors
 (viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Antigenes
 Cytokines
 Fusion proteins (chimeric proteins)
 Interleukin 12
 Interleukin 2
 Tumor antigens
 Tumor antigens
 Tumor necrosis factors
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Minerals, biological studies
 Polyphosphazenes
 Saponins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Emulsions
 (water-in-oil; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT Interferons
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (α ; viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)


IT 521333-27-7 521333-28-8 521333-29-9 521333-30-2
 521333-31-3
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT 60-18-4D, Tyrosine, acetylated derivs. 7439-89-6D, Iron, salts
 7440-66-6D, Zinc, salts 7440-70-2D, Calcium, salts 7784-30-7, Aluminum phosphate 14257-69-3D, β -D-Glucosamine, aminoalkyl phosphate derivs. 21645-51-2D, Aluminum hydroxide, gel 141256-04-4, QS 21
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

IT 521333-28-8
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

RN 521333-28-8 HCAPLUS
 CN Decanoic acid, (1R)-1-[2-[[[(1S)-1-carboxy-2-[[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxodecyl)oxy]dodecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxodecyl)oxy]pentadecyl]-4-O-phosphono- β -D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:182118 HCAPLUS
 DN 136:217004
 ED Entered STN: 14 Mar 2002
 TI Preparation of aminoalkyl glucosamine phosphates and their use as
 adjuvants and immunoeffectors
 IN Johnson, David A.; Sowell, C. Gregory
 PA Corixa Corporation, USA
 SO U.S., 37 pp., Cont.-in-part of U.S. 6,113,918.
 CODEN: USXXAM

DT Patent
 LA English
 IC ICM A61K045-00
 ICS C07H001-00; C07H011-04; C07H013-02
 INCL 424278100
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 1, 15, 63


FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355257	B1	20020312	US 1998-74720	19980507
	US 6113918	A	20000905	US 1997-853826	19970508
	ES 2224397	T3	20050301	ES 1998-922138	19980507
PRAI	US 1997-853826	A2	19970508		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6355257	ICM	A61K045-00
	ICS	C07H001-00; C07H011-04; C07H013-02
	INCL	424278100
US 6355257	NCL	424/278.100; 536/001.110; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D

OS MARPAT 136:217004
 GI



- AB Aminoalkyl glucosamine phosphate compds. I (R = substituted alkyl; R1, R2 = H, phosphono; R3, R4 = fatty acid residue; R5 = undecyl; X = O, S; Y = O, NH) were prepared as adjuvants and immunoeffectors. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosamine ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immunoeffectors are also disclosed. Thus, N-carboxymethyl-N-[(R)-3-decanoyloxytetradecanoyl]-3-aminopropyl-2-deoxy-4-O-phosphono-2-[(R)-3-decanoyloxytetradecanoylamino]-3-O-[(R)-3-decanoyloxytetradecanoyl]-β-D-glucopyranoside triethylammonium salt was prepared and tested as adjuvant and immunoeffector for anti-tetanus and anti-influenza activities.
- ST virucide vaccine aminoalkyl glucosamine phosphate prepn; cytokine prodn vaccine aminoalkyl glucosamine phosphate; vaccine antiinfluenza aminoalkyl glucosamine phosphate prepn; immunization antitetanus aminoalkyl glucosamine phosphate prepn; antitetanus IgG aminoalkyl glucosamine phosphate prepn; aminoalkyl glucosamine phosphate prepn immunoeffector adjuvant
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG, immobilized; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antiviral agents
Immunization
Vaccines
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Glycosides
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT 109361-17-3

RL: CAT (Catalyst use); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
 216013-47-7P 216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P
 216013-82-0P 216013-88-6P 216013-97-7P
 216014-06-1P 216014-15-2P 216014-21-0P
 216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P
 216014-56-1P 216014-63-0P 216014-69-6P 216014-76-5P
 216014-82-3P 216014-88-9P 216014-92-5P 216014-98-1P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 76062-98-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P
 216013-02-4P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
 216013-10-4P 216013-11-5P 216013-12-6P 216013-13-7P 216013-14-8P
 216013-15-9P 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P
 216013-26-2P 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P
 216013-31-9P 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P
 216013-38-6P 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P
 216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P
 216013-56-8P 216013-60-4P 216013-61-5P 216013-62-6P 216013-63-7P
 216013-66-0P 216013-67-1P 216013-69-3P 216013-70-6P 216013-71-7P
 216013-75-1P 216013-77-3P 216013-78-4P 216013-79-5P 216013-80-8P
 216013-83-1P 216013-85-3P 216013-86-4P 216013-89-7P 216013-90-0P
 216013-91-1P 216013-92-2P 216013-93-3P 216013-95-5P 216013-98-8P
 216013-99-9P 216014-00-5P 216014-01-6P 216014-02-7P 216014-04-9P
 216014-07-2P 216014-08-3P 216014-09-4P 216014-11-8P 216014-12-9P
 216014-13-0P 216014-16-3P 216014-17-4P 216014-19-6P 216014-22-1P
 216014-23-2P 216014-24-3P 216014-25-4P 216014-26-5P 216014-27-6P
 216014-30-1P 216014-31-2P 216014-32-3P 216014-33-4P 216014-34-5P
 216014-35-6P 216014-38-9P 216014-39-0P 216014-40-3P 216014-41-4P
 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P 216014-52-7P
 216014-53-8P 216014-54-9P 216014-57-2P 216014-59-4P 216014-60-7P
 216014-61-8P 216014-65-2P 216014-66-3P 216014-67-4P 216014-72-1P
 216014-73-2P 216014-74-3P 216014-77-6P 216014-78-7P
 216014-80-1P 216014-83-4P 216014-84-5P 216014-85-6P
 216014-89-0P 216014-90-3P 216014-93-6P 216014-94-7P 216014-95-8P
 216014-99-2P 216015-00-8P 216015-01-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic

preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 66-84-2, D-Glucosamine hydrochloride 99-73-0, 2,4'-Dibromoacetophenone
 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3,
 Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl
 chloride 764-85-2, Nonanoyl chloride 1738-72-3, L-Serine benzyl ester
 2528-61-2, Heptanoyl chloride 22348-97-6, Methyl 3-oxotetradecanoate
 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66270-36-8
 66937-71-1 91578-89-1 122078-72-2 133099-79-3, D-Serine benzyl ester
 142982-11-4 166193-98-2 216013-74-0 216014-70-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)


RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Bulusu; Cyclic Analogues of Lipid A: Synthesis and Biological Activities 1992, P3463 HCAPLUS
- (2) Eustache; Carbohydrate Research 1994, V251, P251 HCAPLUS
- (3) Ikeda; Chem Pharm Bull 1993, V41(10), P1879 HCAPLUS
- (4) Ikeda; Synthesis of Biologically Active N-Acylated L-serine Containing Glucosamine-4-Phosphate Derivatives of Lipid A 1993, P1879 HCAPLUS
- (5) Miyajima; Chem Pharm Bull 1996, V44(12), P2268
- (6) Miyajima; Lipid A and Related Compounds XXXI 1996, P2268

(7) Shimizu; Antitumor Activity and Biological Effects of Chemically Synthesized Monosaccharide Analogues of Lipid A in Mice 1985, P4621 HCAPLUS
 (8) Shimizu; Biological Activities and Antitumor Effects of Synthetic Lipid A Analogs Linked N-Acylated Serine 1995, P425 HCAPLUS
 (9) Shimizu; Biological Activities of Chemically Synthesized N-acylated Serine-linked Lipid A Analog in Mice 1994, P659 HCAPLUS
 IT 216013-82-0P
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
 RN 216013-82-0 HCAPLUS
 CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 216013-81-9
 CMF C93 H175 N2 O19 P

Absolute stereochemistry.



CM 2
 CRN 121-44-8
 CMF C6 H15 N



L37 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:868475 HCAPLUS
 DN 136:628
 ED Entered STN: 30 Nov 2001
 TI Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
 IN Persing, David H.; Crane, Richard Thomas; Elliot, Gary T.; Ulrich, J. Terry; Lacy, Michael J.; Johnson, David A.; Baldridge, Jory R.; Wang, Rong
 PA Corixa Corporation, USA

SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07H015-00
 CC 1-7 (Pharmacology)
 Section cross-reference(s): 15, 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090129	A2	20011129	WO 2001-US16327	20010518
	WO 2001090129	A3	20020606		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2409221	AA	20011129	CA 2001-2409221	20010518
	EP 1284740	A2	20030226	EP 2001-948222	20010518
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004508292	T2	20040318	JP 2001-586316	20010518
	BR 2001010975	A	20040323	BR 2001-10975	20010518
	NZ 522755	A	20040528	NZ 2001-522755	20010518
	ZA 2002009438	A	20040220	ZA 2002-9438	20021120
PRAI	US 2000-205820P	P	20000519		
	US 2001-281567P	P	20010404		
	WO 2001-US16327	W	20010518		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001090129	ICM	C07H015-00
WO 2001090129	ECLA	A61K031/7024; C07H013/04C; C07H013/06C; C07H011/00; C07H015/14D
JP 2004508292	FTERM	4C057/BB02; 4C057/BB03; 4C057/CC03; 4C057/DD02; 4C057/DD03; 4C057/GG06; 4C057/HH02; 4C057/HH03; 4C057/JJ04; 4C076/AA16; 4C076/BB25; 4C076/BB31; 4C076/CC03; 4C076/CC04; 4C076/CC07; 4C076/CC15; 4C076/CC20; 4C076/CC31; 4C076/CC34; 4C076/CC35; 4C076/DD15E; 4C076/DD63E; 4C076/FF15; 4C076/FF16; 4C076/FF57; 4C076/FF68; 4C086/AA01; 4C086/AA02; 4C086/EA05; 4C086/MA01; 4C086/MA02; 4C086/MA04; 4C086/MA05; 4C086/MA21; 4C086/NA02; 4C086/NA10; 4C086/NA14; 4C086/ZA15; 4C086/ZA34; 4C086/ZA59; 4C086/ZA67; 4C086/ZA68; 4C086/ZA75; 4C086/ZA89; 4C086/ZA90; 4C086/ZA96; 4C086/ZB02; 4C086/ZB09; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37; 4C086/ZB38; 4C086/ZC55

OS MARPAT 136:628

AB Methods and compns. for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compds. for selectively stimulating immune responses in animals and plants.

ST infectious disease treatment monosaccharide disaccharide immunostimulant
 IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TLR-1 (Toll-like receptor-1); prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Dermatitis
 (atopic; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to

- toxicity)
- IT Infection
(bacterial; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Mycosis
(candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Infection
(chronic viral hepatitis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Surfactants
(drug formulations containing; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Interleukin 10
Interleukin 6
Interleukin 8
Macrophage inflammatory protein 1 β
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(induction; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Human immunodeficiency virus
(infection treatment in relation to infection with; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT AIDS (disease)
(infection treatment in; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Mouth, disease
Vagina, disease
(infection, candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Enterobacter
Escherichia
Human papillomavirus
Klebsiella
Periodontium, disease
Pneumocystis carinii
Proteus (bacterium)
Pseudomonas
Serratia
Staphylococcus
(infection; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Intestine, disease
(inflammatory; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(infusions; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(inhalants; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
(injections, i.v.; prophylactic and therapeutic treatment of infectious

- and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Lipid A
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monophosphates; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
 (mucosal; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
 (nasal; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Infection
 Pneumonia
 (nosocomial; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Infection
 (oral, candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
 (oral; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Drug delivery systems
 (parenterals; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Allergy inhibitors
 Antiarthritics
 Antiasthmatics
 Antirheumatic agents
 Autoimmune disease
 Drug delivery systems
 Hay fever
 Immunostimulants
 Infection
 Influenza
 Mycosis
 Pneumonia
 Psoriasis
 (prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Disaccharides
 Monosaccharides
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Inflammation
 Nose, disease
 (rhinitis, allergic and infectious; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)
- IT Inflammation
 Respiratory tract, disease
 (sinusitis, allergic and infectious; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Multiple sclerosis
(therapeutic agents; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Drug delivery systems
(transdermal; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Infection
(vaginal, candidiasis; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Hepatitis
(viral, chronic; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT Infection
(viral; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT 216013-82-0 216013-88-6 216013-97-7
216014-15-2 216014-21-0 216014-29-8
216014-37-8 376394-26-2
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT 2644-64-6, Dipalmitoyl phosphatidylcholine 4537-76-2, Distearoyl phosphatidylethanolamine 4537-77-3, Dipalmitoyl phosphatidyl glycerol 4537-78-4, Distearoyl phosphatidyl glycerol 4539-70-2, Distearoyl phosphatidylcholine 5681-36-7, Dipalmitoyl phosphatidylethanolamine 17966-25-5, Distearoyl phosphatidic acid 18656-38-7, Dimyristoyl phosphatidylcholine 19698-29-4, Dipalmitoyl phosphatidic acid 20255-95-2, Dimyristoyl phosphatidylethanolamine 30170-00-4, Dimyristoyl phosphatidic acid 61361-72-6, Dimyristoyl phosphatidyl glycerol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant, drug formulations containing; prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

IT 216013-82-0
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

RN 216013-82-0 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanolamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216013-81-9

CMF C93 H175 N2 O19 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L37 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:757768 HCAPLUS
 DN 135:302901
 ED Entered STN: 17 Oct 2001
 TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
 IN Johnson, David A.; Sowell, C. Gregory
 PA Corixa Corporation, USA
 SO U.S., 44 pp., Cont.-in-part of U.S. 6,113,918.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM C12P019-04
 ICS A61K045-00; C07H001-00; C07H015-00; C07H011-04
 INCL 435101000
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 63
 FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6303347	B1	20011016	US 1999-439839	19991112
US 6113918	A	20000905	US 1997-853826	19970508
ES 2224397	T3	20050301	ES 1998-922138	19980507
CA 2391299	AA	20010517	CA 2000-2391299	20001113
WO 2001034617	A2	20010517	WO 2000-US31340	20001113
WO 2001034617	A3	20011108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

Search done by Noble Jarrell

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1230250 A2 20020814 EP 2000-982119 20001113
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2000015501 A 20030225 BR 2000-15501 20001113
 JP 2003514783 T2 20030422 JP 2001-537329 20001113
 NZ 518860 A 20041126 NZ 2000-518860 20001113
 US 2002045586 A1 20020418 US 2001-808669 20010314
 US 6699846 B2 20040302
 US 2002048588 A1 20020425 US 2001-905160 20010712
 US 6764840 B2 20040720
 AU 2001019189 A5 20010606 AU 2001-19189 20011113
 AU 773921 B2 20040610
 US 2003092643 A1 20030515 US 2002-43086 20020108
 US 2003199460 A1 20031023 US 2002-137730 20020430
 NO 2002002207 A 20020710 NO 2002-2207 20020508
 PRAI US 1997-853826 A2 19970508
 US 1991-815250 A 19911231
 US 1998-138305 A1 19980821
 US 1999-429238 A 19991028
 US 1999-439839 A 19991112
 US 2000-190444P P 20000317
 WO 2000-US31340 W 20001113
 US 2001-905160 A2 20010712
 US 2002-43086 A2 20020108

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6303347	ICM	C12P019-04
	ICS	A61K045-00; C07H001-00; C07H015-00; C07H011-04
	INCL	435101000
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
WO 2001034617	ECLA	C07H013/06C; C07H015/04D
US 2002045586	NCL	514/053.000; 514/054.000; 514/175.000; 536/053.000; 536/055.000; 536/055.100; 536/123.130
	ECLA	A61K031/70L15L; C07H015/04
US 2002048588	NCL	435/101.000; 424/278.100; 536/001.110
	ECLA	C07H015/04D
US 2003092643	NCL	514/042.000; 536/053.000; 536/054.000; 424/234.100
	ECLA	C07H013/06C; C07H015/04D
US 2003199460	NCL	514/042.000; 536/053.000
	ECLA	C07H013/06C; C07H015/04D

OS MARPAT 135:302901

AB Aminoalkyl glucosaminide phosphate (AGP) compds. that are adjuvants and immunoeffectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immunoeffectors are also disclosed.

ST adjuvant immunoeffector aminoalkyl glucosaminide phosphate compd

IT Immunoglobulins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (A; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

IT Immunoglobulins

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

- (G1; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunoglobulins
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (G2a; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunoglobulins
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (G2b; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunoglobulins
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (G; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunoglobulins
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (M; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Macrophage
 (activation; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
 (adjuvants; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antioxidants
 Egg, poultry
 Emulsions
 Influenza virus
 Vaccines
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antibodies
 Cytokines
 Immunoglobulins
 Ovalbumin
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antigens
 Phosphatidylcholines, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Phosphatidylethanolamines, biological studies
 Sphingomyelins
 Sphingosines
 Tocopherols
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Structure-activity relationship
 (antigenic; aminoalkyl glucosaminide phosphate compds. and their use as

- adjuvants and immunoeffectors)
- IT Drug delivery systems
(carriers; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT T cell (lymphocyte)
(cytotoxic; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Micelles
(dispersion; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatitis B surface; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
(immunoeffector; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(liqs., dispersions; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Cell activation
(macrophage; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(microparticles; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(microspheres; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Immunity
(mucosal; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(nasal, intra-; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Drug delivery systems
(oily, metabolizable; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT Toxoids
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetanus; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT 60-18-4, L-Tyrosine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adsorbate; aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT 125978-95-2, Nitric oxide synthetase
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT 3416-24-8D, 2-Deoxy-2-amino-D-glucose, aminoalkyl phosphate derivs.
27194-79-2D, D-Glucosamine phosphate, aminoalkyl derivs.
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
- IT 66-84-2, D-Glucosamine hydrochloride 111-64-8, Octanoyl chloride
112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8,
Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl
chloride 1738-72-3, L-Serine benzyl ester 2528-61-2, Heptanoyl
chloride 2937-50-0, Allyl chloroformate 17341-93-4,
2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl

3-oxotetradecanoate 33243-33-3 58577-87-0 65414-74-6, L-Serinamide
hydrochloride 66937-71-1, N-(2-Hydroxyethyl)glycine tert-butyl ester
91578-89-1 109977-90-4 122078-72-2 133099-79-3, D-Serine benzyl
ester 134304-48-6 142982-11-4 166193-98-2 216013-74-0
216013-98-8 216014-16-3 216014-22-1 216014-30-1 216014-38-9
216014-70-9 252042-31-2 339078-52-3 367273-92-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants
and immunoeffectors)

IT 58577-88-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P
186383-49-3P 195434-34-5P 216013-03-5P 216013-05-7P 216013-06-8P
216013-07-9P 216013-10-4P 216013-12-6P 216013-13-7P 216013-14-8P
216013-15-9P 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P
216013-26-2P 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P
216013-31-9P 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P
216013-38-6P 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P
216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P
216013-56-8P 216013-60-4P 216013-61-5P 216013-62-6P 216013-63-7P
216013-83-1P 216013-85-3P 216013-86-4P 216013-89-7P 216013-90-0P
216013-91-1P 216013-93-3P 216013-95-5P 216013-99-9P 216014-00-5P
216014-02-7P 216014-04-9P 216014-07-2P 216014-08-3P 216014-09-4P
216014-12-9P 216014-13-0P 216014-17-4P 216014-19-6P 216014-23-2P
216014-24-3P 216014-26-5P 216014-27-6P 216014-31-2P 216014-32-3P
216014-34-5P 216014-35-6P 216014-39-0P 216014-40-3P 216014-42-5P
216014-44-7P 216014-47-0P 216014-48-1P 216014-52-7P 216014-53-8P
216014-54-9P 216014-57-2P 216014-59-4P 216014-60-7P 216014-61-8P
216014-65-2P 216014-66-3P 216014-67-4P 216014-72-1P 216014-73-2P
216014-74-3P 216014-77-6P 216014-78-7P 216014-80-1P
216014-83-4P 216014-84-5P 216014-85-6P 216014-89-0P
216014-90-3P 216014-93-6P 216014-94-7P 216014-95-8P 216014-99-2P
216015-00-8P 216015-01-9P 220048-54-4P 339078-58-9P 339078-82-9P
339078-86-3P 367273-64-1P 367273-66-3P 367273-67-4P 367273-68-5P
367273-69-6P 367273-70-9P 367273-71-0P 367273-74-3P 367273-75-4P
367273-76-5P 367273-77-6P 367273-78-7P 367273-79-8P 367273-82-3P
367273-83-4P 367273-86-7P 367273-87-8P 367273-88-9P 367273-89-0P
367273-95-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants
and immunoeffectors)

IT 339078-83-0P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants
and immunoeffectors)

IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
216013-47-7P 216013-52-4P 216013-59-1P 216013-82-0P
216013-88-6P 216013-97-7P 216014-06-1P
216014-15-2P 216014-21-0P 216014-29-8P
216014-37-8P 216014-46-9P 216014-50-5P 216014-56-1P
216014-63-0P 216014-69-6P 216014-76-5P 216014-82-3P
216014-88-9P 216014-92-5P 216014-98-1P 339078-61-4P
339078-63-6P 339078-67-0P 339078-69-2P
339078-71-6P 339078-73-8P 339078-75-0P
339078-77-2P 339078-79-4P 339078-81-8P 339079-17-3P
367273-73-2P 367273-81-2P 367273-91-4P 367273-94-7P
367273-97-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)

(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants
and immunoeffectors)

IT 56-81-5, Glycerol, biological studies 83-44-3 102-71-6,
Triethanolamine, biological studies 111-02-4, Squalene 121-44-8,
Triethylamine, biological studies 123-78-4, Sphingosine 360-65-6
923-61-5 998-07-2, 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine

1305-62-0, Calcium hydroxide, biological studies 7732-18-5, Water, biological studies 10103-46-5, Calcium phosphate 21645-51-2, Aluminum hydroxide, biological studies 106392-12-5D, PLURONIC F 68, block copolymer

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Baldridge; IBC Vaccine Conference 1998
- (2) Bulusu; J Med Chem 1992, V35(19), P3463 HCAPLUS
- (3) Eustache; Carbohydrate Research 1994, V251, P251 HCAPLUS
- (4) Ikeda; Chem Pharm Bull 1993, V41(10), P1879 HCAPLUS
- (5) Johnson; US 6113918 2000 HCAPLUS
- (6) Johnson; Bioorg Med Chem Lett 1999, V9(15), P2273 HCAPLUS
- (7) Meyers; US B14912094 1994
- (8) Miyajima; Chem Pharm Bull 1996, V44(12), P2268
- (9) Myers; US 4912094 1990 HCAPLUS
- (10) Shimizu; Chem Pharm Bull 1985, V33(10), P4621 HCAPLUS
- (11) Shimizu; Int J Immunopharmacol 1994, V16(8), P659 HCAPLUS
- (12) Shimizu; Int J Immunopharmacol 1995, V17(5), P425 HCAPLUS


IT 216014-80-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

RN 216014-80-1 HCAPLUS

CN Tetradecanamide, N-[(1S)-2-amino-1-[[[2-deoxy-4-O-(diphenoxyphosphinyl)-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranosyl]oxy]methyl]-2-oxoethyl]-3-[(1-oxotetradecyl)oxy]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:713123 HCAPLUS

DN 135:267269

ED Entered STN: 28 Sep 2001

TI Mono- and disaccharides for the treatment of nitric oxide related disorders

IN Elliot, Gary; Johnson, David; Weber, Patricia A.; Sowell, Greg

PA Corixa Corp., USA

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent

Search done by Noble Jarrell

LA English
 IC A61K031-00
 CC 1-12 (Pharmacology)
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070209	A2	20010927	WO 2001-US8513	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2403075	AA	20010927	CA 2001-2403075	20010315
	EP 1265620	A2	20021218	EP 2001-920455	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004521062	T2	20040715	JP 2001-568407	20010315
PRAI	US 2000-190444P	P	20000317		
	US 2001-808669	A	20010314		
	WO 2001-US8513	W	20010315		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001070209	IC	A61K031-00
WO 2001070209	ECLA	A61K031/70L15L; C07H015/04
JP 2004521062	FTERM	4C057/BB02; 4C057/BB03; 4C057/CC03; 4C057/DD02; 4C057/DD03; 4C057/HH03; 4C057/JJ10; 4C086/AA02; 4C086/AA03; 4C086/EA05; 4C086/MA02; 4C086/MA06; 4C086/MA52; 4C086/MA55; 4C086/MA65; 4C086/NA14; 4C086/ZA36; 4C086/ZA51; 4C086/ZA54; 4C086/ZA59; 4C086/ZB35

OS MARPAT 135:267269

AB Methods for treating diseases or conditions modulated or ameliorated by nitric oxide, particularly ischemia and reperfusion injury, are provided, using glycolipids structurally related to monophosphoryl lipid A but with notable reduction in proinflammatory and pyrogenic activity.

ST nitric oxide related disorder treatment disaccharide; monosaccharide nitric oxide related disorder treatment; ischemia reperfusion injury treatment nitric oxide disaccharide

IT Leg

(amputation and reattachment, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury)

IT Artery

(angioplasty, restenosis in, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)

IT Drug delivery systems

(bolus; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)

IT Cytoprotective agents

(cardioprotective; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)

IT Blood vessel

(clamping, treatment of ischemia and reperfusion injury from; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)

IT Artery, disease

- (coronary, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Death
(drowning, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery systems containing; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(emulsions; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Skin
(flap translocation, treatment of ischemia and reperfusion injury from; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Hypoxia, animal
(hypoxemia, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Heart, disease
Intestine, disease
(infarction, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inflammatory, low ability for induction of; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(infusions; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(injections, i.v.; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Reperfusion
(injury; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity).
- IT Drug delivery systems
(lipid vesicles; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(liposomes; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Interleukin 1 β
Interleukin 8
Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

- (low ability for induction of; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Anti-ischemic agents
Anticoagulants
Drug delivery systems
Fever and Hyperthermia
Inflammation
(mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Disaccharides
Monosaccharides
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Surgery
(myoplasty, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Emulsions
(oil-in-water, drug delivery systems containing; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(oral; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(parenterals; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Surgery
(plastic, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Intestine
(resection, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Artery, disease
(restenosis, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Shock (circulatory collapse)
(septic, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Bronchi
(spasm, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Artery
(stenting, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less


- proinflammatory and pyrogenic activity)
- IT Brain, disease
(stroke, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Drug delivery systems
(surfactant-containing vesicles; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Heart
Thorax
(surgery, treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Thrombolytics
(treatment of ischemia and reperfusion injury from; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT Artery, disease
Blood vessel, disease
Lung, disease
Multiple organ failure
Pregnancy
Surgery
Thrombosis
Transplant and Transplantation
(treatment of ischemia and reperfusion injury in; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT 125978-95-2, Nitric oxide synthase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(constitutive and inducible; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 7732-18-5, Water, biological studies 25322-68-3, Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery systems containing; mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT 216014-36-7 216014-45-8 216014-55-0 216014-75-4
216014-81-2 245515-64-4 245515-66-6
245515-68-8 252042-16-3 252042-50-5 253119-91-4, RC-552
362594-85-2 362594-86-3 362594-87-4 362594-88-5
362594-89-6 362594-90-9 362594-91-0
362594-92-1
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT 10102-43-9, Nitric oxide, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)
- IT 216014-36-7
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or

effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mono- and disaccharides for treatment of nitric oxide related disorders particularly ischemia and reperfusion injury but with less proinflammatory and pyrogenic activity)

RN 216014-36-7 HCAPLUS

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxoheptyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:360008 HCAPLUS

DN 134:353474

ED Entered STN: 18 May 2001

TI Preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors

IN Johnson, David A.; Sowell, C. Gregory

PA Corixa Corporation, USA

SO PCT Int. Appl., 147 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 15, 34, 63

FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034617	A2	20010517	WO 2000-US31340	20001113
WO 2001034617	A3	20011108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6303347	B1	20011016	US 1999-439839	19991112
CA 2391299	AA	20010517	CA 2000-2391299	20001113
EP 1230250	A2	20020814	EP 2000-982119	20001113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				


BR 2000015501	A	20030225	BR 2000-15501	20001113
JP 2003514783	T2	20030422	JP 2001-537329	20001113
NZ 518860	A	20041126	NZ 2000-518860	20001113
AU 2001019189	A5	20010606	AU 2001-19189	20011113
AU 773921	B2	20040610		
NO 2002002207	A	20020710	NO 2002-2207	20020508
PRAI US 1999-439839	A	19991112		
US 1997-853826	A2	19970508		
WO 2000-US31340	W	20001113		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001034617	ICM	C07H
WO 2001034617	ECLA	C07H013/06C; C07H015/04D
US 6303347	NCL	435/101.000; 424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D

OS MARPAT 134:353474

GI



AB Aminoalkyl glucosaminide phosphate compds. (AGP) I were prepared wherein, X is selected from the group consisting of O and S at the axial or equatorial position; Y is selected from the group consisting of O and NH; Q is (CH₂)_n; L is (CH₂)_m; W is (CH₂)_q; n, m, p, q are integers from 0 to 6; R is (CH₂)₁₀Me; R₁-R₃ are the same or different and are normal fatty acyl residues having from 1 to about 20 carbon atoms and where one of R₁-R₃ is optionally hydrogen; R₄ and R₅ are the same or different and are selected from the group consisting of H and methyl; R₆ and R₇ are the same or different and are selected from the group consisting of H, hydroxy, alkoxy, phosphono, phosphonoxy, sulfo, sulfoxy, amino, mercapto, cyano, nitro, formyl and carboxy, and esters and amides thereof; and R₈ and R₉ are the same or different and are selected from the group consisting of phosphono and H, and at least one of R₈ and R₉ is phosphono, that are adjuvants and immuno-effectors are described and claimed. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compds. are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immuno-effectors are also disclosed. Thus, N-[(R)-3-hydroxytetradecanoyl]-O-[2-deoxy-4-O-phosphono-2-[(R)-3-dodecanoyloxytetradecanoylamino]-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-α-L-D-glucopyranosyl]-L-serine triethylammonium salt was prepared and tested in mice as adjuvants and immuno-effectors. Mice vaccinated with formalin-inactivated influenza and the AGP compds. of the subject invention mounted a protective immune response to an influenza challenge as well as produced antibody to that antigen.

ST antiinfluenza IgG immunoefector aminoalkyl glucosaminide phosphate prepn; cytokine adjuvant immunoefector antitetanus toxoid amino acid prepn

glycoside; aminoalkyl glucosaminide phosphate prepn adjuvant
immunoefector antitetanus toxoid antibody

IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G1; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G2a; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G2b; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Influenza
(anti; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Macrophage
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Amino acids, preparation
Antibodies
Cytokines
Glycosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT Toxoids
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tetanus; preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P
216013-82-0P 216013-88-6P 216013-97-7P
216014-06-1P 216014-15-2P 216014-21-0P
216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P
216014-56-1P 216014-63-0P 216014-69-6P 216014-76-5P
216014-82-3P 216014-88-9P 216014-92-5P 216014-98-1P
339078-59-0P 339078-61-4P 339078-63-6P 339078-65-8P
339078-67-0P 339078-69-2P 339078-71-6P
339078-73-8P 339078-75-0P 339078-77-2P
339078-79-4P 339078-81-8P 339078-85-2P 339079-17-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 109361-17-3
RL: CAT (Catalyst use); USES (Uses)
(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 66-84-2 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride

112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl chloride 2456-81-7, 4-Pyrrolidinopyridine 2528-61-2, Heptanoyl chloride 17341-93-4, 2,2,2-Trichloroethyl chloroformate 22348-97-6, Methyl 3-oxotetradecanoate 22572-40-3, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide methiodide 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66270-36-8, 2,2,2-Trichloro-1,1-dimethylethyl chloroformate 66937-71-1 109977-90-4 122078-72-2 133099-79-3, D-Serine benzyl ester 134304-48-6 166193-98-2 190586-91-5 216014-70-9 339078-52-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 1738-72-3P 2524-64-3P, Diphenyl chlorophosphate 76062-98-1P
87357-76-4P 91578-89-1P 91681-56-0P 122105-45-7P 122210-01-9P
186383-49-3P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
216013-10-4P 216013-12-6P 216013-13-7P 216013-14-8P 216013-15-9P
216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P 216013-26-2P
216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P 216013-31-9P
216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P 216013-38-6P
216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P 216013-53-5P
216013-54-6P 216013-55-7P 216013-56-8P 216013-60-4P 216013-61-5P
216013-62-6P 216013-63-7P 216013-66-0P 216013-67-1P 216013-69-3P
216013-70-6P 216013-71-7P 216013-75-1P 216013-77-3P 216013-78-4P
216013-79-5P 216013-80-8P 216013-83-1P 216013-85-3P 216013-89-7P
216013-90-0P 216013-91-1P 216013-92-2P 216013-93-3P 216013-95-5P
216013-98-8P 216013-99-9P 216014-00-5P 216014-01-6P 216014-02-7P
216014-04-9P 216014-07-2P 216014-08-3P 216014-09-4P 216014-11-8P
216014-12-9P 216014-13-0P 216014-16-3P 216014-17-4P 216014-19-6P
216014-22-1P 216014-23-2P 216014-24-3P 216014-25-4P 216014-26-5P
216014-27-6P 216014-30-1P 216014-31-2P 216014-32-3P 216014-33-4P
216014-34-5P 216014-35-6P 216014-38-9P 216014-39-0P 216014-40-3P
216014-41-4P 216014-42-5P 216014-44-7P 216014-47-0P 216014-48-1P
216014-52-7P 216014-53-8P 216014-54-9P 216014-57-2P 216014-59-4P
216014-60-7P 216014-61-8P 216014-65-2P 216014-66-3P 216014-67-4P
216014-72-1P 216014-73-2P 216014-74-3P 216014-77-6P 216014-78-7P
216014-80-1P 216014-83-4P 216014-84-5P 216014-85-6P
216014-89-0P 216014-90-3P 216014-93-6P 216014-94-7P 216014-95-8P
216014-99-2P 216015-00-8P 216015-01-9P 220048-54-4P 339078-53-4P
339078-54-5P 339078-58-9P 339078-82-9P 339078-83-0P 339078-86-3P
339078-87-4P 339079-15-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bulusu, M; J Med Chem 1992, V35, P3463 HCAPLUS
- (2) Ikeda, K; Chem Pharm Bull 1993, V41(10), P1879 HCAPLUS
- (3) Miyajima, K; Chem Pharm Bull 1996, V44(12), P2268
- (4) Shimizu, T; Chem Pharm Bull 1985, V33(10), P4621 HCAPLUS
- (5) Shimizu, T; Int J Immunopharmac 1994, V16(8), P659 HCAPLUS
- (6) Shimizu, T; Int J Immunopharmac 1995, V17(5), P425 HCAPLUS

IT 216013-82-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

RN 216013-82-0 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

Absolute stereochemistry.




CRN 121-44-8
CMF C6 H15 N



L37 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:769093 HCAPLUS
DN 132:137639
ED Entered STN: 06 Dec 1999
TI Synthesis and biological evaluation of a new class of vaccine adjuvants:
aminoalkyl glucosaminide 4-phosphates (AGPs). [Erratum to document cited
in CA131:272113]
AU Johnson, David A.; Sowell, C. Gregory; Johnson, Craig
L.; Livesay, Mark T.; Keegan, David S.; Gustafson, Gary L.; Rhodes,
Michael J.; Ulrich, J. Terry; Ward, Jon R.; Cantrell, John L.; Brookshire,
Valerie G.
CS Pharmaceutical Discovery Division, Ribic ImmunoChem Research, Inc.,
Hamilton, MT, 59840, USA
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(22), 3260
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
CC 33-7 (Carbohydrates)
Section cross-reference(s): 1
AB The name of coauthor Gary L. Gustafson was omitted fro the list of
authors' names; the complete list is reprinted.
ST erratum vaccine adjuvant aminodeoxyphosphonoglucopyranoside; vaccine
adjuvant aminodeoxyphosphonoglucopyranoside erratum; aminoalkyl serine
glucosaminide phosphate prepn erratum; serine glucosaminide phosphate
prepn immunostimulant erratum
IT Immunostimulants
(adjuvants; synthesis and biol. evaluation of a new class of vaccine
adjuvants: aminoalkyl glucosaminide phosphates (Erratum))

- IT T cell (lymphocyte)
(cytotoxic; synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates (Erratum))
- IT Immunostimulants
Vaccines
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates (Erratum))
- IT Toxoids
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(tetanus; synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates (Erratum))
- IT 216013-08-0P 216013-18-2P 216013-81-9P 216013-87-5P
216014-05-0P 216014-14-1P 216014-28-7P
216014-45-8P 216014-49-2P 216014-55-0P 216014-62-9P 216014-68-5P
216014-75-4P 216014-81-2P 216014-87-8P
245515-64-4P 245515-66-6P 245515-68-8P 245515-70-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates (Erratum))
- IT 216013-92-2 216014-11-8 216014-33-4 216014-47-0 216014-52-7
216014-57-2 216014-59-4 216014-65-2 216014-72-1 216014-77-6
216014-83-4 245515-71-3 245515-73-5 245515-74-6 245515-75-7
245515-76-8 245515-77-9 245515-78-0 245515-79-1 245515-80-4
245515-82-6 245515-83-7 245515-84-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates (Erratum))
- IT 216013-81-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates (Erratum))
- RN 216013-81-9 HCAPLUS
- CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry:



L37 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:536699 HCAPLUS
DN 131:272113

Search done by Noble Jarrell

ED Entered STN: 27 Aug 1999

TI Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)

AU Johnson, David A.; Sowell, C. Gregory; Johnson, Craig L.; Livesay, Mark T.; Keegan, David S.; Rhodes, Michael J.; Ulrich, J. Terry; Ward, Jon R.; Cantrell, John L.; Brookshire, Valerie G.

CS Pharmaceutical Discovery Division, Ribl ImmunoChem Research, Inc., Hamilton, MT, 59840, USA

SO Bioorganic & Medicinal Chemistry Letters (1999), 9(15), 2273-2278
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

CC 33-7 (Carbohydrates)
Section cross-reference(s): 1

AB A novel series of acylated α -aminoalkyl 2-amino-2-deoxy-4-phosphono- β -D-glucopyranosides (aminoalkyl glucosaminide 4-phosphates) was synthesized and screened for immunostimulant activity. Several of these compds. enhance the production of tetanus toxoid-specific antibodies in mice and augment vaccine-induced cytotoxic T cells against EG.7-ova target cells.

ST vaccine adjuvant aminodeoxyphosphonoglucopyranoside; aminoalkyl serine glucosaminide phosphate prepn immunostimulant

IT Immunostimulants
(adjuvants; synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

IT T cell (lymphocyte)
(cytotoxic; synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

IT Immunostimulants
Vaccines
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

IT Toxoids
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(tetanus; synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

IT 216013-08-0P 216013-18-2P 216013-81-9P 216013-87-5P
216014-05-0P 216014-14-1P 216014-28-7P
216014-45-8P 216014-49-2P 216014-55-0P 216014-62-9P 216014-68-5P
216014-75-4P 216014-81-2P 216014-87-8P
245515-64-4P 245515-66-6P 245515-68-8P 245515-70-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

IT 216013-92-2 216014-11-8 216014-33-4 216014-47-0 216014-52-7
216014-57-2 216014-59-4 216014-65-2 216014-72-1 216014-77-6
216014-83-4 245515-71-3 245515-73-5 245515-74-6 245515-75-7
245515-76-8 245515-77-9 245515-78-0 245515-79-1 245515-80-4
245515-82-6 245515-83-7 245515-84-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abiko, A; Tetrahedron Lett 1992, V33, P5517 HCAPLUS
- (2) Beutler, B; Ann Rev Immunol 1989, V7, P625 HCAPLUS
- (3) DeForge, L; J Immunol 1992, V148, P2133 HCAPLUS
- (4) Durum, S; Ann Rev Immunol 1985, V3, P263 HCAPLUS
- (5) Fukase, K; Tetrahedron 1998, V54, P4033 HCAPLUS
- (6) Gustafson, G; Bacterial Endotoxins: Lipopolysaccharides from Genes to Therapy, Progress in Clinical and Biological Research 1995, V392, P567 HCAPLUS

- (7) Hibbs, J; Biochem Biophys Res Commun 1988, V157, P87 HCAPLUS
 (8) Johnson, A; Clin Microbiol Rev 1994, V7, P277 HCAPLUS
 (9) Johnson, D; J Carbohydr Chem 1998, V17, P1421 HCAPLUS
 (10) Johnson, D; J Med Chem submitted
 (11) Kawai, Y; Infect Immun 1989, V57, P2086 HCAPLUS
 (12) Keegan, D; Tetrahedron: Asymmetry 1996, V7, P3559 HCAPLUS
 (13) Kiso, M; Carbohydr Res 1987, V162, P127 HCAPLUS
 (14) Kusama, T; Chem Pharm Bull 1991, V39, P3244 HCAPLUS
 (15) Moore, M; Cell 1988, V55, P777
 (16) Myers, K; Cellular and Molecular Aspects of Endotoxin Reactions 1990, V1, P145
 (17) Nerad, J; J Leukocyte Biol 1992, V52, P687 HCAPLUS
 (18) Quereshi, N; The Bacteria 1990, V11, P319
 (19) Rudbach, J; Theory and Practical Application of Adjuvants 1995, P287
 (20) Seydel, U; Immunobiol 1993, V187, P191 HCAPLUS
 (21) Shiozaki, M; Tetrahedron 1998, V54, P11861 HCAPLUS
 (22) Snapper, C; Fundamental Immunology 4th ed 1999, P831
 (23) Ulrich, J; Vaccine Design: The Subunit and Adjuvant Approach 1995, P495 HCAPLUS
 (24) Werner, G; Eur J Biochem 1996, V242, P1 HCAPLUS


IT 216013-81-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and biol. evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide phosphates)

RN 216013-81-9 HCAPLUS

CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:745066 HCAPLUS

DN 130:14164

ED Entered STN: 24 Nov 1998

TI Preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors

IN Johnson, David A.; Sowell, C. Gregory

PA Ribi Immunochem Research, Inc., USA

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H015-04


Search done by Noble Jarrell

ICS A61K031-70
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 1, 15, 63
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850399	A1	19981112	WO 1998-US9385	19980507
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6113918	A	20000905	US 1997-853826	19970508
	CA 2288601	AA	19981112	CA 1998-2288601	19980507
	AU 9874747	A1	19981127	AU 1998-74747	19980507
	AU 740663	B2	20011108		
	EP 983286	A1	20000308	EP 1998-922138	19980507
	EP 983286	B1	20040728		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9809791	A	20000627	BR 1998-9791	19980507
	JP 2002512623	T2	20020423	JP 1998-548512	19980507
	NZ 500938	A	20020531	NZ 1998-500938	19980507
	AP 1181	A	20030630	AP 1999-1693	19980507
	W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
	AT 272067	E	20040815	AT 1998-922138	19980507
	PL 188046	B1	20041130	PL 1998-343205	19980507
	ES 2224397	T3	20050301	ES 1998-922138	19980507
	MX 9910262	A	20000831	MX 1999-10262	19991108
PRAI	US 1997-853826	A	19970508		
	WO 1998-US9385	W	19980507		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9850399	ICM	C07H015-04
	ICS	A61K031-70
WO 9850399	ECLA	C07H015/04D
US 6113918	NCL	424/278.100; 536/001.110; 536/018.400; 536/117.000; 536/119.000
	ECLA	C07H015/04D
AP 1181	ECLA	C07H015/04D
OS	MARPAT	130:14164
GI		



AB Aminoalkyl glucosamine phosphate compds. I (R = substituted alkyl; R1, R2 = H, phosphono; R3, R4 = fatty acid residue; R5 = undecyl; X = O, S; Y = O, NH) were prepared as adjuvants and immunoeffectors. The compds. have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon)

group. Compsds. are phosphorylated at the 4 or 6 carbon on the glucosamine ring and comprise three 3-alkanoyloxyalkanoyl residues. The compds. augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compds. as adjuvants and immunoeffectors are also disclosed. Thus, N-carboxymethyl-N-[(R)-3-decanoyloxytetradecanoyl]-3-aminopropyl-2-deoxy-4-O-phosphono-2-[(R)-3-decanoyloxytetradecanoylamino]-3-O-[(R)-3-decanoyloxytetradecanoyl]- β -D-glucopyranoside triethylammonium salt was prepared and tested as adjuvant and immunoeffector for anti-tetanus and anti-influenza activities.

- ST virucide vaccine aminoalkyl glucosamine phosphate prepn; cytokine prodn vaccine aminoalkyl glucosamine phosphate; vaccine antiinfluenza aminoalkyl glucosamine phosphate prepn; immunization antitetanus aminoalkyl glucosamine phosphate prepn; antitetanus IgG aminoalkyl glucosamine phosphate prepn; aminoalkyl glucosamine phosphate prepn immunoeffector adjuvant
- IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Immunostimulants
(adjuvants; preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antiviral agents
Immunization
Vaccines
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Glycosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT Antibodies
Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT 216013-09-1P 216013-19-3P 216013-24-0P 216013-34-2P 216013-41-1P
216013-47-7P 216013-52-4P 216013-59-1P 216013-65-9P 216013-73-9P
216013-82-0P 216013-88-6P 216013-97-7P
216014-06-1P 216014-15-2P 216014-21-0P
216014-29-8P 216014-37-8P 216014-46-9P 216014-50-5P
216014-56-1P 216014-63-0P 216014-69-6P 216014-76-5P
216014-82-3P 216014-88-9P 216014-92-5P 216014-98-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT 109361-17-3
RL: CAT (Catalyst use); USES (Uses)
(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)
- IT 76062-98-1P 87357-76-4P 91681-56-0P 122105-45-7P 122210-01-9P
216013-02-4P 216013-03-5P 216013-05-7P 216013-06-8P 216013-07-9P
216013-10-4P 216013-11-5P 216013-12-6P 216013-13-7P 216013-14-8P
216013-15-9P 216013-16-0P 216013-20-6P 216013-21-7P 216013-22-8P
216013-26-2P 216013-27-3P 216013-28-4P 216013-29-5P 216013-30-8P
216013-31-9P 216013-32-0P 216013-35-3P 216013-36-4P 216013-37-5P
216013-38-6P 216013-42-2P 216013-43-3P 216013-44-4P 216013-45-5P
216013-49-9P 216013-50-2P 216013-53-5P 216013-54-6P 216013-55-7P

216013-56-8P	216013-60-4P	216013-61-5P	216013-62-6P	216013-63-7P
216013-66-0P	216013-67-1P	216013-69-3P	216013-70-6P	216013-71-7P
216013-75-1P	216013-77-3P	216013-78-4P	216013-79-5P	216013-80-8P
216013-83-1P	216013-85-3P	216013-86-4P	216013-89-7P	216013-90-0P
216013-91-1P	216013-92-2P	216013-93-3P	216013-95-5P	216013-98-8P
216013-99-9P	216014-00-5P	216014-01-6P	216014-02-7P	216014-04-9P
216014-07-2P	216014-08-3P	216014-09-4P	216014-11-8P	216014-12-9P
216014-13-0P	216014-16-3P	216014-17-4P	216014-19-6P	216014-22-1P
216014-23-2P	216014-24-3P	216014-25-4P	216014-26-5P	216014-27-6P
216014-30-1P	216014-31-2P	216014-32-3P	216014-33-4P	216014-34-5P
216014-35-6P	216014-38-9P	216014-39-0P	216014-40-3P	216014-41-4P
216014-42-5P	216014-44-7P	216014-47-0P	216014-48-1P	216014-52-7P
216014-53-8P	216014-54-9P	216014-57-2P	216014-59-4P	216014-60-7P
216014-61-8P	216014-65-2P	216014-66-3P	216014-67-4P	216014-72-1P
216014-73-2P	216014-74-3P	216014-77-6P	216014-78-7P	
216014-80-1P	216014-83-4P	216014-84-5P	216014-85-6P	
216014-89-0P	216014-90-3P	216014-93-6P	216014-94-7P	216014-95-8P
216014-99-2P	216015-00-8P	216015-01-9P		

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 66-84-2, D-Glucosamine hydrochloride 99-73-0, 2,4'-Dibromoacetophenone 111-64-8, Octanoyl chloride 112-13-0, Decanoyl chloride 112-16-3, Lauroyl chloride 112-37-8, Undecanoic acid 112-64-1, Myristoyl chloride 764-85-2, Nonanoyl chloride 1738-72-3, L-Serine benzyl ester 2528-61-2, Heptanoyl chloride 22348-97-6, Methyl 3-oxotetradecanoate 58577-87-0 65414-74-6, L-Serinamide hydrochloride 66270-36-8 66937-71-1 91578-89-1 122078-72-2 133099-79-3, D-Serine benzyl ester 142982-11-4 166193-98-2 216013-74-0 216014-70-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Eustache, J; Carbohydrate Research 1994, V251, P251 HCAPLUS
- (2) Ikeda, K; Chemical and Pharmaceutical Bulletin 1993, V41(10), P1879 HCAPLUS
- (3) Miyajima, K; Chemical and Pharmaceutical Bulletin 1996, V44(12), P2268

IT 216013-82-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

RN 216013-82-0 HCAPLUS


CN L-Serine, O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-N-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 216013-81-9

CMF C93 H175 N2 O19 P

Absolute stereochemistry.



CRN 121-44-8
CMF C6 H15 N



```
==> d bib abs hitrn 138 tot
```

```

L38  ANSWER 1 OF 12  USPATFULL ON STN
AN   2005:125210  USPATFULL
TI   Processes for the production of aminoalkyl glucosaminide phosphate and
      disaccharide immunoeffectors, and intermediates therefor
IN   Johnson, David A., Hamilton, MT, UNITED STATES
      Johnson, Craig L., Hamilton, MT, UNITED STATES
      Bazin-Lee, Helene G., Stevensville, MT, UNITED STATES
      Sowell, C. Gregory, Mukilteo, WA, UNITED STATES
PA   Corixa Corporation, a corporation of the state of Delaware,
      Seattle, WA, UNITED STATES (U.S. corporation)
PI   US 2005107600      A1      20050519
AI   US 2004-897194      A1      20040721 (10)
RLI  Continuation-in-part of Ser. No. US 2004-472991, filed on 12 Aug 2004,
      PENDING A 371 of International Ser. No. WO 2003-US21504, filed on 8 Jul
      2003
PRAI US 2002-394487P      20020708 (60)
DT   Utility
FS   APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
      FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN  Number of Claims: 115
ECL   Exemplary Claim: 1
DRWN  No Drawings
LN.CNT 1991

```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to processes for production of alkylamino glucosaminide phosphate compounds, and of disaccharide compounds, including various novel intermediates and intermediate processes. In one aspect, glycosyl halides are produced by reaction of an O-silyl glycoside with a dihalomethyl alkyl ether.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216014-15-2P

(processes for the production of amino-alkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor via glycosylation reaction)

L38 ANSWER 2 OF 12 USPATFULL on STN

AN 2004:335912 USPATFULL

TI Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor

IN Johnson, David A., Hamilton, MT, UNITED STATES
Johnson, Craig L., Hamilton, MT, UNITED STATES
Bazin, Helene G., Stevensville, MT, UNITED STATES
Sowell, C. Gregory, Mukilteo, WA, UNITED STATES

PI US 2004267007 A1 20041230

AI US 2004-472991 A1 20040812 (10)

WO 2003-US21504 20030708

PRAI US 2002-60394487 20020708

US 2003-60438585 20030106

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 113

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to processes for production of alkylamino glucosaminide phosphate compounds, and of disaccharide compounds, including various novel intermediates and intermediate processes. In one aspect, glycosyl halides are produced by reaction of an O-silyl glycoside with a dihalomethyl alkyl ether.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216014-15-2P

(processes for production of aminoalkyl glucosaminide phosphate and disaccharide potential immunoeffectors via silylation and halogenation reactions)

L38 ANSWER 3 OF 12 USPATFULL on STN

AN 2004:190707 USPATFULL

TI Prophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds

IN Persing, David H., Redmond, WA, UNITED STATES
Crane, Richard T., Hamilton, MT, UNITED STATES
Elliott, Gary T., Stevensville, MT, UNITED STATES
Ulrich, J. Terry, Corvallis, MT, UNITED STATES
Lacy, Michael J., Hamilton, MT, UNITED STATES
Johnson, David A., Hamilton, MT, UNITED STATES
Baldridge, Jory R., Victor, MT, UNITED STATES
Wang, Rong, Missoula, MT, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2004147480 A1 20040729

AI US 2004-757233 A1 20040113 (10)

RLI Continuation of Ser. No. US 2001-991376, filed on 20 Nov 2001, PENDING
Continuation-in-part of Ser. No. US 2001-861466, filed on 18 May 2001, PENDING

PRAI US 2001-281567P 20010404 (60)
US 2000-205820P 20000519 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1470

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216013-82-0 216013-88-6 216013-97-7
216014-15-2 216014-21-0 216014-29-8
216014-37-8 376394-26-2
(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

L38 ANSWER 4 OF 12 USPATFULL on STN

AN 2003:324306 USPATFULL
TI Compositions and methods for viral delivery
IN Mossman, Sally, Seattle, WA, UNITED STATES
Evans, Lawrence, Seattle, WA, UNITED STATES
Swanson, Ryan M., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)
PI US 2003228279 A1 20031211
AI US 2002-283484 A1 20021029 (10)
PRAI US 2002-369715P 20020403 (60)
US 2001-335512P 20011031 (60)

DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods comprising a recombinant virus and an immunostimulant are provided for enhancing the immune response to a polypeptide expressed from the recombinant virus. Preferably this is done without also enhancing the neutralizing antibody response to the recombinant virus. Illustrative compositions comprise an adenovirus and an adjuvant such as, for example, monophosphoryl lipid A, an alkyl glucosaminide phosphate, a saponin, or a combination thereof. The disclosed compositions and methods are useful, for example, in the treatment of diseases such as cancer or infectious disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 521333-28-8
(viral vector and immunostimulant for delivering vaccine and enhancing immune response without causing neutralizing antibody response to viral vector)

L38 ANSWER 5 OF 12 USPATFULL on STN

AN 2003:283116 USPATFULL
TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
IN Johnson, David A., Hamilton, MT, UNITED STATES

Sowell, C. Gregory, Mukilteo, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003199460 A1 20031023

AI US 2002-137730 A1 20020430 (10)

RLI Continuation-in-part of Ser. No. US 2002-43086, filed on 8 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2001-905160, filed on 12 Jul 2001, PENDING Continuation of Ser. No. US 1999-439839, filed on 12 Nov 1999, GRANTED, Pat. No. US 6303347 Continuation-in-part of Ser. No. US 1997-853826, filed on 8 May 1997, GRANTED, Pat. No. US 6113918

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5737

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216013-82-0P 216013-88-6P 216013-97-7P
 216014-06-1P 216014-15-2P 216014-21-0P
 216014-29-8P 216014-37-8P 216014-76-5P
 216014-82-3P 339078-59-0P 339078-61-4P
 339078-67-0P 339078-69-2P 339078-71-6P
 339078-73-8P 339078-75-0P 339078-77-2P
 339079-17-3P
 (preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

IT 216014-80-1P 216014-85-6P
 (preparation of aminoalkyl glucosaminide phosphates and their use as adjuvants and immuno-effectors)

L38 ANSWER 6 OF 12 USPATFULL on STN

AN 2003:201370 USPATFULL

TI Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds

IN Persing, David H., Redmond, WA, UNITED STATES
 Crane, Richard T., Hamilton, MT, UNITED STATES
 Elliot, Gary T., Stevensville, MT, UNITED STATES
 Ulrich, J. Terry, Corvallis, MT, UNITED STATES
 Lacy, Michael J., Hamilton, MT, UNITED STATES
 Johnson, David A., Hamilton, MT, UNITED STATES
 Baldridge, Jory R., Victor, MT, UNITED STATES
 Wang, Rong, Missoula, MT, UNITED STATES

PI US 2003139356 A1 20030724

AI US 2001-991376 A1 20011120 (9)

RLI Continuation-in-part of Ser. No. US 2001-861466, filed on 18 May 2001, PENDING

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 35 Drawing Page(s)

LN.CNT 1561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216013-82-0 216013-88-6, RC 560 216013-97-7,
 RC 538 216014-06-1 216014-15-2, RC 527
 216014-21-0, RC 537 216014-29-8, RC 555
 216014-37-8, RC 554 216014-82-3 376394-26-2,
 RC 526 566170-23-8 566170-24-9 566170-25-0
 566170-26-1 566170-28-3 566170-30-7
 (prophylaxis and treatment of infectious diseases and allergy with
 mono- and disaccharide-based compds.)

L38 ANSWER 7 OF 12 USPATFULL on STN

AN 2003:153364 USPATFULL

TI Phophylactic and therapeutic treatment of infectious and other diseases
 with mono-and disaccharide-based compounds

IN Persing, David H., Sammamish, WA, UNITED STATES
 Crane, Richard Thomas, Hamilton, MT, UNITED STATES
 Elliott, Gary T., Pacifica, CA, UNITED STATES
 Ulrich, J. Terry, Corvallis, MT, UNITED STATES
 Lacy, Michael J., Hamilton, MT, UNITED STATES
 Johnson, David A., Hamilton, MT, UNITED STATES
 Baldrige, Jory R., Victor, MT, UNITED STATES
 Wang, Rong, Missoula, MT, UNITED STATES

PI US 2003105032 A1 20030605

AI US 2002-128156 A1 20020422 (10)

RLI Continuation-in-part of Ser. No. US 2001-991376, filed on 20 Nov 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-861466, filed on 18 May
 2001, PENDING

PRAI US 2001-281567P 20010404 (60)

US 2000-205820P 20000519 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
 FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 35 Drawing Page(s)

LN.CNT 1656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216013-82-0 216013-88-6 216013-97-7
 216014-15-2 216014-21-0 216014-29-8
 216014-37-8 376394-26-2
 (prophylactic and therapeutic treatment of infectious and other
 diseases with mono- and disaccharide-based compds. in relation to
 toxicity)

L38 ANSWER 8 OF 12 USPATFULL on STN

AN 2003:134554 USPATFULL

TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants
 and immunoeffectors

IN Johnson, David A., Hamilton, MT, UNITED STATES
 Sowell, C. Gregory, Mukilteo, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)
 PI US 2003092643 A1 20030515
 AI US 2002-43086 A1 20020108 (10)
 RLI Continuation-in-part of Ser. No. US 2001-905160, filed on 12 Jul 2001,
 PENDING Continuation of Ser. No. US 1999-439839, filed on 12 Nov 1999,
 GRANTED, Pat. No. US 6303347 Continuation-in-part of Ser. No. US
 1997-853826, filed on 8 May 1997, GRANTED, Pat. No. US 6113918
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 48
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Page(s)
 LN.CNT 5672

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants
 and immunoeffectors are described and claimed. The compounds have a
 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl
 (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on
 the glucosaminide ring and comprise three 3- alkanoyloxyalkanoyl
 residues. The compounds augment antibody production in immunized animals
 as well as stimulate cytokine production and activate macrophages.
 Compositions and methods for using the compounds as adjuvants and
 immunoeffectors are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216014-80-1P 216014-85-6P
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds.
 as adjuvants and immunoeffectors for treating cancerous and infectious
 diseases)
 IT 216014-37-8P 339078-67-0P 339078-71-6P
 339078-75-0P 339078-77-2P 339079-17-3P
 525604-83-5P
 (vaccine compns. comprising aminoalkyl glucosaminide phosphate compds.
 as adjuvants and immunoeffectors for treating cancerous and infectious
 diseases)

L38 ANSWER 9 OF 12 USPATFULL on STN

AN 2002:149148 USPATFULL
 TI Prophylactic and therapeutic treatment of infectious and other diseases
 with mono- and disaccharide-based compounds
 IN Persing, David H., Redmond, WA, UNITED STATES
 Crane, Richard Thomas, Hamilton, WA, UNITED STATES
 Elliott, Gary T., Stevensville, MT, UNITED STATES
 Ulrich, J. Terry, Corvallis, MT, UNITED STATES
 Lacy, Michael J., Hamilton, MT, UNITED STATES
 Johnson, David A., Hamilton, MT, UNITED STATES
 Baldridge, Jory R., Victor, MT, UNITED STATES
 Wang, Rong, Missoula, MT, UNITED STATES
 PI US 2002077304 A1 20020620
 US 6800613 B2 20041005
 AI US 2001-861466 A1 20010518 (9)
 PRAI US 2001-281567P 20010404 (60)
 US 2000-205820P 20000519 (60)

DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 29
 ECL Exemplary Claim: 1
 DRWN 14 Drawing Page(s)
 LN.CNT 1143

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or ameliorating diseases and other
 conditions, such as infectious diseases, autoimmune diseases and

allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 376394-26-2, RC 526 376394-27-3, RC 554
376394-28-4, RC 555 376394-29-5, RC 537
376394-30-8, RC 527 376394-31-9, RC 538
376394-32-0, RC 560 376394-46-6, RC 512
(prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compds. in relation to toxicity)

L38 ANSWER 10 OF 12 USPATFULL on STN

AN 2002:50623 USPATFULL

TI Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors

IN Johnson, David A., Hamilton, MT, United States

Sowell, C. Gregory, Hamilton, MT, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6355257 B1 20020312

AI US 1998-74720 19980507 (9)

RLI Continuation-in-part of Ser. No. US 1997-853826, filed on 8 May 1997

DT Utility

FS GRANTED

EXNAM Primary Examiner: Park, Hankyel

LREP Kullick, Ronald H.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 3451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aminoalkyl glucosamine phosphate compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosamine ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216013-82-0P 216013-88-6P 216013-97-7P
216014-06-1P 216014-15-2P 216014-21-0P
216014-29-8P 216014-37-8P 216014-76-5P
216014-82-3P

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

IT 216014-80-1P 216014-85-6P

(preparation of aminoalkyl glucosamine phosphates and their use as adjuvants and immunoeffectors)

L38 ANSWER 11 OF 12 USPATFULL on STN

AN 2001:178851 USPATFULL

TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors

IN Johnson, David A., Hamilton, MT, United States

Sowell, C. Gregory, Kirkland, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6303347 B1 20011016

AI US 1999-439839 19991112 (9)

RLI Continuation-in-part of Ser. No. US 1997-853826, filed on 8 May 1997, now patented, Pat. No. US 6113918

DT Utility

Search done by Noble Jarrell

FS GRANTED
 EXNAM Primary Examiner: Park, Hankyel T.
 LREP Seed Intellectual Property Law Group PLLC
 CLMN Number of Claims: 36
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216014-80-1P 216014-85-6P
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)
 IT 216013-82-0P 216013-88-6P 216013-97-7P
 216014-06-1P 216014-15-2P 216014-21-0P
 216014-29-8P 216014-37-8P 216014-76-5P
 216014-82-3P 339078-61-4P 339078-67-0P
 339078-69-2P 339078-71-6P 339078-73-8P
 339078-75-0P 339078-77-2P 339079-17-3P
 367273-91-4P
 (aminoalkyl glucosaminide phosphate compds. and their use as adjuvants and immunoeffectors)

L38 ANSWER 12 OF 12 USPAT2 on STN

AN 2002:149148 USPAT2
 TI Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
 IN Persing, David H., Redmond, WA, United States
 Crane, Richard Thomas, Hamilton, MT, United States
 Elliott, Gary T., Stevensville, MT, United States
 Ulrich, J. Terry, Corvallis, MT, United States
 Lacy, Michael J., Hamilton, MT, United States
 Johnson, David A., Hamilton, MT, United States
 Baldrige, Jory R., Victor, MT, United States
 Wang, Rong, Missoula, MT, United States
 PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 6800613 B2 20041005
 AI US 2001-861466 20010518 (9)
 PRAI US 2001-281567P 20010404 (60)
 US 2000-205820P 20000519 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Maier, Leigh C.
 LREP Townsend and Townsend and Crew LLP
 CLMN Number of Claims: 53
 ECL Exemplary Claim: 1
 DRWN 25 Drawing Figure(s); 14 Drawing Page(s)
 LN.CNT 1175

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216013-82-0 216013-88-6 216013-97-7
216014-15-2 216014-21-0 216014-29-8
216014-37-8 376394-26-2
(prophylactic and therapeutic treatment of infectious and other
diseases with mono- and disaccharide-based compds. in relation to
toxicity)

=> b home
FILE 'HOME' ENTERED AT 08:44:39 ON 05 AUG 2005

=>